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The ability of cancer cells to become simultaneously resistant to various chemotherapeutic 
agents, a phenomenon known as multidrug resistance, remains the cause that prevents 
successful treatment of cancer. The tyrocidines and analogues, produced by soil bacterium 
Brevibacillus parabrevis, have been shown to be active anticancer peptides. As with many 
other anticancer peptides, the tyrocidines are toxic to human red blood cells which limits 
their use as anticancer agent. Fortunately, many different strategies exist to reduce drug 
toxicity and improve delivery to target sites such as targeted nanocarriers or liposomal 
formulations. As little research has been done on the formulation and incorporation of the 
tyrocidines in nanocarrier systems to target cancer cells, the formulation strategies in the 
present study were kept simple.  
We set out in this basic strategy to formulate selected tyrocidines with three lipid-based 
molecules, cholesterol sulfate (CS), palmitic acid (C16) and lysophosphatidylcholine (LPC), 
with subsequent biophysical analyses and determination of biological activity of the peptides 
alone and in formulation. The spherical constructs formed by the Trcs was a novel 
discovery. This formation of the spherical structures was hampered or completely disrupted 
by the formulants suggesting detergent-like effects. Decreased dimers and loss of total 
signal of ionic species of the C16 and LPC formulations indicated the formation of stable 
neutral peptide-formulant complexes. On the other hand, CS formulation maintained total 
ionic species signal suggesting a less stable formulation. Significant blue shifts in the 
fluorescence spectrums were seen for the CS formulated peptides, indicating pronounced 
stacking of aromatic rings in a hydrophobic environment. It was clear to us that these 
formulants have significant effects on the oligomerisation of the peptides, which dictates 
their antimicrobial activity.  
The CS and C16 formulations significantly decreased the haemolytic activity of the peptides 
which was one of the main goals of this study. We confirmed that all the tyrocidines 
investigated in this study are highly active against three cancerous cell lines (LNCaP, C4-
2B, HT-29) Interestingly, no direct relationship between hydrophobicity or size of the 
peptides and the activity of the peptides towards cancer and non-cancerous cells were 
observed, strongly suggesting alternative targets, possibly of internal nature. Selectivity 









Die vermoë van kankerselle om gelyktydig weerstandig te raak teen verskillende 
chemoterapeutiese agente, ŉ verskynsel bekend as multimedikament-weerstand, is die 
oorsaak wat suksesvolle kanker behandeling verhoed. Die tirosidiene en analoë, vervaardig 
deur die grondbakterium Brevibacillus parabrevis, is aktiewe antikanker peptiede. Soos baie 
ander antikanker peptiede, is die tirosidiene toksies teen menslike rooibloedselle, wat hul 
gebruik as antikanker agente beperk. Gelukkig bestaan daar strategieë om middel-toksisiteit 
te verlaag en die aflewering by teikenselle te verbeter soos byvoorbeeld nanodraers of 
liposomale formulasies. Omdat daar min navorsing is oor die formulering en gebruik van 
tirosidiene in nanodraer sisteme om kankerselle te teiken, was die formuleringstrategieë in 
die huidige studie eenvoudig gehou.  
Ons het in die eenvoudige strategie geselekteerde tirosidiene geformuleer met drie lipied-
gebaseerde molekules, cholesterolsulfaat (CS), palmitiensuur (C16) en lisofosfatidielcholien 
(LPC), gevolg deur  biofisiese analises en bepaling van biologiese aktiwiteit van die peptiede 
alleen en in formulasies. Die sferiese konstrukte wat deur die tirosidiene gevorm is, is ŉ 
nuwe ontdekking. Hierdie vorming van die sferiese konstrukte was verminder of heeltemal 
ontwrig deur die formulante, wat dui op ‘n detergent-agtige effek. Afname in dimere en 
verlies van totale sein van ioniese spesies in die C16 en LPC formulasies het die vorming 
van stabiele neutrale peptied-formulant komplekse aangedui. Daarteenoor is die totale sein 
van ioniese spesies in die CS formulasies behou wat dui op minder stabiele formulasies. 
Beduidende verskuiwings in die fluoressensie spektra is vir die CS formulasies 
waargeneem, wat uitgesproke pakking van aromatiese ringe in ŉ hidrofobiese omgewing 
aandui. Dit was duidelik dat die formulante beduidende effekte op die oligomerisasie van die 
peptiede het, wat hulle antimikrobiese aktiwiteit dikteer. 
Die CS en C16 formulasies verlaag hemolitiese aktiwiteit van die peptiede wat een van die 
hoofdoelwitte van die studie was. Ons het bevestig dat al die bestudeerde tirosidiene hoogs 
aktief is teen drie kankersellyne (LNCaP, C4-2B en HT-29). Geen direkte verhouding tussen 
die hidrofobisiteit of grootte van die peptiede en hul aktiwiteit teenoor kankerselle en 
normale menslike selle kon gevind word nie, wat op alternatiewe teikens dui, waarskynlik 
intern van natuur. Selektiwiteit studies het ŉ belowende voorloper formulasie, TpcC:C16,  
met potentiaal as alternatiewe antikanker agent, uitgewys.    
 
 















“When you’re at the end of your rope, tie a knot  
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The development of multidrug-resistance (MDR) in cancer has become a worldwide crisis in 
the healthcare industry. The increasing number of cancer cases can be attributed to 
increased exposure to risk factors and failure of current cancer treatments. In addition, 
chemotherapy is non-selective and destroys healthy tissues and cancerous tissues. 
Consequently, the immune systems of the patients are compromised. Cancer patients with 
compromised immune systems are therefore at a higher risk to contract an untreatable 
nosocomial infections. Antibiotics are ineffective in treating such infections due to MDR and 
the lack of novel antibiotics. Therefore, cancer patients face three problems, i) the failure of 
chemotherapy due to MDR, ii) side-effects caused by non-selectivity of chemotherapeutics 
and iii) contraction of an untreatable nosocomial fungal infection. It is of utmost importance 
to find new anticancer drugs with complementary activity against microbial pathogens that 
can overcome MDR and the non-selectivity of current cancer therapeutics.  Promising 
alternatives to conventional drugs are antimicrobial peptides (AMPs), specifically the 
tyrocidines (Trcs) and analogues from the tyrothricin complex. The Trcs show high activity 
towards bacteria, fungi and cancer, with potentially low accumulation in tissues and minimal 
risk of resistance development. Although these peptides have the potential as alternative 
therapeutic drugs, major drawbacks do exist due to their tendency to form oligomers and 
their non-selective cytotoxicity, specifically their haemolytic activity. The hypothesis that will 
be tested in this study is if the formulation of tyrocidines in specific biocompatible lipid 
nanocarriers will modulate the toxicity associated with the peptides by influencing both the 
biophysical properties of the peptides in solution, as well as masking the toxic moieties 
without compromising activity. To test the hypothesis a number of aims and objectives were 
set as described below. 
RESEARCH AIMS AND OBJECTIVES 
Aim 1: The production, extraction, purification and characterization of selected tyrocidines 
and analogues from the tyrothricin complex.  
Objectives: 
1. Purification of tyrocidine mixture and individual tyrocidine peptides from Brevibacillus 
parabrevis culture extracts and commercial tyrothricin mixture using semi-preparative 
high-performance liquid chromatography (HPLC).  
2. Development of C8 HPLC purification method 
3. Confirmation of purity and characterization of the individual purified peptides and 
peptide fractions with electrospray mass spectrometry (ESMS) and ultraperformance 
liquid chromatography coupled to ESI-MS (UPLC-MS).  
The results from this study are presented in Chapter 2 





Aim 2: Formulation and biophysical analysis of the purified peptides and peptide 
formulations.  
Objectives:  
1. Preparation of peptide formulations with lipid-based molecules, cholesterol sulphate 
(CS), palmitic acid (C16) and lysophosphatidylcholine (LPC)  
2. Visual analysis of self-assembly/aggregation of peptides and formulations with 
scanning electron microscopy  
3. Analysis of self-assembly/aggregation and stability of peptides and formulations with 
traveling wave ion mobility mass spectrometry (TWIM-MS) and fluorescence 
spectroscopy (FS). 
The results from this study are presented in Chapter 3 
Aim 3: Characterization of anti-cancer and toxicity of the optimized peptide formulations. 
1. Determination of the toxicity of the peptides and formulations against human 
erythrocytes and human embryonic kidney (HEK293) cells. 
2. Determination of the anticancer activity of the peptides and formulations towards 
human prostatic adenocarcinoma  (LNCaP), human colorectal adenocarcinoma (HT-
29) and human prostatic carcinoma (C4-2B) cells of  the selected optimized 
formulations. 
3. Determination of selectivity indexes (HC50/IC50 and LC50/IC50) of the peptides and 
formulations from toxicity and activity assays. 
The results from this study are presented in Chapter 4 
THESIS CONTENT 
The thesis comprises of literature background in Chapter 1 on multidrug resistance, 
antimicrobial peptides with anticancer activity and current nanodrug delivery strategies for 
effective drug delivery.    The experimental methods, results and discussions are given in 
Chapters 2-4. As this study reports statistical significances on the biological activity of many 
different formulations and peptides towards 5 different cell lines, an addendum with 
summarised statistics is given at the end of Chapter 4. Finally, Chapter 5 summarises 
conclusion and future studies in the field of tyrocidine formulations.  
OUTPUTS OF MSc STUDY 
• Van Wyk RJ* (March 2018) Formulation of peptides from the tyrothricin complex, 
Biochemistry Forum, University of Stellenbosch, Oral presentation 
• Van Wyk RJ*, Rautenbach M (2018) Characterization of the anti-cancer activity of 
formulated and modified tyrocidine peptides, SASBMB 2018 Conference, 
Potchefstroom, South Africa 
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• Van Wyk RJ, Kumar V, Rautenbach M* (2019) The influence of lipid formulants on 
the self-assembly and toxicity of cyclodecapeptides from tyrothricin, article to be 
submitted to MBio.  
*Presenter/Corresponding author 




OVERVIEW OF CHEMOTHERAPEUTIC RESISTANCE AND 
ANTIMICROBIAL PEPTIDES AS ALTERNATIVE 
ANTICANCER DRUGS 
1.1 INTRODUCTION 
Cancer is well-known to be one of the leading causes of death worldwide and has 
been ranked as first or second cause of death at <70 years of age in 91 of 172 
countries and third or fourth in an additional 22 countries according to estimates by 
the world health organisation (WHO)1. t is evident that cancer incidence and mortality 
rates are growing rapidly worldwide with an estimated 18.1 million new cases and 9.6 
million deaths in 2018 according to International Agency for Research on Cancer 
(IARC) 1. The increasing number of cancer cases and deaths can be attributed to 
various factors. These factors include aging, size of population and the prevalence of 
risk factors including behavioural, occupational, environmental risk factors, and which 
are mostly related to socioeconomic development1, 2, 3. 
Cancer treatment methods may be used alone, in combination or sequentially and 
depends on health status of the patient, the molecular characteristics of the tumour, 
location of the tumour, and severity of the disease. Surgical removal of tumours is 
usually the first line of treatment and is often used in combination with radiotherapy for 
localised cancers. The most common treatment for metastatic tumours is 
chemotherapy which consists of a wide range of cytotoxic drugs that are employed to 
preferentially target proliferating cancer cells 4. However, chemotherapeutic drugs 
have very low selectivity and also target normal healthy cells leading to adverse side 
effects such as hair loss, vomiting and suppression of the immune system in patients 
5. Cancer can reoccur, and this is primarily due to inherent or acquired resistance to 
the chemotherapeutic drugs used 6. In many cases the tumours are resistant to a wide 
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range of drugs which is known as multiple drug resistance (MDR) 6. MDR is the major 
implication in the overall failure of chemotherapy and as a result higher mortality rates 
are observed 1. Cancer patients are also at a higher risk of contracting nosocomial 
fungal infections due to their compromised immune systems caused by invasive 
surgery and chemotherapy 7, 8. This chapter presents a brief overview of mechanism 
of action of conventional cytotoxic agents used for cancer treatment and how 
resistance develops towards these agents. The use of antimicrobial peptides as 
alternative chemotherapeutic agents and the formulation of AMPs to improve delivery, 
stability and toxicity of the peptides are broadly also discussed.  
1.2 BROAD OVERVIEW OF CONVENTIONAL CYTOTOXIC DRUGS 
AND THEIR MECHANISM OF ACTIONS 
Chemotherapy is the most widely used treatment for various types of cancer, 
especially for metastatic tumours 9. Chemotherapy consists of a diverse group of 
cytotoxic agents that acts by  targeting various biosynthetic processes involved in the 
proliferation of cancer cells. These cytotoxic agents can be classified according to their 
target sites and mode of actions 4. The groups include the antimetabolites, alkylating 
agents, anthracyclines, camptothecins and analogues, epipodophyllotoxins and 
mitotic spindle poisons (Vinca alkaloids and taxanes)4,  10-13 .  
The antimetabolites consist of antifolates and pyrimidine and purine antagonists which 
results in the disruption of DNA and RNA synthesis 11. Examples of antimetabolites 
are methotrexate (MTX), 5-fluorouracil (5-FU) and N-(phosphonacetyl)-L-aspartate 
(PALA)14-16. MTX is an antifolate which inhibits dihydrofolate reductase (DHFR), an 
enzyme involved in the metabolism of folates 15, 16 . Inhibition of DHFR results in 
reduced folate synthesis which are co-factors that are essential for the synthesis of 
both pyrimidine and purine 15, 16. The analogue of uracil, 5-FU, is converted to active 
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metabolites, fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP) and fluorouridine triphosphate (FUTP), intracellularly 14. These 
fluoronucleotides are then mis-incorporated into RNA and DNA. Furthermore, 5-FU 
also inhibits thymidylate synthase (TS) which is involved in nucleotide synthesis 14. 
PALA inhibits aspartate transcarbamylase, the enzyme that catalyses the second 
reaction of pyrimidine nucleotide synthesis 16. The antimetabolite antitumor drugs all 
interact with enzymes involved in the synthesis of nucleotides which are essential 
building blocks for DNA and RNA 16. 
The alkylating agents exerts antitumor activity by binding to DNA, which leads to cross-
linking between DNA strands, causing disruptions of the normal processes of 
transcription and replication. Examples of alkylating agents are the antibiotic, 
mitomycin C 17, isolated from Streptomyces caespitosus and the platinum coordination 
complex cis-diamminedichloroplatinum (II), cisplatin 18, 19. Alkylation and cross-linking 
of DNA is also a mechanism of action of the anthracycline antibiotics doxorubicin 20 
and daunorubicin 21. However, the anthracyclines have various additional mechanisms 
of action including intercalation into DNA, damage of DNA via free radical formation 
and inhibition of DNA topoisomerase II 21. The camptothecins and analogues and 
epipodophyllotoxins inhibit topoisomerase I 22, 23 and poisons topoisomerase II 24, 
respectively. The inhibition of topoisomerase I by camptothecins and analogues 
(example topotecan) leads to formation of DNA single-strand breaks thereby inhibiting 
DNA replication and synthesis 22, 23. Whereas,  epipodophyllotoxins such as etoposide 
poisons rather than inhibits the topoisomerase II, leading to single-strand and double-
strand breaks in DNA which ultimately cause cell apoptosis 24, 25. 
The last major group of cytotoxic agents are the mitotic spindle poisons which includes 
the Vinca alkaloids and taxanes which influences polymerisation dynamics of 
Stellenbosch University  https://scholar.sun.ac.za
1-4 
 
microtubules leading to mitotic blocking 11, 26. The Vinca alkaloids are derived from the 
periwinkle plant Vinca rosea and include antitumor drugs, vinblastine and vincristine. 
The taxanes are also derived from plants, however, are semisynthetic and include 
paclitaxel and docetaxel 26, 27. At high drug concentrations, the Vinca alkaloids inhibit 
microtubule polymerisation whereas the taxanes stimulate and stabilise microtubule 
polymerisation.  The mechanisms of action of the Vinca alkaloids and taxanes are the 
same at low drug concentration with the suppression of microtubule dynamics 
resulting in mitosis disruption at metaphase/anaphase transition 26.  
1.3 MULTIDRUG RESISTANCE DEVELOPMENT IN CANCERS 
Although there is a diverse group of cytotoxic agents available for the treatment of 
cancer, their effectiveness has been limited due to resistance development of cancer 
tumours 28. Tumours may be intrinsically resistant to chemotherapeutic drugs or may 
acquire resistance to the initial chemotherapeutic agent after treatment and often show 
cross-resistance to other unrelated drugs 6. The ability of tumours to become resistant 
to multiple drugs is known as multidrug-resistance (MDR), a phenomenon preventing 
successful treatment of cancers 6, 9, 28. The mechanisms of MDR and how it develops 
remains complex and is not fully understood, however two general MDR mechanisms 
include i) reduced accumulation of the cytotoxic drugs in the tumour cells due to 
decreased drug influx or increased drug efflux and ii) genetic and epigenetic alteration 
in the tumour cells leading to activated detoxifying systems and blocking of apoptotic 
pathways which affects tumour sensitivity towards drugs (Figure 1.1)9, 28. 
 




Figure 1.1 Schematic depiction of general mechanisms involved in MDR 9. One mechanism is 
the increased activity of efflux pumps such with overexpression of the ATP dependent 
transporters observed. Additionally, reduced influx of drugs that enter the cells via endocytosis 
or via intracellular carriers. Activation of detoxifying systems, such as cytochrome P450 mixed 
function oxidases, results in drug resistance in the cases where drug accumulation is not 
influenced. Alteration in the DNA repair mechanisms which results in repairment of DNA 
damage caused by cytotoxic drugs is another mechanism of drug resistance. Lastly,  
disruption of apoptotic signalling pathways in cells with mutant/non-functional p53 or 
decreased ceramide levels is also implicated in multidrug resistance9. Figure reproduced from 
9 
1.3.1 ATP-dependent efflux pumps as major MDR systems 
The family of ATP-binding cassette (ABC) transporters are a group ATP-dependent 
efflux pumps that share sequence and structural homology29. The ABC transporter 
genes are divided into seven sub-families (ABCA-ABCG) according to sequence 
homology and domain organisation 29. A total of 48 human ABC transporter genes 
have been identified 29 and 11 of these transporters are implicated in MDR (Table 1.1) 
9. The basis of the mechanism of action by which all these ABC transporters causes 
resistance is by overexpression of these ATP-dependent pumps in various tumours 
leading to efficient removal of cytotoxic drugs.  
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Overexpression of P-glycoprotein (PGP) in MDR cells is one of the best characterised 
ABC-transporter associated with MDR in terms of biochemical and genetic aspects 30, 
31. PGP is encoded by the ABCB1 gene (also known as MDR1 gene) 32, 33 and consists 
of 12 transmembrane regions 34 that bind various hydrophobic drugs such as Vinca 
alkaloids and anthracyclines 31 (Table 1.1). Subsequent ATPase activity stimulation 
induces conformational change that transfers the drugs to the outer leaflet of the 
membrane or to the extracellular space 35. Another well-researched ABC transporter 
implicated in MDR is the multidrug-resistance-associated protein 1 (MRP1) also 
known as ABBC1 36. The structure of MRP1 is similar to that of PGP, however has 
amino-terminal extension composed of five membrane-spanning domains 36. The 
mechanism of MRP1 is based on the ATP-dependent transport of 
glutathione/glucuronate conjugates of chemotherapeutic drugs 37, 38 as well as the 
cotransport of unmodified drugs, such as vincristine, with glutathione to extracellular 
space 39. An additional five members of the ABCC (ABCC2-ABCC6 or MPR2-MRP6) 
subfamily have been identified and characterised 40 of which the majority have been 
implicated in MDR of tumours (MPR2-MPR5), with specificity towards various 
chemotherapeutic drugs (refer to Table 1.1) 9, 40. Some chemotherapeutic drugs are 
poor substrates for PGP and MPR1 with cancer cells resistant to the drug, 
mitoxantrone, expressing genes encoding distant members of the ABC transporter 
family. These distant members are known as ABCG2 or by their common name MXR 
(mitoxantrone-resistant gene) 41, BCRP (breast cancer resistant protein)42 or ABC-P 
(ABC-transporter in placenta) 43. The substrate specificity of these ABCG2 
transporters is broadened by acquired mutation of the MXR/BCRP/ABC-P genes 44, 
45. 
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Table 1.1 Summary of ABC transporters implicated in MDR and their chemotherapeutic 
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Other ABC transporters implicated in MDR include BSEP (bile salt export protein) 
which was originally named SPGP (sister of PGP)61, the phosphatidylcholine flippase 
MDR2 (also known as MDR3) 46, 47, 68 which is closely related to MDR1/PGP and 
steroid transporter ABCA2 29, 66, 67 (refer to Table 1.1).  
Although the over-expression of ABC transporters in cancers  has a major detrimental 
effect on chemoterapeutic drug potency and is leading to treatment failures, these 
proteins can be potential targets for blocking agents that could have synergistic actions 
with chemotherapeutic drugs. The over-expression of ABC transporters in cancers 
could be  beneficial for selectively targeting cancers with peptides, ligands and 
antibodies. These membrane-bound proteins would also be very sensitive to 
membrane-active compounds such as the antimicrobial peptides (AMPs) which will be 
discussed in the next section. 
1.4 ANTIMICROBIAL PEPTIDES AS ALTERNATIVE 
CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF 
CANCER 
It is of utmost importance to find new anticancer drugs that can overcome MDR and 
the non-selectivity of current cancer therapeutics, in particular the negative influence 
of chemotherapeutic drugs on the immune system8. Novel drugs to target MDR 
cancers without compromising the immune system, is an important consideration in 
anticancer drug development. Promising alternatives to conventional 
chemotherapeutic drugs are the AMPs. AMPs have received much attention as 
alternative antibiotics due to their potent activity against a broad spectrum of microbes 
including bacteria 69, viruses 70, fungi 71, as well as cancer 72, 73, 74. This group of 
peptides also has high selectivity, potentially low toxicity, low accumulation in tissues 
and low risk of resistance development 74. AMPs form part of the innate immune 
systems of various living multicellular organisms 75, as well as defence molecules of 
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bacteria and consist of a wide range of structurally diverse peptides73, 74. Regardless 
of their structural diversity all AMPs have an amphipathic nature which underlies their 
interaction with target cells and mechanism of action 71, 76. Most AMPs selectively 
target the anionic membranes of bacterial and fungal cells, inserts into the membrane, 
destabilizes the membrane and essentially induces cell death 77. The cell membranes 
of prokaryotes and eukaryotes differ in their composition and arrangement of lipids 
and sterols. Prokaryotic membranes have significant amounts of anionic 
phospholipids on the membrane outer leaflet 78, whereas eukaryotic membranes 
consist of zwitterionic phospholipids on the outer leaflet leading to a predominately 
neutral cell surface79. Healthy eukaryotic cells are also protected against AMPs by 
membrane-stabilizing cholesterol 76, 80. Cancer cells on the other hand display a quite 
different cell surface due to their rapid proliferation 81, 82. Cancer cells alter their 
membrane composition by increasing expression of anionic molecules such as 
phosphatidylserine (PS)83, O-glycosylated mucins84, saililated gangliosides85 and 
heparan sulfates 86 which results in an overall negative membrane charge. An 
additional difference between tumour cells and healthy mammalian cells is the 
elevated amount of microvilli on the surface of tumour cells 87 which increases the 
surface area of the cancer cells allowing increased amount of AMPs to interact 88. 
Therefore AMPs with anticancer properties have been extensively researched and 
although it is thought that AMPs have will selective activity for tumour cells, 
development of such AMPs, so-called anticancer peptides (ACPs) for clinical 
application has been slow. Activity towards tumours cannot be predicted according to 
the structures of ACPs as of yet, and are regarded as unique chemotherapeutic agents 
with various modes of actions81, 89. The ACPs can be categorised into the ACPs with 
membranolytic activity and ACPs with non-membranolytic activity towards cancers 
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cells. The ACPs with membranolytic activity include the magainins 90, melittin 91, 92, 
cecropin 93 and the beetle defensin D-peptides A, B, C and D 94 (refer to Table 1.2 for 
a summary and references). Initial evidence of membranolytic activity was discovered 
in a study done by Cruciani et al. 90 on magainin 2 that showed cytolytic activity towards 
hematopoietic and solid tumour cell lines. Other studies showed that the 
membranolytic activity of these ACPs can be achieved via the accumulation on the 
cell membrane surface in a carpet-like manner (carpet model)95 or accumulate via 
hydrophobic interaction and forming transmembrane channels or pores (toroidal pore 
or barrel-stave model) 96. In these models the end result is membrane permeabilization 
and cell lysis. Alternatively, apoptosis can be induced by the permeation and swelling 
of the mitochondria resulting in release of cytochrome C 97. Release of cytochrome C 
induces Apaf-1 oligomerisation, caspase 9 activation and conversion of pro-caspase 
3 to caspase 3 98. Buforin IIb, a histone-H2A derived peptide has been shown to kill 
cancer cells by mitochondrial dependent-apoptosis pathway 85. The mitochondrial-
dependent apoptosis pathway is also associated with upregulation of molecules in the 
death receptor pathway as in the case for tachyplesin 99. ACPs with non-
membranolytic activity has also been described such as the insect derived, alloferon 
1 and 2 peptides which have immunomodulatory properties 100. Refer to Table 1.2 for 
examples of some of the major ACPs and their anticancer activities.  
Similarly to the major ACPs in Table 1.2 below, a group of other antimicrobial peptides, 
the tyrocidines, possess activity against various cancer cell lines 101. This has sparked 
an interest in these peptides by our group to develop the tyrocidines into future 
anticancer agents which was the main focus of the present study.  
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1.5 OVERVIEW OF TYROCIDINES AND ANALOGUES 
The tyrocidines and analogues, a group of antimicrobial peptides (AMPs), were first 
discovered by Dubos in 1939 from the extracts of a cultured soil bacillus as part of a 
complex known as tyrothricin 103. The tyrothricin complex, produced during the late 
logarithmic growth phase of Brevibacillus parabrevis, consists of the basic 
cyclodecapeptides known as the tyrocidines and the neutral linear gramicidins 104-107. 
The tyrocidines were discovered 10 years after the antibiotic penicillin, however was 
the first antibiotic used in medical industry in the form of topical 108-110 and oral drugs 
(throat lozenges) 111, as their haemolytic toxicity limited their application 112.  
1.5.1 Primary and secondary structure 
The primary structure of Trcs and analogues consists of a conserved sequence 
(cyclo[D-Phe1-L-Pro2-L-X3-D-X4-L-Asn5-L-Gln6-L-X7-L-Val8-L-X9-L-Leu10]). Variations 
(depicted by X) generally occur at position three, four, seven and nine (Figure 1.2). 
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Substitution of position seven with tyrosine (Tyr), phenylalanine (Phe) or tryptophan 
(Trp) gives rise to the Trcs, and the analogues phenycidines (Phcs) and tryptocidines 
(Tpcs), respectively. Whereas, substitution of three and four (Phe and Trp), and nine 
(ornithine, Orn, and lysine, Lys) give rise to the A/A1, B/B’/B1/B1’ and C/C1 analogues 
107, 113, 114. In total 28 different Trcs and analogues have been characterised by Tang 
et al. 113 with 24 accounted for by amino acid variability mentioned above. The 
tyrocidine A, A1, B, B1, C, C1 analogues are detected in highest abundance and are 
considered as the six major Trcs present in the cyclodecapeptide mixture 113, 115.  
 
Figure 1. 2 The primary structure of Tyrocidine A. The amino acids are given by their three 
letter abbreviations with ornithine represented by Orn. The amino acids that are variable at 
certain positions are shown in brackets. Amino acid at position seven can be substituted by 
phenylalanine or tryptophan to produce the phenycidines and tryptocidines, respectively. 
Figure adapted from Tang et al. 113. 
The secondary structure of Trc A and TrcC adopts the conformation of a two-stranded 
antiparallel B-sheet with a type II B-turn, formed by Leu10, Phe1, Pro2, Phe3, and a 
distorted type I -turn, formed by Asn5, Gln6, Tyr7, Val8, at either end of the structure 
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116-121. The secondary structures are stabilised by four intramolecular hydrogen bonds, 
three formed between the amide and carbonyl groups of the backbone and the fourth 
hydrogen bond located between the backbone amide of Val8 and side chain amide of 
Asn5. Further stabilisation of the secondary structure is achieved via hydrophobic 
interactions between amino acid side chains of Phe4, Val8 and Leu10  121. The L-Trp4/L-
Phe4 and L-Orn9 residue are located on the same face of the monomeric -sheet 
structures 120 (Figure 1.3). The tyrocidines have been shown to have low 
amphipathicity in monomeric form as the polar and non-polar residues are not 
separated into hydrophobic and hydrophilic faces 120. Although variation in the amino 
acid sequence of the primary structure of the Trcs, the secondary structure of the 
different tyrocidines are proposed to be conserved 122 (Figure 1.3).  
 
Figure 1.3 The secondary structures of the six major tyrocidines created from TrcC and TrcA 
models of Munyuki et al.120. The two stranded antiparallel B-sheet structure connected by 
the type I and type II B turns are shown. The side chains of the variable amino acids of the 
aromatic dipeptide unit (L-X3-L-X4), L-Lys9/Orn9 and the intramolecular hydrogen bonds are 
also shown. Figures reproduced with permission (M. Rautenbach, unpublished data)  
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Homodimers of Trc A 120, 121 and TrcC 120 lead to highly amphipathic structures which 
are formed by strong association of the -sheets of two monomers in an edge to edge 
fashion120, 121 (creating a continuous four-stranded antiparallel  -sheet) or by stacking 
on top of each other120. Similar to the monomer stabilisation, stabilisation of dimer 
formed edge to edge is achieved by hydrogen bonds between the backbones of the 
amino acid residues of  two monomers 120, 121. Whereas, dimers formed by stacking 
on top of each other are stabilised by hydrophobic interactions 120. The possibility of 
the tyrocidines to form dimers via various orientations indicates that the 
cyclodecapeptides can form larger oligomers120. Loll et al. 121 elucidated the dimeric 
structure of Trc A by means of X-ray crystallography (Figure 1.4). The dimers are 
formed by two monomers that strongly associate into highly amphipathic structures 
consisting of four -strands in a continuous antiparallel -sheet stabilised by 
backbone-backbone hydrogen bonds and hydrophobic interaction between side chain 
of Val8 and Leu10 from two monomers. The four stranded antiparallel -sheet of the 
dimer forms a significant curvature, with the side chains of hydrophobic amino acids 
on the convex face and the side chain of polar L-Orn9 residue on the concave face. 
The backbone carbonyl groups of D-Phe1, Asn5 and Gln6 point outward from concave 
face with the side chain of Gln6 (extending equatorially from dimer) well position to 
orientate toward the concave side of the dimer, giving the concave face a polar 
character.  
1.5.2 Mechanism of action 
The tyrocidines have been shown to interact with the lipids in the lipid-bilayer of the 
cell membrane 123 leading to disruption and permeabilization of the bilayer 124 which 
ultimately results in cell lysis and death 125.  The increased amphipathicity of the 
tyrocidines observed when in dimeric form 120, 121 and the low amphipathicity 
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associated with the monomeric conformation 120 of the tyrocidines suggests that the 
dimers are the active moieties of these cyclodecapeptides.  
In a model developed by Loll et al. 121 the hydrophobic convex face of the highly curved 
dimer structure inserts into lipid bilayer of membranes and the hydrophilic concave 
face orientated towards the extracellular space (aqueous environment). Furthermore, 
the D-Phe4 extending from the centre of the convex face, is proposed to be buried in 
the lipid bilayer while side chain of Tyr7 directed towards the concave face of the dimer 
and is therefore exposed to aqueous environment 121.  
 
Figure 1.4 The dimer structure of Trc A showing A) the highly curved amphipathic structure 
formed by two monomers with hydrophobic side chains at convex face (shown in blue) and 
hydrophilic side chains at concave face (shown in red) and B)  the mechanism of dimer 
interaction with lipid bilayer of membranes with the convex face and D-Phe4 inserting into the 
membrane while Tyr7 and concave face orientated towards exterior of the membrane. The 
figures were reproduced from Loll et al. 121 
The tyrocidines have been shown to  oligomerise into higher order structures which 
are  believed to form pore-like structures that are similar to the homologous Gramicidin 
S (GS) 107,126, 127, 128, 129, 130. TrcA and TrcC were shown to form defined ion-conducting 
pores that do not have a major influence on phospholipid head-group orientation131.  
Alternative targets and mechanisms of actions have been proposed other than the lytic 
activity on the cell membrane, 101, 132, 133, 134 which includes the food vacuole 
morphology 134 and cell cycle regulation 101 of the malaria parasite Plasmodium 
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falciparum, as well as the disruption of glucose metabolism in Gram-positive 
bacteria135, 136. The tyrocidines have also been proposed to target DNA resulting in 
disruption of normal transcription and replication processes 123 after the observation 
that the Trcs binds to the DNA and inhibits transcription in the producer organism in 
vitro 137-140. Wenzel et al. 131 observed the loss of peripheral membrane proteins and 
an influence on intracellular proteins, as well as clustering of fluid regions in the 
Bacillus subtillis cell membrane upon exposure to the Trcs. These non-lytic 
mechanisms would still depend on initial membrane interaction in order to possibly 
translocate into cells or be internalised by cells. Although many mechanisms of action 
for the Trcs have been proposed, the exact mode(s) the Trcs elicit their activity towards 
various microbes, including cancer cells, varies and remains to be fully elucidated for 
each cell type. However, their multiple mechanisms of action, various targets and the 
large library of Trcs analogues reduces the risk of resistance development, making 
these cyclodecapeptides promising compounds for development of alternative 
chemotherapeutic drugs.  
1.6 DRUG FORMULATION AND TARGETING OF CANCERS 
Although AMPs, such as the tyrocidines, have potential as alternative 
chemotherapeutic drugs, major drawbacks do exist due to their chemical and physical 
instability, tendency to form aggregates, enzymatic degradation, short circulating half-
life, rapid elimination and in some of the more potent ACPs, their toxicity 141. The poor 
pharmacokinetic profiles of chemotherapeutic drugs and their associated toxicity led 
to extensive research in the development of drug delivery systems 142.  
Covalent and non-covalent formulations of AMPs can be designed to actively and 
passively target the cancer cells by exploiting the tumour environment, a concept that 
dates back to 1960 when Ehrlich first described the “magic bullet”143. However, “active 
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targeting” happens after “passive targeting” and therefore cannot be separated 144. 
Differences in the tumour vasculature and pH compared to normal tissues are the 
major characters taken into consideration when designing nano-formulations and 
nanocarriers for drug delivery systems. For active targeting, different ligands can be 
coupled to the AMP (or drug) or incorporated at the surface of nanocarriers (covalently 
or non-covalently) to target receptors/enzymes overexpressed in the targeted cancer 
cells 145. For passive targeting, nanocarrier and nano-formulations can be used with 
the so-called enhanced permeability and retention (EPR) effect that traps larger 
particles around the more permeable tumour sites146, 147. Figure 1.5 shows the basis 
of active and passive targeting of tumours. 
 For the nano-formulation of AMPs (or ACPs) it is hypothesised that the nano-
formulation will protect the peptide from degradation and mask its toxic activity, but if 
toxic peptides in nano-particles are released in the vicinity of tumour they will lyse 
cancer cells displaying a more positive cell membrane 149. Necrosis of the cancer cells 
will elicit an acute sterile inflammation 150 that could promote removal of cancerous 
cells. The released AMPs would also be degraded leaving a low general toxicity 
footprint on the heathy tissue. 
1.6.1 Active targeting of cancers 
Targeting ligands generally used in nanocarrier design includes small molecules, 
peptides, carbohydrates, proteins and antibodies 151. Receptors that can be targeted 
in cancer therapeutics include the prostate specific membrane antigen (PSMA) 
overexpressed in prostate cancer152, the folate receptors overexpressed in 40% of 
human cancers153, the transferrin receptor (TfR)154, CD44 receptor and epidermal 
growth factor receptor (EGFR) overexpressed various cancer cells155, 156, as well as 
the overexpressed ABC transporters in certain cancer cells9.   




Figure 1.5 Schematic showing A. passive and B. active targeting of tumour cells. A. (1) The 
nanocarriers reach the tumour cells via leaky vasculature. (2) Schematic signifying the 
importance of size for the accumulation of nanocarriers in the tumour due to larger size 
compared to smaller drugs that can diffuse back into the tumour blood vessel. B. Targeted 
nanocarrier that actively target receptors overexpressed or expressed by (1) cancer cells or 
(2) angiogenic endothelial cells. Figure reproduced from 148 
The PSMA is also known as folate hydrolase and catalyses the hydrolytic cleavage of 
α- or γ-linked glutamates from small molecules and peptides152. Therefore poly-
glutamate or poly-glutamate folates can be used as targeting ligands in the design of 
anti-prostate cancer drugs 152. Folic acid (Vitamin B9), transferrin, hyaluronan and 
EGF can be used as ligand for targeting of folate receptors153, TfRs 154, CD44s157 and 
EGFRs155, respectively. Antibodies were the first class of ligands used to decorate 
micelles for targeted delivery to tumour cells and are so efficient due to high affinity for 
their targets. Antibodies, used as ligand used to target cancer cells, include anti-CD3 
Ab158, anti-HER2 (Herceptin)159, anti-CD20 Mab (Rituximab)160 to name a few. Refer 
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to a comprehensive review by Nicolas et al. 145 for other ligands used in nanocarrier 
drug delivery systems. Enzymatic degradation of the ligand upon ligand/receptor 
interaction leads to the disruption of the nanocarrier and could subsequently release 
the drug or ACP at the target site 151-161. Incorporation of acid-labile bonds (ester, 
hydrazine, imine etc.) between the ligands and nanocarrier can also be used to 
achieve pH triggered release of drugs with the bond being disrupted as it enters the 
acidic environment of cancer tumours 162.  
1.6.2 Passive targeting of cancers 
Passive targeting can be achieved via the enhanced permeability and retention (EPR) 
effect 146147. Tumour and metastatic cancer cell in tissues lead to increased 
permeability of the environment around the cancer due to angiogenesis and low level 
chronic inflammation146, 147. The EPR effect is achieved by significantly increasing the 
circulation time of a drug by incorporating it in a nanocarrier thereby maximizing the 
opportunity for the drug to reach the more permeable target site, without dilution in the 
healthy tissues which the nano-drug cannot enter due to its size 163.  
Polymer-type nanocarriers 
Poly(ethylene glycol) modified (PEGylated) nanocarriers have received much 
attention due to their biocompatibility and prolonged circulation time. In 2007, 
amphiphilic poly(lactic-acid)-block-poly(ethylene glycol) (PLA-b-PEG) nanocarriers 
loaded with Paclitaxel were brought to the market 151 and more recently PEG amide 
conjugates of the membrane active an toxic amphotericin B  were shown to cure mice 
suffering from candidiasis 164. Popular amphiphilic (co)polymers currently investigated 
in the field of drug delivery are PLA-b-PEG, poly(glycolic acid)-b-PEG (PGA-b-PEG), 
poly(lactide-co-glycolide)-b-PEG (PLGA-b-PEG), poly(ε-caprolactone)-b-PEG (PCL-
b-PEG) and poly(valero lactone)-b-PEG (PVL-b-PEG). The core of the nanocarrier is 
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formed by the hydrophobic polymer(PLA, PGA, PLGA, PCL and PVL) and the shell by 
the hydrophilic PEG polymer 151. Lipids, poly-amino acids (PAAs) and carbohydrates 
can also be conjugated to PEG to form polymeric liposomes, combining the benefits 
of both liposomes and polymeric nanocarriers. Studies on the antibacterial activity of 
PEGylated AMPs (nisin-PEG165, PEG-CaLL166 and BacE-PEG167) revealed decreased 
activity for all of the PEG-conjugates compared to their parent AMP alone indicating 
that even though PEGylation can improve biocompatibility and prevent their 
degradation by enzymes, the risk of compromising their activity exists. However, all 
the PEGylated AMPs mentioned are hydrophilic and therefor PEGylation of 
hydrophobic peptides may prove to be beneficial considering their increased solubility 
by PEG 168.  
A cyclodecapeptide mixture of the tyrocidines has been used to construct a peptide-
polymer conjugate with activity towards malaria169. The tyrocidines alone possesses 
antimalarial activity but selective need to be improved. The tyocidines were conjugated 
to biocompatible and pH-labile linker on poly(N-vinylpyrrolidone) (PVP). The Trc-PVP 
construct formed nanoparticles due to the self-assembly of the tyrocidines and these 
nanoparticles were decorated with a targeting peptide ligand which targets the red 
blood cells infected with the malaria parasite.  
Carbohydrate-type nano-formulations and carriers 
An ideal carbohydrate for design of targeted nanocarriers is cyclodextrin which forms 
a circular ring consisting of glucose monomers 170. The hydroxyl groups are exposed 
to the exterior and the glycosidic oxygen and non-exchangeable hydrogen atoms 
orientated inwards Therefor a hydrophobic cavity is formed by cyclodextrins that is 
ideal to sequester hydrophobic drugs. The hydroxyl groups on the exterior can easily 
be modified to functionalize the structure with ligands or other small molecules. Bellocq 
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et al. 171 synthesized a polymer based cyclodextrin nanoparticle comprised of three 
parts i) a linear cyclodextrin polycation used to condensate nucleic acids into the 
nanoparticle, ii) a Tf-PEG-adamantane (Tf-PEG-AD) conjugate for targeted delivery 
and iii) AD-PEG for stabilization of the nanoparticle. The cyclodextrin-based particle 
formulation with 0.05% Tf-PEG-AD increased the transfection of K562 cancer cells 4-
fold, indicating retention of high receptor binding affinity and TfR mediated 
internalization 171. The carbohydrate, chitosan is also extensively employed in targeted 
drug delivery due to the easily modifiable amino groups in the backbone. Chitosan 
modified nanocarriers include trimethylated chitosan, N-octyl-O, N-carboxymethyl 
chitosan (OCC), hydrophobically modified glycol chitosan-cholanic acid (HGC) and 
octadecyl-quaternised lysine modified chitosan (OQLCS) 151. Interestingly, chitosan 
itself has activity against fungi, including and interacts with the anionic phospholipids 
present on fungi cell membranes thereby disrupting the cell membrane172. Wang et al. 
173developed a polymeric liposome (PoLp) consisting of cholesterol and OQLCS 
conjugated to FA or PEG. The OQLCS-FA and OQLCS-PEG functions as targeting 
and protection moieties, respectively. In the acidic environment of cancer cells, 
OQLCS bonds unfold and slowly releases drugs at the target site. It was also shown 
that the FA-PEG coated OQLCS PoLp’s are taken up by MCF-7 cancer cells, which 
may be attributed to the positive charge of the nanocarrier and folate receptor-
mediated endocytosis 173. This endocytic pathway has limits due to the inability of the 
nanocarrier to escape the endosomal vesicle. Subsequently, the endosomal 
entrapped drug and nanocarrier enters lysosomal vesicles followed by enzymatic 
degradation. Examples of AMP-chitosan conjugates include the chitosan-pexiganan 
conjugate174 and anoplin-chitosan conjugates175 The successful novel synthesis of 
chitosan-pexiganan (a magainin AMP analogue) was reported by Batista et al.174 as 
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potential treatment of infected wounds, however no activity assays were performed. 
In addition, a study of the antimicrobial activity of the anoplin-chitosan conjugate 
revealed lower MIC toward Escherichia coli compared to the free anoplin which is a 
promising result for AMP-chitosan conjugates as future drug delivery systems 175. 
Lipid nano-formulations and carriers 
Encapsulation of AMPs and ACPs in liposomes and micelles has been proven to be a 
successful way of delivering these peptides to target cells 176. Due to their amphiphilic 
nature, both hydrophobic and hydrophilic peptides can be delivered via these lipid-
nanocarriers 177. Their ability to reduce toxicity and increase circulating half-life of the 
AMPs makes them very attractive to medical industry176. Examples of AMPs that have 
been formulated with these carriers include nisin 178, 179, polymyxin B 180 and LL-37 181. 
Many chemotherapeutic drugs have also been formulated with liposomes for improved 
delivery and reduced toxicity of the drug.  Refer to Table 1.3 for summary of FDA 
approved liposome formulations combined with different drugs. Amphotericin B, a 
rather toxic membrane-active antifungal drug, is also used as liposomal formulation 
(AmBisome, and Albecet) for the treatment of fungal infections with reduced toxicity 
184. How the toxicity of Amphotericin B was reduced without compromising its 
membrane active mode of action can be used as guide to formulate toxic ACPs and 
AMPs. 
Peptides as nanocarrier ligands 
To improve the intracellular uptake of nanocarriers by target cells, cell penetrating 
peptides (CPPs), many of which are also AMPs, have been investigated largely for 
their enhancement of cellular entry by different mechanisms. Examples of CPPs 
include transactivator of transcription protein (TATp), penetratin, polyarginines and 
lysine containing transportan and Pep-1 182. It was shown by Torchilin et al. 183 that 
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liposomes conjugated with TAT along with protection moiety, PEG, abolishes the 
liposome internalization ability. This can be attribute to the steric hindrance created by 
PEG that prevents direct contact of the CPP with the target cell surface183. Formulation 
of drugs with liposomes conjugated to TAT alone results in improved internalization 
but off target attack of cells due to non-selectivity of CPPs. 
Table 1.3 Summary of FDA approved liposomal drug therapies with nano-formulation 
advantages and year approved. (Adapted from Bobo et al. 184) 
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Fortunately, the steric hindrance of PEG can be overcome by use of “smart” pH-
sensitive PEG blocks as protection and shielding moieties instead 185. Kale et al.185 
developed TATp-liposomes coated with acid labile PEG moieties to function as CPP 
shielding. The acid labile bond between the liposome and the PEG enables the 
removal of PEG when the PL enters the acidified environment at the surface of cancer 
cells. Subsequently, the TATp is exposed, induces internalization and overcomes 
endosomal entrapment of the drug 185. 
Considering the membranolytic activity of various AMPs, there is potential that such 
peptides can be used as both a CCP ligand and as an ACP in anticancer drug 
conjugates which gives AMPs multifunctionality in terms of its uses in drug delivery 
systems. 
Prodrug nano-formulations 
The universal term used for drugs that have been chemically modified to improve their 
pharmacological properties are known as “prodrugs”. This method uses derivatives of 
the drug which are temporarily inactive and become activated by enzymatic or non-
enzymatic conversion when the drug reaches its target site 186. Extensive research 
has gone into micellular prodrug approaches as targeted drug delivery systems for 
various diseases including cancer.  In micellular prodrug systems the drug is 
covalently linked to either diblock copolymers or phospholipids via a chemically labile 
bond. For instance, Seetharaman et al. 187introduced N,N’-dimethylaminoethyl 
methacrylate (DMAEMA) as a pH-responsive cross linker between the drug, ibuprofen 
(Ibu), and diblock copolymer consisting of methoxy-PEG-polypropylene fumarate 
(mPEG-PPF). The pH-sensitive Ibu-mPEG-PPF micellular prodrug showed controlled 
release of Ibu as the acidity of solution increases. Transmission electron microscopy 
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(TEM) analysis confirmed that the protonation (at acidic pH) of DMAEMA crosslinker 
results in micelle swelling, disassembly and ultimately drug release 188.  In a different 
prodrug study, an enzyme-sensitive glycylphenylalanylleucylglycine (GFLG) 
tetrapeptide was used as a linker between anticancer drug, paclitaxel (PTX), and 
PEGylated peptide dendrimer 189. The GFLG oligopeptide is degraded upon 
internalization by cathepsin B, a lysosomal cysteine protease overexpressed in breast 
cancer cells. Subsequently, PTX is released in the cytoplasm of the cancer cells 189. 
The functional groups of AMPs, for instance the amino group of Lys and the Tyr 
hydroxyl group of the tyrocidines, present sites for covalent linkage of pH-sensitive or 
enzyme sensitive cross linkers to produce AMP-prodrugs which can then be 
incorporated into liposomal/micellar, PVP or PEG diblock copolymer nanocarriers.  
Klumperman et al. 169 used this strategy of pH-dependent release of the Trcs from a 
PVP-nanocarrier to target the red blood cell stage of the malaria parasite. Due to the 
anaerobic metabolism of the parasite leading to lower pH in the infected red blood cell 
and in the food vacuole, the tyrocidines were hypothesised to be release as a toxic 
bolus eradicating the intracellular parasite169. 
1.7 Formulation of the tyrocidines and analogues 
The cyclodecapeptides, tyrocidines and analogues, have four functional groups 
(amino group of Lys, amide groups of Asn and Gln, and hydroxyl group of Tyr) as 
possible sites of covalent conjugation of various ligands such as PEG, carbohydrates, 
lipids and other peptides (CPPs or cross linkers). However, as little research has been 
done regarding Trcs as ACPs and the fact that the solution behaviour of the Trcs is 
quite complex, the exploratory formulation of these peptides was kept basic. The fact 
that so many AMPs, similar to tyrocidines, have been incorporated into lipid 
formulations with associated reduced toxicity and improved delivery, micellular non-
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covalent formulations were chosen as strategy to reduce toxicity and improve delivery 
of the tyrocidines in the present study.  In this we followed some of the formulations 
used for detoxifying amphotericin B for the Trcs and analogues in this study. The lipids 
chosen for formulation were cholesterol sulfate (CS), an anionic sterol, palmitic acid 
(C16) a saturated fatty acid (anionic), and lyso-phosphatidylcholine (LPC), a neutral 
lipid and derivative of phosphatidylcholine with one fatty acyl group, as the third 
formulant. 
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Chapter 2  
THE PRODUCTION, PURIFICATION AND 
CHARACTERISATION OF THE TYROCIDINES AND 
ANALOGUES 
2.1 INTRODUCTION 
The phenomenon of multi-drug resistance (MDR) has been described in fungi, 
viruses, Gram-positive- and Gram-negative bacteria 1-2. The rise of MDR greatly 
decreases the efficacy of current treatments against bacterial and fungal infections. 
Not only do we see this rise of MDR in bacteria and fungi, but also in one of the most 
fatal diseases around the world, known as cancer.  In addition, the immune systems 
of cancer patients are compromised due to the non-selective nature of 
chemotherapeutic drugs subsequently increasing the risk of cancer patients 
contracting dangerous pathogenic infections 3. Therefore, the discovery of alternative 
bactericidal and chemotherapeutic agents which limits resistance development and 
minimises damage to healthy tissue is critical. A group of peptides, known as 
antimicrobial peptides (AMPs), have received a great deal of attention in this regard. 
AMPs are generally cationic and exhibit broad spectrum of activity towards fungi, 
bacteria and cancer cells 4,5. It has been shown by various studies that the cationic 
nature of AMPs promotes electrostatic interaction between the peptides and the 
negatively charged cell membranes/membrane patches of target cells, while their 
amphipathicity leads to disruption of the cell membrane function, increased 
permeability and cell lysis 6-7. Various membranolytic mechanisms of actions have 
been proposed for AMPs such as the carpet model 8, barrel stave model 9, toroidal-
pore model 7,10,11 and detergent type membrane lytic mechanism 12. The rapid 
membranolytic activity of AMPs decreases the potential of resistance development 
Stellenbosch University  https://scholar.sun.ac.za
2-2 
 
towards these peptides which make them a very attractive alternative to conventional 
antibacterial and anticancer drugs 13,14.  
In the present study the biophysical and biological activity of a group of AMPs, 
known as the tyrocidines, will be investigated. The tyrocidines are produced by soil 
bacterium Brevibacillus parabrevis, as part of the tyrothricin complex which consists 
of the cationic cyclodecapeptides, known as the tyrocidines, and the neutral linear 
pentadecapeptides, known as the gramicidins 15. The tyrocidines were first 
discovered in 1939 by Dubos 16 and later 19 related cyclodecapeptides in tyrothricin 
(Table 2.1) were identified and characterised by Tang et al. 17.  The primary structure 
of these cyclodecapeptides is conserved with variations generally at residues three 
and four (aromatic dipeptide unit), residue seven and residue nine. The tyrocidine 
analogues are formed by substitution of position seven with tyrosine (Tyr), while 
substitution with phenylalanine (Phe) or tryptophan (Trp) give rise to the 
phenycidines (Phcs) and tryptocidines (Tpcs), respectively 17-18. 
Due to the highly conserved primary structure of the tyrocidines and analogues, the 
isolation of single peptides from the crude peptide extracts becomes a tedious and 
difficult task 17. Our group (BIOPEPTM Peptide Group) have developed a large-scale 
method to produce and extract the complex mixture of tyrocidines and analogues. 
The method involves the supplementation of the culture broth of Br. parabrevis with 
specific amino acids to enrich the produced peptide complex with specific peptides of 
interest 19. To investigate the biophysical and biological activity of the peptides of 
interest, purities of 90 % or higher are required, as determined by ultraperformance 
liquid chromatography (UPLC) linked to high resolution electrospray ionisation mass 
spectrometry (ESI-MS) (abbreviated as UPLC-MS). To obtain such high chemical 
purity, reverse-phase high performance liquid chromatography (RP-HPLC) is 
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generally utilised in peptide purification as it is an efficient technique to separate and 
purify peptides according to their physiochemical properties. 
Table 2.1  Summary of the tyrocidines and analogues present in tyrothricin extract from Br. 
parabrevis.  




Tyrocidine A analogues (Ff) 
Phenycidine Ad PhcA or FA Cyclo-(fPFfNQFVOL) 1253.6597 
Phenycidine A1d PhcA1 or FA1 Cyclo-(fPFfNQFVKL) 1267.6753 
Tyrocidine A TrcA or YA Cyclo-(fPFfNQYVOL) 1269.6546 
Tyrocidine A1 TrcA1 or YA1 Cyclo-(fPFfNQYVKL) 1283.6703 
Tryptocidine A TpcA or WA Cyclo-(fPFfNQWVOL) 1292.6706 
Tryptocidine A1 TpcA1 or WA1 Cyclo-(fPFfNQWVKL) 1306.6862 
Tyrocidine B analogues (Wf) 
Tyrocidine B/B’ TrcB/B’ or YB/B’ Cyclo-(fP(Wf/Fw)NQYVOL) 1308.6655 
Tyrocidine B1/B1‘ TrcB1/B1‘or YB1/B1’ Cyclo-(fP(Wf/Fw)NQYVKL) 1322.6812 
Tryptocidine B/B’ d TpcB/B’ or WB/B’ Cyclo-(fP(Wf/Fw)NQWVOL) 1331.6815 
Tryptocidine B1d/B1‘d TpcB1/B1‘ or WB1/B1’ Cyclo-(fP(Wf/Fw)NQWVKL) 1345.6971 
Tyrocidine C analogues (Ww) 
Tyrocidine C TrcC or YC Cyclo-(fPWwNQYVOL) 1347.6764 
Tyrocidine C1 TrcC1 or YC1 Cyclo-(fPWwNQYVKL) 1361.6921 
Tryptocidine C TpcC or WC Cyclo-(fPWwNQWVOL) 1370.6924 
Tryptocidine C1d TpcC1 or WC1 Cyclo-(fPWwNQWVKL) 1384.7080 
a Abbreviations refer to the amino acid residue at position seven i.e. phenylalanine (Phc/F, tyrosine (Trc/Y) and 
tryptophan (Tpc/W).  
b One letter abbreviations representing the amino acids sequences as used by Tang et al. 17 with O representing 
Ornithine and lower case letters representing the D-amino acids. 
c Theoretical monoisotopic Mr calculated as the sum of the molecular masses of amino acid residues of each 
peptide.     
d Low amounts detected 
 
The hydrophobicity of the peptides is exploited during RP-HPLC, allowing separation 
based on the interaction of the peptides with the hydrophobic stationary and 
hydrophilic mobile phase of the system.  Eyéghé-Bickong 20 optimised a C18 HPLC 
method for the purification of the tyrocidines and their analogues which involved the 
investigation of the influence of the solvent composition, gradient profile and column 
temperature on the resolution of the RP-HPLC.  Optimal resolution was achieved 
with a non-linear gradient, column temperature set at 35 °C and solvent A and B 
consisting of 0.1 % (v/v) trifluoroacetic acid (TFA) in water and 10 % solvent A in 100 
% acetonitrile (ACN) (v/v), respectively 20.  Although an optimised method has been 
developed, the isolation of single peptides remains a daunting task due to minimal 
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structural and chemical differences 17, as well as their tendency to form homo- and 
hetero-oligomeric structures 21, 22.  
After purification with semi-preparative RP-HPLC, the peptide identity and purity 
must be determined by UPLC-MS, a powerful analytical technique in which high 
resolution and sensitivity are combined.  ESI-MS is an analytical technique in which 
high accuracy molar mass of  a compound (e.g. a peptide) can be determined. After 
the identification of the peptide identity and integrity with ESI-MS, the chemical purity 
can be determined with UPLC-MS from the resolved peaks in the resultant positive 
ion chromatogram 22, 23.  
The aim of the study was to produce, extract and purify selected peptides from the 
tyrothricin complex extracted from bacterial producer cultures. The peptides that 
were selected to purify and characterise in the present project were TrcA, TrcB, TrcC 
and TpcC. The TrcA, TrcB and TpcC is usually extracted and purified from amino 
acid supplemented culture broths of Br. parabrevis. Whereas, high purity TrcC is 
usually more easily obtained from commercially available tyrothricin complex. The 
commercially available tyrothricin was originally obtained from Sigma-Aldrich 
(SteinHeim, Germany), but this product has been discontinued. Therefore, it would 
be ideal if TrcC can also be extracted and purified from supplemented Br. parabrevis 
culture broth, thereby ensuring cost and time effective future purification of TrcA, 
TrcB and TrcC. The purification of selected peptides by the C18 HPLC method of 
Eyéghé-Bickong 20 and the optimisation of a C8 RP-HPLC method is described in 
this chapter. The C8 RP-HPLC method is a potential alternative method for the 
purification of the tyrocidines and analogues, including TrcC from the crude peptide 
extracts of supplemented Br. parabrevis culture broths.   
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2.2  RESEARCH MATERIALS 
The producer strain, Br. parabrevis ATCC 8185, used for tyrothricin complex 
production from which the single tyrocidine peptides were purified, was obtained 
from the American Type Culture Collections (Manassas, VA, USA). The tryptic soy 
broth (TSB), agar, D-glucose, tryptone, monopotassium phosphate (KH2PO4), 
magnesium sulphate (MgSO4), calcium chloride (CaCl2), ferric sulphate (FeSO4), 
manganese sulphate (MnSO4), sodium chloride (NaCl), ethanol (EtOH), diethyl ether 
and acetone were supplied by Merck (Darmstadt, Germany). Sigma-Aldrich (St 
Louis, USA) supplied methanol (MeOH), trifluoroacetic acid (TFA, >98%), potassium 
chloride (KCl), phosphorous pentoxide and commercial tyrothricin extract. Activated 
carbon and the L- amino acids (L-tryptophan and L-phenylalanine) were purchased 
from Lurgi (Frankfurt, Germany) and Sigma-Aldrich (SteinHeim, Germany), 
respectively. Mixed cellulose syringe filters (0.22 µm) were purchased from Merck-
Millipore (Massachusetts, USA). Becton Dickson Labware (Lincoln Park, USA) and 
Lasec (Cape Town, South Africa) supplied Falcon® tubes and petri dishes, 
respectively. The acetonitrile (ACN, HPLC-grade, far UV cut-off) was purchased from 
Romil Ltd (Cambridge, United Kingdom). Analytical grade water was prepared by 
filtering water from a reverse osmosis plant through a Millipore-Q® water purification 
system (Milford, USA).  The Nova-Pak HR C18 RP-HPLC semi-preparative column (6 
µm particle size, 300 mm x 7.8 mm), C18 Nova-Pak® analytical RP-HPLC column (5 
μm particle size, 150 mm x 3.9 mm) and Acquity HSS T3 (2.1 × 150 mm; 1.8 μm 
particle size) UPLC column were purchased from Waters (Milford, USA). The 
Spherisorb® C8 column (5 m particle size, 250 mm X 3.2 mm) was purchased from 
PhaseSep Pty Ltd (Victoria, Australia).  




2.3.1 Production of the tyrocidines and analogues.  
The producer strain (Br. parabrevis ATCC 8185) was streaked out on TSB agar 
plates (30 g/L TSB and 1.5 % agar) using standard sterile techniques and incubated 
for 24 hours at 37 °C. Subsequently, overnight cultures were prepared by inoculating 
20 mL of TSB with a single colony from the pre-culture agar plates followed by 
incubation for 24 hours at 37 °C on a shaker set at 150 rpm.  Culture media were 
supplemented  with 10 mM Trp or 20 mM Phe and peptide production by Br. 
parabrevis proceeded as described by Vosloo et al.19, except that incubation at 37 
°C proceeded for 13 days. 
2.3.2 Extraction of the tyrocidines and analogues 
The extraction methodologies that were used to isolate the individual peptides were 
developed by the BIOPEP Peptide Group (Stellenbosch, South Africa) and are 
protected under  a non-disclosure agreement. In brief, the supplemented Br. 
parabrevis cultures were subjected to acidification steps and centrifuged at 10 621 
xg for 10 minutes to obtain wet biomass. Subsequently, culture pellets were 
subjected to extraction and precipitation steps to obtain crude peptide extracts. This 
optimised method to produce crude extracts containing 40-85 % (m/m) peptide is 
protected under a non-disclosure agreement with BIOPEPTM, Stellenbosch 
University. The linear gramicidins were removed by several washing steps with 
diethyl ether: acetone (1:1 v/v) with intermittent centrifugation (5 minutes at 3030 xg) 
steps. The crude peptide extracts were dried under N2 gas flow, resuspended in 50 
% ACN in water, transferred to pyrolised and analytically weighed 20 mL vials 
followed by lyophilisation. Commercial tyrothricin was also subjected to a few organic 
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extraction steps with diethyl ether: acetone (1:1 v/v) and centrifuged intermittently for 
5 minutes at 3030 xg  to remove linear gramicidins and to purify tyrocidine mixture 
(Trcmix).  
2.3.3 Semi-preparative HPLC purification of the tyrocidines and 
analogues  
Tyrocidines were purified from Trcmix (extracted from commercial tyrothricin) and 
the crude peptide extracts from supplemented Br. parabrevis culture broths. The 
crude peptide extracts and purified Trcmix were made up to a concentration of 10 
mg/mL and 5 mg/mL, respectively, in 50% ACN in water and subjected to semi- 
preparative RP-HPLC purification as previously described by Eyéghé-Bickong 20 and 
Rautenbach et al. 24 . Volumes of 100 µL were injected onto a Nova-Pak HR C18 
semi-preparative HPLC column. The HPLC system consisted of a Waters 6000A 
pump, Waters 510 pump and a Waters 440 absorbance detector (set at 254 nm) and 
was controlled by Millenium32 software (Waters, Milford, USA). A non-linear gradient 
(Table 2.2) at a flow rate of 3 mL/min and column temperature set at 35 °C was used 
to achieve elution with solvent A consisting of 0.1 % (v/v) TFA in water and solvent B 
of 10 % A in 100 % ACN (v/v). The fractions collected were transferred to weighed 
and pyrolised 20 mL vials, lyophilised and stored at room temperature until 
characterization with UPLC-MS analysis. 
Table 2.2 The non-linear gradient program used for the semi-preparative HPLC purification 
of the tyrocidines and analogues  
Minutes % Eluent A % Eluent B Curve* 
0.00 50 50 - 
0.50 50 50 6 
23.0 20 80 5 
24.0 0 100 6 
26.0 0 100 6 
30.0 50 50 6 
35.0 50 50 6 
*6 depicts linear and 5 a non-linear concave curve (WatersTM) 
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2.3.4 Characterisation of crude peptide extracts and single purified 
peptides with ESI-MS and UPLC-MS analysis 
Peptide samples were resuspended in 50% ACN in water to concentrations 1000 
µg/mL (for crude peptide extracts) and 250 µg/mL (for pure peptides samples/HPLC 
fractions). The samples were subsequently centrifuged at 10 621 xg for 10 min to 
remove any particulate material. Volumes of 2 µL (for direct MS analysis) and 3 µL 
(UPLC separation) of the samples were injected into the UPLC-MS system. The 
system consisted of a Waters Acquity UPLC® and a Waters Synapt G2 quadrupole 
time-of-flight (TOF) mass spectrometer and a photo diode array detector. UPLC 
separation was achieved with a Waters Acquity UPLC® HSS T3 column (2.1 × 150 
mm; 1.8 μm particle size) and a minimum and maximum column temperature of 45 
°C and 60 °C, respectively. Elution of peptides was achieved with a linear gradient 
program (Table 2.3) set at a flow rate of 0.3 mL/min with solvent A and B consisting 
of 1 % formic acid (v/v) in water and 100 % ACN containing 1 % formic acid (v/v), 
respectively. For the analysis of the crude peptide extracts and HPLC fractions, a Z-
spray electrospray ionization source in the positive mode was used and data 
acquisition achieved by scanning the mass/charge (m/z) ratio range of 300 to 2000. 
Waters MassLynx V4.1 software (Milford, USA) was used for analysis and 
characterisation of all samples.  
Table 2.3 The linear gradient program used during UPLC-MS analysis of the crude peptide 
extracts and the respective purified tyrocidines and analogues 
Minutes % Eluent A % Eluent B Curve* 
0.00 0 0 6 
0.50 100 0 6 
1.00 70 30 6 
10.0 40 60 6 
15.0 20 80 6 
15.1 0 0 6 
18.0 100 0 6 
*6 depicts linear curve (WatersTM) 
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2.3.5 The optimisation of a C8 HPLC method for the purification of 
the tyrocidines from crude peptide extract  
Trcmix was dissolved in 50 % ACN in water to a concentration of 2 mg/mL. The 
sample solution was centrifuged at 10 621 xg for 10 minutes to remove any 
particulate material. A volume of 80 µL (160 µg) of sample solution was injected onto 
a C18 Nova-Pak® analytical RP-HPLC column (5 μm particle size, 150 mm x 3.9 
mm) and a Spherisorb® C8 RP-HPLC column (5 µm particle size, 250 mm X 3.2 
mm). Three different HPLC non-linear gradient programs (Table 2.4-2.6, program A-
C) were tested with protocol A being the analytical C18 HPLC linear gradient program 
optimised by Eyéghé-Bickong 20 which is the general program used for the 
purification of tyrocidines and analogues by our group. Program A was also tested at 
different temperatures (25 °C and 35 °C). The C8 HPLC program D (Table 2.7) is a 
combination of program B and C. The resolution (Rs) was the HPLC parameter used 
to compare the separation of peaks achieved with the different HPLC programs, 
columns and temperatures.  The resolution (Rs) is the quantitative measure of the 
separation of two peaks (n and n+1) in terms of their retention times (tR) and average 




   2.1 
The partially purified Phe supplemented crude peptide extract (160 µg) was 
subjected to the optimised C8 HPLC using program D and fractions manually 
collected to validate this purification method.  Fractions were transferred to pyrolised 
analytically weighed vials and analysed with ESI-MS and UPLC-MS as described 
above (Section 2.3.4).   
 
Stellenbosch University  https://scholar.sun.ac.za
2-10 
 
Table 2.4 The C8 HPLC gradient program A 
Minutes Flow 
mL/min 
% Eluent A % Eluent B Curve 
0.00 1.0 50 50 - 
0.50 1.0 50 50 6 
23.0 1.0 20 80 5 
24.0 1.0 0 100 6 
26.0 1.0 0 100 6 
30.0 1.0 50 50 6 
35.0 1.0 50 50 6 
 
Table 2.5 The C8 HPLC gradient program B 
Minutes Flow 
mL/min 
% Eluent A % Eluent B Curve 
0.00 1.0 40 60 - 
0.50 1.0 40 60 6 
23.0 1.0 20 80 5 
24.0 1.0 0 100 6 
26.0 1.0 0 100 6 
30.0 1.0 50 50 6 
35.0 1.0 50 50 6 
 
Table 2.6 The C8 HPLC gradient program C 
Minutes Flow 
mL/min 
% Eluent A % Eluent B Curve 
0.00 1.5 50 50 - 
0.50 1.5 50 50 6 
23.0 1.5 20 80 5 
24.0 1.5 0 100 6 
26.0 1.5 0 100 6 
30.0 1.5 50 50 6 
35.0 1.5 50 50 6 
 
Table 2.7 The optimised C8 HPLC program D 
Minutes Flow 
mL/min 
% Eluent A % Eluent B Curve 
0.00 1.5 40 60 - 
0.50 1.5 40 60 6 
23.0 1.5 20 80 5 
24.0 1.5 0 100 6 
26.0 1.5 0 100 6 
30.0 1.5 50 50 6 
35.0 1.5 50 50 6 
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2.4 RESULTS AND DISCUSSION 
2.4.1 The purification of tyrocidines from the culture broth of Br. 
parabrevis.  
The tyrothricin complex, produced by the soil bacterium Br. parabrevis, consists of a 
basic fraction containing cyclic decapeptides known as the tyrocidines and a neutral 
fraction containing linear peptides known as the gramicidins 16,17. Removal of the 
linear gramicidins provides a complex mixture of tyrocidines and analogues that 
differ from one another with only one or two amino acid residues.  The highly 
conserved structure of the tyrocidines and analogues make the purification of single 
peptides a tedious and difficult task 17. To simplify the purification process of the 
peptides, the culture medium of Br. parabrevis ATCC 8185 was supplemented with 
Phe and Trp as described by Vosloo et al. 19 to produce increased amounts of TrcA 
and TpcC, respectively. After 13 days of incubation the supplemented cultures were 
subjected to various extraction and precipitation steps to obtain a crude extract with 
>50% peptide per dry weight. UPLC-MS analysis of the Phe supplemented crude 
peptide extract revealed that TrcA (Rt = 10.84) and TrcB (Rt = 9.72) are the peptides 
contributing to the two major peaks (Figure 2.1 A). Furthermore, it is evident from the 
ESI-MS spectra that all six major tyrocidines, TrcA (1269.6403), TrcA1 (1283.6618), 
TrcB (1308.6541), TrcB1 (1322.6652), TrcC (1347.6731) and TrcC1 (1361.6806) are 
present in the extract (Figure 2.1  C and E). The largest signal intensities are seen 
for TrcA and TrcB thereby confirming that higher amounts were produced and 
extracted for these peptides. Some of the tyrocidine analogues, such as PhcA 
(1253.6557), TpcA (1292.6604) and TpcB (1331.6662) are also present in smaller 
amounts indicated by lower signal intensities.  




Figure 2.1 The UPLC-MS and ESI-MS analysis of the Phe and Trp supplemented crude 
peptide extracts. The UPLC chromatograms of A) the Phe supplemented and B) Trp 
supplemented crude peptide extract shows the peptide retention times above their 
representative peaks in minutes. The ESI-MS spectra of C) Phe supplemented and D) Trp 
supplemented crude extracts after MaxEnt 3 analysis over m/z 200-6000 range shows the 
monomeric to tetrameric species of the tyrocidines. E) The enlarged ESI-MS spectrum of the 
monomeric peptides present in the Phe supplemented extract. F) The enlarged ESI-MS 
spectrum of the monomeric peptides present in the Trp supplemented extract.  
The tendency of these tyrocidines peptides to oligomerise is evident, with formation 
of dimers, trimers and tetramers clearly shown in the ESI-MS spectrum (Figure 2.1 
C).  The UPLC-MS analysis of the Trp supplemented crude peptide extract revealed 
one major peak, consisting of TpcC (Rt = 9.68), and two minor peaks, consisting of 
TrcC (Rt = 8.96) and TpcB (R t= 10.38) (Figure 2.1 B). The ESI-MS spectra indicated 
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and confirmed that TpcC (1370.6849) was the analogue produced and extracted in 
the largest amounts (Figure 2.1 D and F).   
The supplementation of the Br. parabrevis culture broth with Trp and Phe both 
resulted in increased production of the peptides and analogues of interests, thereby 
simplifying the purification methodology. After partial purification of the tyrocidine 
peptides and analogues, both supplemented crude peptide extracts were subjected 
to semi-preparative RP-HPLC and several fractions were collected subsequently. In 
the case of the Phe supplemented crude peptide extract, a total of five fractions were 
collected between 8 and 19 minutes (Figure 2.2).  
 
Figure 2.2 The semi-preparative RP-HPLC chromatogram of the Phe supplemented crude 
peptide extract. The five fractions that were collected between 8 and 19 minutes are shown 
above the chromatogram. 
The peptide composition of each collected fraction was determined by ESI-MS and 
are summarised in Table 2.8. The tendency of the peptides to form sodium (Na+) and 
potassium (K+) adducts are observable from the ESI-MS analysis with TrcA (fraction 
3-5) and TrcB (fraction 2) forming both cation adducts. 
 1             2                 3         4  
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Table 2.8 Summary of the peptide composition of each fraction collected during RP-HPLC of 
the Phe supplemented crude peptide extract. The enlarged ESI-MS spectrum of each 
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a Monoisotopic Mr as determined from the individual ESI-MS spectra.  
b Theoretical monoisotopic Mr calculated as the sum of the molecular weights of amino acid residues of each 
peptide. 
  
From the initial ESI-MS analysis (Table 2.8) it was obvious that fraction two and 
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MS. The UPLC-MS analysis revealed that fraction three contained >90 % pure TrcA 
(TrcA1 contamination) and fraction two contained >90 % pure TrcB (TpcC 
contamination) (Figure 2.3 A-B, Figure 2.4 A-B).  
 
Figure 2.3 The UPLC and ESI-MS analysis of purified TrcA (93.7 % pure). A) The UPLC 
chromatogram of purified TrcA (250 µg/mL) showing the retention time in min and TrcA1 
peptide contamination. B) The ESI-MS spectrum of purified TrcA showing the Mr of the 
monomeric species and TrcA1 contamination present in the fraction.  The presence of the 
Na+ and K+ adducts in the fraction  are also shown. 
A second preparation of pure TrcB was achieved in a similar manner and the UPLC-
MS analysis is shown in Figure 2.4 C-D. The analytical weight of the pure TrcA (93.7 
% pure) was 8.96 mg, whereas the analytical weights for the two TrcB preparations 
(94.0 % pure and 95.8 % pure) were and 4.51 mg and 0.90 mg, respectively.  
In a similar manner, the Trp supplemented crude peptide extract was subjected to 
semi-preparative RP-HPLC. A total of six fractions were collected between 11 and 
16 minutes (Figure 2.5). The peptide composition of each collected fraction was 






































Figure 2.4 The UPLC and ESI-MS analysis of purified two preparations of pure TrcB A) The 
UPLC chromatogram of the first preparation of purified TrcB (94.0 % pure) (250 µg/mL) 
showing the retention time in minutes B) The ESI-MS spectrum of the first preparation of 
purified TrcB showing the Mr of the monomeric species and TrcB1 contamination present in 
the fraction. C) The UPLC chromatogram of the second preparation of purified TrcB (95.8 % 
pure) (250 µg/mL) showing the retention time in minutes. The retention time of TrcB differs 
slightly from the first preparation because a new UPLC column was used.  D) The ESI-MS 
spectrum of the second preparation of purified TrcB showing the Mr of the monomeric 







































































Figure 2.5 The semi-preparative RP-HPLC chromatogram of the Trp supplemented crude 
peptide extract.  The six fractions that were collected between 11 and 16 minutes are shown 
above the chromatogram.  
Similar to the tyrocidines, the TpcC analogues also have the tendency to form Na+ 
and K+ adducts with the presence of Na+ adducts being more prevalent than the K+ 
adducts.   From the initial ESI-MS analysis (Table 2.9) it was evident that fraction 
three to five had the highest purity of peptide and were subsequently subjected to 
UPLC-MS. The UPLC-MS analysis (data not shown) confirmed that fraction three to 
five contained TpcC with purities of > 90 %, therefore these fractions were pooled 
together. The purity of the pooled TpcC fractions was determined as 94.5 % pure 
with contamination due to TpcC1 (Figure 2.7 A-B).  A second TpcC preparation was 
achieved in a similar manner and UPLC-MS analysis is shown in Figure2.7 C-D. The 
purity of the second TpcC preparation was determined as 93.1 %.  The analytical 
weight of the two preparations of pure TpcC (94.5 % pure and 93.1 % pure) was 
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Table 2.9 Summary of the peptide composition of each fraction collected during RP-HPLC of 
the Trp supplemented crude peptide extract. The enlarged ESI-MS spectrum of each fraction 
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a Monoisotopic Mr as seen in ESI-MS spectrum. 














































































































Figure 2.6 The UPLC and ESI-MS analysis of two preparations of pure TpcC. A) The UPLC 
chromatogram of the first preparation of purified TpcC (94.5 % pure) (250 µg/mL) showing 
the retention time in minutes and TrcC and TpcC1 peptide contamination. B) The ESI-MS 
spectrum of the first preparation of purified TpcC showing the Mr of the monomeric species 
present in the pooled fraction. C) The UPLC chromatogram of the second preparation of 
purified TpcC (93.1 % pure) (250 µg/mL) showing the retention time in minutes and TpcC1 
contamination. The retention time of TpcC differs slightly from the first preparation because a 
new UPLC column was used. D) The ESI-MS spectrum of the second preparation of purified 
TpcC showing the Mr of the monomeric species present in the pooled fraction. 
2.4.2 The purification of tyrocidine mix and TrcC from commercial 
tyrothricin 
Commercial tyrothricin complex was used to purify Trcmix and TrcC. The 
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and acetone to remove the linear gramicidins. The masses of linear gramicidins 
range from 1882.0862 to 1896.1018. UPLC-ESI-MS was used to analyse the 
extracted Trcmix and revealed that the six major tyrocidines (TrcA, TrcA1, TrcB, 
TrcB1, TrcC and TrcC1) and their tryptocidine (TpcA, TpcA1, TpcB1, TpcC and TpcC1) 
and phenicidine (PhcA, PhcA1 and PhcC) analogues were present and that the linear 
gramicidins were successfully removed (Figure 2.7 A-B).  
 
Figure 2.7 The UPLC-MS and ESI-MS analysis of the Trcmix purified from commercial 
tyrothricin complex. A) The enlarged UPLC chromatogram showing the retention times of the 
six major tyrocidines above their representative peaks in minutes. B) The enlarged ESI-MS 
spectrum of the monomeric peptides present in Trcmix.  
The purified Trcmix was then subjected to semi-preparative RP-HPLC to purify TrcC. 
The HPLC chromatogram revealed three major peaks with the first peak having a 
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(Figure 2.8). A summary of the peptide composition and ESI-MS spectra of the five 
fractions collected are shown in Table 2.10. The UPLC-MS analysis (data not 
shown) indicated that fraction two and three contained the highest purity of TrcC and 
these fractions were pooled. The purity of the TrcC after pooling of fractions two and 
three was determined with UPLC-MS analysis and was calculated as 96.4 % pure 
(Figure 2.9 A-B). A second preparation of pure TrcC was achieved in a similar 
manner and the UPLC-MS analysis is shown in Figure 2.9 C-D. The analytical 
weights of the two preparations of pure TrcC  (96.4 % pure and 99.5 % pure) was 
determined as 3.05 mg and 3.36 mg, respectively.  
 
 
Figure 2.8 The semi-preparative RP-HPLC chromatogram of Trcmix.  The five fractions that 
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Table 2.10 Summary of the peptide composition of each fraction collected during RP-HPLC 
of the purified commercial Trcmix extract. The enlarged ESI-MS spectrum of each fraction is 

















































a Monoisotopic Mr as determined from the individual ESI-MS spectra. 
b Theoretical monoisotopic Mr calculated as the sum of the molecular weights of amino acid residues of each 
peptide.    












































































Figure 2.9 The UPLC and ESI-MS analysis of the two preparation of pure TrcC. A) The 
UPLC chromatogram of the first preparation of purified TrcC (96.4 % pure) (250 µg/mL) 
showing the retention time in min. B) The ESI-MS spectrum of the first preparation of purified 
TrcC showing the Mr of the monomeric species and TrcC1 contamination present in the 
pooled fraction. C) The UPLC chromatogram of the second preparation of purified TrcC 
(99.5 % pure) (250 µg/mL) showing the retention time in minutes. The retention time of TrcC 
differs slightly from the first preparation because a newer UPLC column was used.   D) The 
ESI-MS spectrum of the second preparation of purified TrcC showing the Mr of the 
monomeric species and the Na+ adduct present in the pooled fraction. 
The purification of four peptides was successful and all the peptides were more than 
93 % pure. A summary of the peptides purified with the standard C18 HPLC protocol 
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percentage yield of each peptide from extracts that the purification of TrcB is the 
least time and cost efficient. The separation of TrcB from TrcB’ is nearly impossible 
with C18 HPLC column because the two peptides consists of the same amino acid 
composition and sequence except that the amino acid residues in aromatic dipeptide 
unit are switched around (Wf to Fw). The inability of the C18 HPLC column to 
separate TrcB’ from TrcB is the reason that it is more difficult to purify TrcB than 
TrcA or TrcC.  
Table 2.11 A summary of the selected and purified peptides for the present study. The 
determined purities and total amount and percentage yield of each peptide from the extract 
are tabulated.   













Phe supplemented crude extract 











Commercial Trcmix extract 











Trp supplemented crude extract 







a The purity of the specific peptide achieved with the first preparation. 
b The purity of the specific peptide achieved with the second preparation.  
c The % mass yield determined from crude culture extract. 
 
2.4.3 A C8 HPLC purification method development  
The six major tyrocidines found in the tyrothricin complex all differ from each other 
with only one amino acid residue. Subsequently the isolation of these peptides is 
difficult from such a complex mixture, especially separating Lys and Orn analogues 
differing only from each other in CH2 group, for example TrcA/A1 and TrcC/C1, 
combined with the problem in the group of B-analogues, TrcB/B’/B1/B1’, where the 
aromatic dipeptide can be either Wf or Fw. The purification is further complicated by 
the high propensity of the tyrocidines to form homo- and hetero-oligomers leading to 
fronting peak shapes as can been seen in Figure 2.2, 2.5 and 2.8. The current 
purification method consists of RP-HPLC using a C18 semi-preparative column and 
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the previously described non-linear gradient program which has been optimised by 
Rautenbach et al. 24 and Eyéghé-Bickong 20 for the purification of the tyrocidines and 
analogues. It was shown by Eyéghé-Bickong 20 by simply adapting the non-linear 
gradient program did not result in vastly improved peak shapes and separation of 
TrcA1, TrcB1 and TrcC1 from TrcA, TrcB and TrcC, respectively. However, 
application of this optimised non-linear gradient program (protocol A, Table 2.4) to an 
alternative RP-HPLC column could potentially improve the separation of the 
tyrocidines. Subsequently, Trcmix was subjected to RP-HPLC on an analytical C18 
and C8 column while elution was achieved with program A at 35 °C and 25 °C 
(Figure 2.10 A-C). It is evident from the number of peaks present in the C8 HPLC 
chromatogram (Figure 2.10 B) that more tyrocidine peptides (specifically the TrcB1, 
TrcB1’, TrcB and TrcB’) were separated to purer fractions than with the C18 column 
(Figure 2.10  A). However, the retention times of the major peaks (TrcC species, 
TrcB species and TrcA species) were increased with 10 minutes (compare Figure 
2.10  A and B) with the C8 column. The decrease of temperature from 35 °C to 25 °C 
resulted in a further ±1.0 minute peak retention time increase, however, the peak 
shapes of the TrcB and TrcA species were slightly improved (Figure 2.10 C). The 
peak resolution between TrcC and TrcC1, TrcB1 and TrcB, and TrcB and TrcB’ 
produced by the different columns, temperatures and elution programs are 
summarised in Table 2.12. The C8 column improved the resolution between TrcC 
and TrcC1 from 0.5 to 1.19 with elution program A and a column temperature set at 
25 °C.   The effect of different solvent flow rates and solvent composition on the peak 
retention times and resolution using the C8 column at 25 °C was investigated. 
Program D, which is the combination of a higher flow rate (1.5 mL/min) and a solvent 
composition of 40 % A to 60 % B, resulted in the lowest peak retention times with 
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elution of all peaks before 21 minutes. The resolution between TrcC and TrcC1 was 
not significantly affected by the alternative solvent ratios (program B) and higher flow 
rate (program C). However, the combined change (program D) increased the 
resolution from 1.19 to 1.28. The alternative solvent ratios (program B) and higher 
flow rate (program C) both increased the resolution of TrcB1 and TrcB significantly 
(from 0.86 to 0.96 and 1.00, respectively), whereas the combined change (program 
D) had no marked influence. The resolution between TrcB and TrcB’ was not 
significantly affected by any of the different elution programs (program B-D) with 
resolution differences of less than 0.05. The total resolution (sum of the resolutions 
of TrcC and TrcC1, TrcB1 and TrcB, and TrcB and TrcB’) was improved most by the 
combination of higher flow rate and alternative solvent composition (program D), with 
the higher flow rate contributing the most to this total resolution improvement. Taken 
together, elution program D produces the best separation and lowest retention times 
of the major peaks. The purification of the tyrocidines with a C8 column and elution 
program D at 25 °C was validated by subjecting both the commercial Trcmix and 
Phe supplemented crude peptide extract to RP-HPLC (Figure 2.11 A and Figure 
2.12 A). The peak resolution of the major peaks of the Phe supplemented crude 
peptide extract was also determined (Table 2.12). The differences observed in the 
peak resolution between TrcC1 and TrcC (Rs = 1.63), TrcB1 and TrcB (Rs = 1.39) and 
TrcB and TrcB’ (Rs = 0.32) may be due to the differences in the amounts of the 
peptides present in the crude peptide extract compared to commercial Trcmix (Table 
2.12). The total resolution on the C8 column for the Phe-supplemented extract was 
determined as 3.34 which is 0.57 units higher than that of the total resolution 
determined for Trcmix (Table 2.12). A total of 10 fractions were manually collected 
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between 8-21 minutes and 7-28 minutes for commercial Trcmix (Figure 2.11 A) and 
Phe supplemented crude peptide extract (Figure 2.12Figure 2.12 A), respectively.  
 
Figure 2.10 The RP-HPLC chromatograms of Trcmix (160 µg) developed on different 
columns, temperatures and elution programs: A) program A, C18 column at 35 °C; B) 
program A, C8 column at 35 °C; C) program A, C8 column at 25 °C. D) HPLC chromatogram 
achieved with program B, C8 column at 25 °C; E) program C, C8 column at 25 °C; F) HPLC 
chromatogram achieved with program D, C8 column at 25 °C. For simplicity the letters ‘y’ 
and ‘w’ were used in the place of Trc and Tpc, respectively, to label the peaks, e.g. TrcC 
































































































The UPLC-MS analysis of these fractions collected revealed that all of the major 
tyrocidines (TrcC1, TrcC, TrcB1, TrcB, TrcA1 and TrcA) were isolated from the 
commercial Trcmix (Figure 2.11 B), whereas only five (TrcC1, TrcC, TrcB1, TrcB and 
TrcA) of the six major tyrocidines were isolated from the Phe supplemented crude 
peptide extract (Figure 2.12 B). The failure to isolate TrcA1 from the Phe 
supplemented crude extract may be due to the supplementation only promoting 
increased production of TrcA and not TrcA1. Interestingly, different peptides were 
isolated in fraction six for Trcmix (isolation of TpcC, Figure 2.11 B) and Phe 
supplemented crude extract (isolation of TrcB’, Figure 2.12 B), even though fraction 
6 represents the same RP-HPLC peak collected for both peptide extracts (Figure 
2.11 A and Figure 2.12 A)  
Table 2.12 A summary of the resolutions achieved with the different elution programs, HPLC 












A C18 35 0.5 0 0 0.5 
A C8 35 1.06 -a -a - 
A C8 25 1.19 0.86 0.47 2.52 
B C8 25 1.20 0.96 0.42 2.56 
C C8 25 1.21 1.00 0.44 2.66 
D C8 25 1.28 1.03 0.46 2.77 
Dc C8 25 1.63 1.39 0.32 3.34 
a Peak shapes prevented Rs determination. 
b The total resolution is the sum of the resolutions achieved between TrcC1 and TrcC, TrcB1 and TrcB, and TrcB 
and TrcB’. 
c Resolution determined from the C8 HPLC chromatogram produced by elution program D at 25 °C of the 
tyrocidines present in Phe supplemented crude extract 




Figure 2.11 The analytical C8 RP-HPLC chromatogram of the commercial Trcmix extract 
(160 µg) and UPLC-MS analysis of the fractions (F1-10) collected. A) The analytical C8 RP-
HPLC separation of the major tyrocidines showing the fractions collected above the 
chromatogram. B) Left: The UPLC chromatogram of each fraction (F1-10) showing the major 
peaks in black, labelled with the respective peptides. Right: The ESI-MS spectra showing the 
singly charged monomeric species [M+H]+ of the peptide present in the major peak (in black) 
















































































































Figure 2.12 The analytical C8 RP-HPLC chromatogram of the Phe supplemented crude 
peptide extract (160 µg) and UPLC-MS analysis of the fractions (F1-10) collected. A) The 
analytical C8 RP-HPLC separation of the major tyrocidines showing the fractions collected 
above the chromatogram. B) Left: The UPLC chromatogram of each fraction (F1-10) 
showing the major peaks in black, labelled with the respective peptides. Right: The enlarged 
ESI-MS spectra showing the singly charged monomeric species [M+H]+ of the peptide 
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A summary the peptides detected in each C8 HPLC fraction of the commercial 
Trcmix and Phe supplemented crude peptide extract are given in Table 2.13 and 
2.14, respectively.  
Table 2.13 Summary of the peptides detected in the C8 HPLC fractions that were collected 
from commercial Trcmix. The fraction numbers, peptide identities, retention times, theoretical 

















TrcC1* 9.24 1361.6921 1361.6788 -9.8 
TpcA 9.57 1292.6706 1292.6351 -27.5 
3 
TrcC* 9.37 1347.6764 1347.6713 -3.8 
Unknown 9.75 - 1375.6893 - 
TrcB1 10.08 1322.6812 1322.6658 -11.6 
4 
TrcC1 9.85 1361.6921 1361.6790 -9.6 
PhcA 9.99 1253.6597 1253.6234 -29.0 
TrcB1* 10.12 1322.6812 1322.6654 -11.9 
PhcA1 10.48 1267.6753 1267.6388 -28.8 
5 
TpcC1 10.05 1384.7080 1384.6898 -13.1 
TrcB* 10.25 1308.6655 1308.6521 -10.2 
unknown 10.64 - 1336.6846 - 
6 
TpcC* 10.10 1370.6924 1370.6827 -7.1 
TrcB’ 10.41 1308.6655 1308.6517 -10.5 
TrcB1 10.79 1322.6812 1322.6676 -10.3 
Unknown  11.00 - 1249.6791 - 
TrcA1 11.38 1283.6703 1283.6591 -8.7 
7 
TpcB1 10.88 1345.6971 1345.6859 -8.3 
TrcA1* 11.36 1283.6703 1283.6637 -5.1 
TrcA 11.55 1269.6546 1269.6428 -9.3 
8 
TpcB1 10.82 1345.6971 1345.6860 -8.2 
TrcA* 11.53 1269.6546 1269.6429 -9.2 
9 
TpcB 11.06 1331.6815 1331.6644 -12.8 
TrcA* 11.55 1269.6546 1269.6412 -10.6 
10 
TpcB 10.92 1331.6815 1331.6687 -9.6 
TrcA 11.53 1269.6546 1269.6483 -5.0 
Oxidised TrcA* 11.72 1270.6624 1270.6328 -23.3 
Unknown 11.90 - 1297.6825 - 
TpcA1 12.01 1306.6862 1306.6820 -3.2 
TrcA1 12.06 1283.6703 1283.6697 -0.5 
aThe peak retention times as determined from the UPLC chromatograms 
bTheoretical monoisotopic Mr calculated as the sum of the molecular weights of amino 
acid residues of each peptide.    
cMonoisotopic Mr as determined from the individual ESI-MS spectra. 
*The peptide contributing to the major peak in the UPLC chromatogram. 
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Astonishingly, 15 of the 19 tyrocidine peptides and analogues were detected (some 
in very small amounts) with the new optimised C8 HPLC method (Table 2.13 and 
2.14). Most of the high-resolution Mr values had <10 ppm compared to the 
theoretical value. Only the peptide fractions with very low concentrations exhibited 
ppm errors of >15 ppm.  
Table 2.14 Summary of the peptides detected in the C8 HPLC fractions that were collected 
from Phe supplemented crude peptide extract. The fraction numbers, peptide identities, 
retention times, theoretical monoisotopic Mr and high resolution experimental monoisotopic 

















Unknown 8.57 - 1340.6527 - 
TrcC1* 8.81 1361.6921 1361.6805 -8.5 
3 
Unknown 8.41 - 1351.6731 - 
Unknown 8.80 - 1324.6586 - 
TrcC* 8.90 1347.6764 1347.6713 -3.8 
4 
Unknown 8.47 - 1354.6658 - 
Unknown 9.02 - 1326.6608 - 
TrcB1* 9.52 1322.6812 1322.6658 -11.6 
5 
TpcC1 9.38 1384.7080 1384.6898 -13.1 
TrcB* 9.67 1308.6655 1308.6519 -10.4 
6 
TpcC 9.47 1370.6924 1370.6827 -7.1 
TrcB’* 9.76 1308.6655 1308.6520 -10.3 
7 
TpcA 10.19 1292.6706 1292.6595 -8.6 
TpcB 10.33 1331.6815 1331.6633 -13.7 
TrcA* 10.81 1269.6546 1269.6400 -11.5 
8 
TpcA 10.19 1292.6706 1292.6639 -5.2 
TpcB 10.30 1331.6815 1331.6649 -12.5 
TrcA* 10.81 1269.6546 1269.6427 -9.4 
9 
TpcA 10.19 1292.6706 1292.6566 -10.8 
TpcB 10.27 1331.6815 1331.6687 -9.6 
TrcA* 10.78 1269.6546 1269.6384 -12.8 
Oxidised  TrcA 11.04 1270.6624 1270.6328 -23.3 
TrcA1 11.28 1283.6703 1283.6644 -4.6 
10 
Unknown 10.20 - 1296.6496 - 
PhcA 11.33 1253.6597 1253.6534 -5.0 
TpcA* 11.47 1292.6707 1292.6577 -10.1 
aThe peak retention times as determined from the UPLC chromatograms 
bTheoretical monoisotopic Mr calculated as the sum of the molecular weights of amino 
acid residues of each peptide.    
cMonoisotopic Mr as determined from the individual ESI-MS spectra. 
*The peptide contributing to the major peak in the UPLC chromatogram. 
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The four peptides that were not detected are very rare namely TrcAv, TrcB1’, TpcB’ 
and TpcB1’. This means that all tyrocidine C analogues were detected and almost all 
the tyrocidine A analogues were detected, with the rare TrcAv being the only 
exception. Furthermore, the new optimised C8 HPLC method allows for the 
separation of degraded TrcA (oxidised TrcA) from non-degraded TrcA, as 
determined from the UPLC-MS of HPLC fractions 9 and 10 of Phe supplemented 
crude extract (Table 2.14) and commercial Trcmix (Table 2.13), respectively. The 
peptides that were isolated with purities more than 70 % during the validation of the 
new C8 HPLC method are summarised in Table 2.15.  
From the Trcmix, all the major tyrocidine peptides were isolated with purities more 
than 70 %. TrcA and TrcC1 and TrcB1 had the highest purities and all were purified to 
> 90 %. From the Phe supplemented crude peptide extract only five of the six major 
tyrocidines were purified to > 70 %, however, TpcA was also isolated with a purity of 
> 70 %.  TrcA and TrcB were both purified to >90 %.  It is important to note that an 
entire peak was collected for each of the ten HPLC  fractions of both Trcmix and the 
Phe supplemented crude peptide extract. Therefore, higher purities can be expected 
if each HPLC peak is fractionated into two or more fractions. This will make it 
possible to purify all major tyrocidines during the same HPLC run from Trcmix, and 
to purify five of the major tyrocidines from Phe supplemented crude peptide extract 
during the same HPLC run. Evidently the new C8 HPLC protocol has great potential 
to make the future semi-preparative purification of the tyrocidines and analogues 
from crude peptide extracts more time and cost efficient, especially TrcB. 
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Table 2.15 Summary of the tyrocidines and analogues isolated from both commercial Trcmix 
and Phe supplemented crude peptide extract (crude) using the optimised C8 HPLC 
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aExperimental monoisotopic Mr was determined from UPLC-MS analysis. 
bThe theoretical monoisotopic Mr  calculated as the sum of the molecular weights of the amino acid residues of each peptide. 
cThe retention times were determined from the UPLC-MS chromatograms. 
dThe purity of each peptide was calculated from the peak areas of the individual UPLC-MS chromatograms.  




Furthermore, TrcC can currently only be purified from the commercial tyrothricin 
mixture which is not manufactured anymore for commercial use. The discontinuation 
of commercial tyrothricin mixture poses a problem for the future purification of TrcC. 
Therefore, it was important to find an alternative way to purify TrcC from crude 
peptide extract and the new C8 HPLC protocol resolves this problem. 
Time




























The methodologies developed by the BIOPEP group to produce and extract the 
tyrocidines and analogues proved to be very successful. Supplementation of the Br. 
parabrevis culture broths with Phe and Trp elevated the production of TrcA and 
TpcC (Figure 2.1 A-F), respectively, which in turn made the purification process 
more effective. Three peptides, TrcA (Figure 2.3 A-B) , TrcB (Figure 2.4 A-D) and 
TpcC (Figure 2.6 A-D), were successfully purified from crude Br. parabrevis peptide 
extracts, all having purities of 90 % or higher. Any minor contamination of the pure 
peptides was due to other tyrocidine peptides. 
The removal of the linear gramicidins from commercial tyrothricin with organic 
extraction was effective. The purity of the subsequent Trcmix was determined as >90 
%, with all six major tyrocidines (TrcA, TrcA1, TrcB, TrcB1, TrcC and TrcC1) present 
(Figure 2.7 A-B). The purification of TrcC was only possible from commercial 
tyrothricin and a final purity was determined as >90 % (Figure 2.9 A-D). The purities 
and amount of the peptides isolated, of which biophysical and biological activity will 
be investigated, are summarised in Table 2.11.  
The optimised C8 HPLC purification method (program D at 25 °C) improved the 
separation of the tyrocidines (Figure 2.10 A-F). The separation of the TrcC1 and 
TrcC, TrcB1 and TrcB, and TrcB and TrcB’/TpcC was notable, with increased 
resolutions from 0.50 to 1.28, 0 to 1.03, and 0 to 0.46, respectively (Table 2.12).  All 
six (TrcA, TrcA1, TrcB, TrcB1, TrcC, and TrcC1) of the major tyrocidines were isolated 
with the optimised C8 HPLC purification method (Table 2.15). Purities of 74.4 %, 
95.5 %, 90.2 %, 93.7 %, 90.8 % and 85.5 % were achieved for TrcA, TrcA1, TrcB, 
TrcB1, TrcC, and TrcC1, respectively. This result is significant, considering the 
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representative peaks for each peptide were not fractionated and the entire peak was 
collected in all instances. The lack of a C8 semi-preparative HPLC column prevented 
the use of the optimised C8 HPLC purification method to purify the peptides of 
interest needed for the subsequent Chapters of the present study. However, 
because of the success of the purification method developed in this chapter the C8 
HPLC method will be used in the future as the primary method for purification of the 
tyrocidines and analogues as a C8 semi-preparative column will be acquired by the 
BIOPEP Peptide Group.   
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THE INFLUENCE OF FORMULANTS ON THE BIOPHYSICAL 
CHARACTER OF THE TYROCIDINES AND ANALOGUES 
3.1 INTRODUCTION 
The rise of MDR towards chemotherapeutic drugs has forced researchers to find and 
develop new chemotherapeutic drugs for the treatment of cancer1, 2. The decreased 
risk of resistance development observed towards antimicrobial peptides due to their 
rapid membranolytic activity has sparked a lot of interest in these peptides1, 3. To 
investigate the factors that modulate the bioactivity of peptides, it is necessary to 
gain insight into their chemical character and behaviour in different formulations and 
solvents. The amino acid sequence and side chains in the primary structure of the 
cyclic cationic decapeptides from tyrothricin dictates their conformation and 
amphipathicity, which in turn influences their self-assembly in oligomers and larger 
polymeric structures 4-9. In addition, the chemical environment (polarity/ionic strength 
of solvent or the presence of other biomolecules) also influences the secondary 
structure and/or self-assembly of cyclic decapeptides 4, 5, 10, 11. The X-ray 
crystallography and nuclear magnetic resonance spectroscopy revealed that TrcA 
and TrcC monomers adopt an amphipathic type I β-turn and type II β-turn/β-pleated 
sheet which is stabilised by four intramolecular hydrogen bonds12-16. These peptides 
have been shown to induce ion conducting pores in model membranes which is 
directly implicated in the antimicrobial activity of the tyrocidines 17. Furthermore, the 
dimers of TrcA and TrcC in an aqueous environment are hypothesised to be the 
antimicrobial moieties and is the proposed membrane active conformation of the 
tyrocidines and analogues 12, 13. On the other hand, overt 
aggregation/oligomerisation at Trc concentrations >100 M have been observed 4-9 
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and such preparations have been found to be less active against a variety of 
microbes by our group (unpublished data). We observed good indications that there 
is a relationship between the state of oligomerisation/self-assembly structures and 
the bioactivity of the tyrocidines and analogues. Although the Trcs have potential as 
a chemotherapeutic lead for drug development, major drawbacks exist due to their 
haemolytic and cytotoxic activity18-20. Extensive research has been done on the 
formulation of AMP’s with different lipid-based molecules with the aim to improve 
stability, delivery and to decrease the toxicity of the peptides 21, 22. Refer to Chapter 1 
for more detail on peptide formulations. 
Many toxic compounds have been successfully formulated, for example the 
nephrotoxicity of Amphotericin B (AmB), a last resort antifungal drug, is significantly 
reduced when formulated with detergent-based (sodium deoxycholate, DOC) and 
lipid-based (cholesterol sulphate, CS) nanocarriers 23. These nanocarriers ensure 
effective transport of the drug to target sites, thereby reducing levels of free AmB in 
the blood and minimising toxicity of AmB 23.  
In this chapter, four cyclodecapeptides of interest (TrcA, TrcB, TrcC and TpcC) were 
formulated with three lipid-based molecules, cholesterol sulphate (CS), lyso-
phosphatidylcholine (LPC) and palmitic acid (C16), with the aim to improve stability 
and reduce toxicity of the peptides while retaining their bioactivity. The investigation 
on oligomerisation and biophysical properties of the four peptides, alone and in 
formulation with CS, LPC and C16, are reported in this chapter. The four 
cyclodecapeptides share a highly conserved primary structure (cyclo(D-Phe1-L-Pro2-
L-X3-D-X4-L-Asn5-L-Gln6-L-X7-L-Val8-L-Orn9-L-Leu10) with four amino acid residue 
variations (denoted by X in sequence) 24. Variation at position three and four, known 
as the aromatic dipeptide unit, gives rise to the A (consisting of L-Phe3-D-Phe4), B 
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(consisting of L-Trp3-D-Phe4) and C (consisting of L-Trp3-D-Trp4) analogues 24. 
Whereas, variation at position seven gives rise to the tyrocidines (L-Tyr7), 
phenycidines (L-Phe7) and tryptocidines (L-Trp7) 25. It has been shown that the 
variation in peptide sequence, especially at the aromatic dipeptide unit (L-X3, D-X4), 
plays a very important role in the structure-activity relationship of the tyrocidines 26, 
27. Therefore, the interactions of the different formulants with the dipeptide unit is of 
interest. 
Circular dichroism, ion-mobility spectrometry linked to mass spectrometry (IM-MS) 
and fluorescence spectroscopy (FS) are established techniques to decipher the 
factors implicated in the oligomerisation and interactions of biomolecules 28-34. 
Unfortunately, the formulation of the peptides with CS and C16 results in opaque 
solutions which prevents the use of CD for the investigation of oligomerisation of the 
Trcs and TpcC in this study. However, both IM-MS and FS are suitable to analyse 
solutions of opaque nature. IM-MS is a highly sensitive gas phase separation 
technique that allows the separation of ionic species with the same or similar mass 
or m/z ratio based on differences in their collision cross-sections (CCS), shape or 
conformation and charged states by monitoring the mobility of an ion through an 
opposing gaseous flow in the presence of a weak electrical field 35. This technique 
can be applied to analyse the size and shape a wide variety of molecules and 
mixtures which include pharmaceutical compounds 36, 32, polymers 37, 38, metabolites 
39, carbohydrates 40, phospholipids 41, proteins 30, 42 and peptides 28, 29. As analysis in 
ESI-MS mode leads to the removal of all water and solvent molecules, the 
hydrophobic effect is diminished and polar interactions (eg. hydrogen bonds, dipolar 
interactions and ionic interactions) will be enhanced 43-45. With the high 
temperatures, sheering and collisional forces and the high potential in the 
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instrument, only the most stable non-covalent complexes and oligomers will be 
stable in the mass spectrometer 43-47.  Munyuki et al. 12 and our group 48-51 illustrated 
that the dimers and larger oligomers of the Trcs and TpcC are stable during ESI-MS. 
Therefore, IM-MS will be used to determine the proportions of ionic species 
(monomers, dimers and larger oligomers) present in each of the four 
cyclodecapeptides alone and in formulation.  
To complement the results of the IM-MS, fluorescence emission maxima and 
quantum yield will be utilised to further elucidate the conformations and intra- and 
intermolecular interactions of the Trcs alone and in formulation. The three amino 
acids that are responsible for the intrinsic fluorescence of the Trcs are phenylalanine 
(Phe, F), tyrosine (Tyr, Y) and tryptophan (Trp, W)33, 34. Phe absorbs at the shortest 
wavelength (λex = 256 nm) of the three fluorescent amino acids and has a highly 
structured emission spectrum with a maximum at 282 nm 33. The general wavelength 
chosen for peptide/protein fluorescence is at 280 nm or higher which excludes the 
excitation wavelength of phenylalanine. Therefore, Phe fluorescence is usually 
disregarded during fluorescence studies of peptides/proteins 33, 34. The most 
extensively used intrinsic fluorophores are Tyr (λex = 276 nm) and Trp (λex = 282 nm) 
which are both excited at a wavelength of 280 nm and emits at wavelengths  with 
maxima at 303 nm and 357 nm, respectively 52-56. Tyr has a low extinction coefficient 
and is less sensitive to solvent polarity compared to Trp and therefore the emission 
of Trp dominates that of Tyr 3334. Furthermore, the fluorescence of Tyr and Phe is 
complicated when a peptide contains all three of the intrinsic fluorophores due to 
resonance energy transfer (RET) from Tyr or/and Phe (photon donors) to Trp 
(photon acceptor) residues in the same peptide33, 57. RET can only occur when there 
is an overlap of donor emission spectrum and acceptor absorption spectrum 57. The 
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indole group of Trp is highly sensitive to the chemical nature (polarity/hydrophobicity) 
of the local environment with occurrence of a spectral shift of emission maximum 
towards a lower wavelength (blue shift or hypsochromic shift) or higher wavelength 
(red shift or bathochromic shift) when located in a more nonpolar or polar 
environment, respectively33, 34, 54, 58. These spectral shifts are due to interaction of the 
solvent with the indole group via hydrogen bonding and general solvent effects 33. 
Another indication of changes in peptide aggregation, conformation or interactions is 
the total fluorescence quantum yields of Tyr and Trp. The fluorescence quantum 
yields of Tyr and Trp can be decreased (quenched) or increased (de-quenched) via 
different molecular mechanisms such as collisional quenching in an aqueous 
environment, ground-state complex formation and excited state reactions with local 
polar groups33, 54, 58.   
3.2 RESEARCH MATERIALS 
The cholesterol sulphate (CS), palmitic acid (C16), commercial tyrothricin extract, 
and methanol (MeOH) were supplied by Sigma-Aldrich (St Louis, USA). Avanti® 
polar lipids (Alabama, USA) supplied the soy lyso-phosphatidyl choline (LPC). 
Acetonitrile (ACN, HPLC-grade, far UV cut-off) was purchased from Romil Ltd 
(Cambridge, United Kingdom) and ethanol (EtOH) was obtained from Merck 
(Darmstadt, Germany). Analytical grade water was prepared by filtering water from a 
reverse osmosis plant through a Millipore-Q® water purification system (Milford, 
USA). The nitrogen (N2) gas was purchased from AFROX (Johannesburg, South 
Africa). The 96-well black flat bottom plates were supplied by Thermo Fisher 
Scientific (Denmark).  




3.3.1 The preparation of peptide formulations  
The pure peptides (TrcA, TrcB, TrcC and TpcC) and formulants (CS, LPC and C16) 
were suspended in 90 % MeOH in water (v/v) to concentrations of 1.00 mM. 
Equimolar amounts of the peptide and the formulant were added together to produce 
15 different peptide formulations (Table 3.1). Subsequently, the 90 % MeOH in water 
(v/v) was evaporated under N2 gas flow. The dried formulations were stored at room 
temperature until used. It is important to note that only pyrolised glassware and ultra-
high purity solvents were utilised in the preparation of the peptides and formulations. 
This is a necessary measure to limit the influence of residual contaminants such as 
detergents and pyrogens on the formulation and on the activity of the peptides and 
their formulations. 
Table 3.1 A summary of the peptide formulations that were prepared with cholesterol 
sulphate (CS), lyso-phosphatidyl choline (LPC) and palmitic acid (C16).  
Peptide Formulations in 1:1 molar ratio 
CS LPC C16 
TrcA TrcA:CS TrcA:LPC TrcA:C16 
TrcB TrcB:CS TrcB:LPC TrcB:C16 
TrcC TrcC:CS TrcC:LPC TrcC:C16 
TpcC TpcC:CS TpcC:LPC TpcC:C16 
Trcmix Trcmix:CS Trcmix:LPC Trcmix:C16 
 
3.3.2 Scanning electron microscopy  
The dried pure TpcC were dissolved at 1.00 mg/mL in 50 % EtOH in water (v/v) or 
500 µM in 15 % EtOH in water (v/v). The dried peptide formulations were diluted to 
500 µM peptide concentration in analytical grade water. Dissolved samples were 
sonicated for 1-2 minutes and incubated at room temperature for at least one hour 
before 5 µL aliquots were dried under vacuum at room temperature on cleaved 
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muscovite mica surfaces. Prior to imaging, the samples were mounted on aluminium 
stubs with double sided carbon tape followed by coating with a layer of gold (± 10 nm 
thickness). The scanning electron microscope images of the TpcC (1.00 mg/mL) in 
50 % EtOH in water (v/v) and CS and LPC formulations (500 M, 15 % EtOH in 
water (v/v)) were recorded by Jai Singh at the Sophisticated Instrument Centre (SIC) 
at the Dr. Harisingh Gour University in Sagar, India. The images were recorded in 
high vacuum mode using high resolution scanning electron microscope dual beam 
system (NOVA 450 NANOLAB, FEI) operating at a working distance (WD) of 4.9 to 
5.8 mm and 20 kV.  
The scanning electron microscope images of the TpcC (500 M) in 15 % EtOH in 
water (v/) and C16 formulations (500 M, 15 % EtOH in water (v/v)) were recorded 
with the assistance of  senior analyst Madelaine Frazenburg at the University of 
Stellenbosch Central Analytical Facilities (CAF). The images were recorded in high 
vacuum mode using Zeiss MERLIN field emission scanning electron microscope 
operating at a working distance (WD) of 4.5 to 4.6 mm and 1 to 3 kV. The WD and 
voltage used to capture each SEM image of the samples are given at the bottom of 
each image in the results section.  
3.3.3 Travelling wave ion mobility mass spectrometric analysis  
Pure peptides and the peptide formulations were resuspended in 1.5 % EtOH in 
water (v/v) and analytical grade water to concentration of 50 µM.  A doubling dilution 
series of each pure peptide solution was prepared. The samples were subsequently 
centrifuged at 10 600 xg for 10 minutes to remove any particulate material. Volumes 
of 3 µL of the samples were injected into the electrospray ionisation mass 
spectrometry (ESI-MS) system via a Waters Acquity® UPLC allowing direct infusion 
at a flow rate of 0.3 mL/min. The ESI-MS solvent that was used was 0.1 % formic 
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acid in 60 % ACN in water (v/v/v). The source temperature and cone voltage were 
set at 120 °C and 15 V, respectively. The ESI-MS system consisted of a Waters 
Synapt G2 quadrupole time-of-flight (Q-TOF) mass spectrometer equipped with a Z-
spray electrospray ionisation source and a photo diode array detector. The ion 
mobility spectrometry linked ESMS (IM-MS) analysis was achieved by enabling the 
traveling-wave ion mobility cell in the ESI-MS system. The travelling wave ion 
mobility experimental parameters were set as follows: Extraction cone at 4V, Helium 
cell gas flow at 180 mL/min, ion mobility buffer (N2) gas at 90 mL/min, trap collision 
energy at 15 V, trapping release period of 200 µs, mobility trap and extract height at 
15 and 0 V, respectively, wave height ramp (100 %) from 8 to 20 V, wave height 
linear velocity ramp (20 %) from 1000 to 650 m/s at 200 m/s. Poly-Alanine (Poly-Ala) 
was used as the calibration standard to calibrate to travelling wave ion mobility cell’s 
drift time. Data was collected in positive mode scanning from 350-2000 (m/z) at a 
rate of 0.2 scans per second. Waters MassLynx V4.1 software (Milford, USA) and 
Driftscope v2.9 software (Milford, MA, USA) were used for the data analysis. The 
calibration curve used for the collision cross-section (CCS) calculations were 
constructed as described by Michaelevski et al. 30 and Rautenbach et al.29. The CCS 
calculation for each of the peptides were determined as described by Ruotolo et al. 
28. Total signal for each molecular ion in the TWIM-MS profile were used to compare 
the contribution of monomers and dimers in a peptide preparation and formulation. 
The [M+H]+ contribution to the total signal of TrcC and TpcC was corrected from the 
ratio between [M+H]+ and [M+2H]2+ using the signals in the resolved direct injection 
(determined in the same run), as the [M+H]+ signal not fully resolved in their TWIM-
MS profile. Dr. Marietjie Stander at the Central Analytical Facility (CAF) of the 
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University of Stellenbosch assisted with the setup and running of the IM-MS 
analyses on the Synapt G2.  
3.3.4 Fluorescence spectroscopy 
The pure peptide aliquots were prepared as previously described in 15 % EtOH (v/v) 
in water to final concentrations of 50 µM. Similarly, the dried peptide formulations 
were resuspended in water to concentrations of 50 µM. Doubling dilution series of 
the peptide solutions and peptide formulation solutions were prepared in triplicate in 
black 96 well microtiter plates. The fluorescence was performed on a Varioskan 
3.01.15 instrument and data collected with SkanIT Software 2.4.3. Excitation was 
performed at 280 nm and emission collected from 300 nm to 400 nm at 10 ms 
intervals. All data was analysed with Graphpad Prism® V 5.0. 
3.4 RESULTS AND DISCUSSION 
The aim of this study is to formulate and reduce the toxic effects of the Trcs  19 on 
normal healthy cells of humans and drug formulations is one of the strategies 
employed to achieve this aim by acting as a carrier system for the drug to the target 
cells 21. 
3.4.1 Scanning electron microscopy of TpcC and formulations 
It is well established that peptides undergo self-assembly which is described as a 
spontaneous organisation of individual molecules into ordered structures (such as 
nanofibers, nanotubes and nanovesicles) by means of weak non-covalent 
interactions 59-61. These non-covalent interactions may include hydrogen bonds, 
ionic, hydrophobic and van der Waals interactions 59. Scanning electron microscopy 
(SEM) is widely used to visualise the self-assembly of compounds 62  and was 
utilised to investigate the self-assembly and formulation with CS, LPC and C16 of 
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one of the peptides, TpcC, in this study. TpcC was chosen because it is a Trp-rich 
peptide as it contains L-Trp7and the aromatic dipeptide unit consisting of L-Trp3-D-
Trp4  24. Therefore, the role the Trp residues play in the self-assembly/aggregation of 
the TpcC alone and in formulation can be elucidated. The SEM analysis revealed 
that TpcC (1.00 mg/mL) form well-defined spheres of different sizes (159 nm to 349 
nm in diameter with high dispersity) when dissolved in 50 % ethanol and allowed to 
self-assemble while slow drying under vacuum (Figure 3.1 A). The preparation 
procedure seems to influence the size of the nano-spheres, in particular the rate of 
drying, initial concentration and type and percentage of organic solvent. Under 
conditions in which 500 M TpcC in 15 % EtOH:water (v/v) was dried under vacuum, 
uniform TpcC spheres of 13 nm to 25 nm were obtained with a few larger spheres of 
63 nm to 88 nm (Figure 3.1 B and D). These larger spheres consisted of multiple 
smaller uniform spheres in a quasicrystal (Insert in Figure 3.1 B). It is evident that the 
TpcC, containing three Trp residues, easily forms large spherical quasicrystals.  
The LPC had a notable effect on the self-assembly of TpcC into large spherical 
structures showing disruption/prevention of these well-defined nano-assemblies 
(Figure 3.1 C). This is reasonable because phospholipids such as lysoPC have been 
shown to have detergent like actions and is a well-known agent used to solubilise 
membranes 63, 64. Therefore, LPC probably act as a detergent on the spheres formed 
by the Trcs and may prevent and retard the formation of ordered structures. 
However, some spherical structures were still observed, and the preparation showed 
polydispersity, which could be related to the preparation of the formulation and will 
need further optimisation in future studies. 
The CS formulation had a similar effect to that of LPC, leading to disruption of the 
spherical nano-assemblies (Figure 3.1 E). However, although fewer well-defined 
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nano-structures were observed, significantly larger spheres were observed in the 
TpcC:CS formulation, with sphere sizes of between 94 nm and 133 nm (Figure 3.1 
E). It is possible that some of the structures are maintained and CS could lead to 
merging of some of the smaller spherical structures into larger assemblies (Figure 
3.1 E). This could likely be due to both electrostatic interactions between the cationic 
L-Orn9 residue and the negative charge on sulfoxide of CS, and hydrophobic 
interaction between the highly non-polar groups CS (carbon rings and aliphatic tail) 
and the Trp residues of TpcC. Faure et al. 65 have shown that the hydration of 
dimyristoylphosphatidylcholine (DMPC) membranes incorporated with CS increases 
compared to DMPC membranes incorporated with cholesterol, which is likely due to 
more hydrogen binding sites on the sulphate group of CS. Therefore, it is possible 
that the sulphate group of CS orientates to the aqueous environment to form 
hydrogen bonds with water molecules and/or interacts with the L-Orn9 residues, 
whereas the non-polar carbon ring/carbon tail end of CS associates with the 
peptides thereby shielding them from the aqueous environment.  




Figure 3.1 The scanning electron microscope micrographs of TpcC alone and in formulation 
with CS, LPC and C16. A) SEM micrograph of TpcC (1.00 mg/mL) in 50 % EtOH in water 
(v/v). B) and D) SEM micrograph of TpcC (500 µM) in 15 % EtOH (v/v) in water. C) SEM 
micrograph of TpcC:LPC (500 µM) in water.  E) SEM micrograph of TpcC:CS (500 µM) in in 
water (v/v). F) SEM micrograph of TpcC:C16 (500 µM) in water. The micrographs in A, C 
and E were recorded on a NOVA 450 NANOLAB dual beam SEM and those in B, D and F, 
with a Zeiss MERLIN field emission SEM. 
Aggregation of nearby spherical structures was observed (Figure 3.1 E) which 
confirmed some self-assembly into larger ordered structures of the CS formulated 
peptides. This polydispersity may also be the result of preparation of the formulation 
and will need further optimisation in future studies. In contrast to the results observed 
for CS and LPC formulations, the TpcC:C16 led to almost complete disruption of the 
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TpcC nano-spheres (Figure 3.1 F). The disruption of the nano-structures indicates 
that the C16 probably has a more pronounced detergent effect than CS and LPC. 
The reduction of the larger nano-assemblies and the smaller spheres of the TpcC by 
C16 is probably due to the formation of small micellular structures between TpcC 
and C16.  
Taken together, each of the formulants have different influences on the self-
assembly of the cyclodecapeptides as interpreted from the size and shape of 
spheres formed. The formation and disruption of the cyclodecapeptide nano-
structures would be dictated, for the most part, by the chemical properties of each of 
the formulants and the peptide character in the formulation. Future studies will focus 
on the optimisation of peptide formulation and preparation, as well as including more 
Trc analogues to assess the role of primary structure in the formation and disruption 
of nano-structures.  
3.4.2 TWIM-MS of the peptides and formulations 
Conventional ion mobility spectrometry (IMS) has become a popular method used to 
rapidly analyse the structures and conformations of a wide variety of molecules 28, 29, 
32, 36, 38-42. IMS is a gas-phase separation technique that separates ions based on 
structure and size by measuring the time (drift time) it takes an ion to travel through a 
pressurised tube (drift tube) filled with an inert gas under the influence of a weak 
uniform electrical field. Larger ions will traverse the drift cell at a slower speed than 
smaller ions due to the greater number of collisions experienced with the opposing 
buffer gas which correlates directly with the collisional cross-sections (CCS) and that 
shape of the molecular ions 41, 42. IMS can also be coupled to MS (IM-MS) which 
enables further separation of heterogenous mixtures with similar masses or mass to 
charge ratios according to differences in their drift times and CCS values 66. An 
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alternative to the conventional IMS techniques is the traveling wave ion mobility 
spectrometry linked to mass spectrometry (TWIM-MS) where electrical wave pulses 
are applied rather than a uniform electrical field 35, 67. In TWIM-MS systems the CCS 
areas are determined from a calibration curve obtained from the drift times and CCS 
values (as determined from conventional IMS experiments) of a suitable internal 
calibrant, whereas the drift time values are directly related to CCS areas in 
conventional IMS systems35, 67. In this study the Trcs were analysed using a TWIM-
MS system and poly-alanine (poly-Ala) was used as an internal calibrant in order to 
obtain a calibration curve from which the CCS areas of the Trcs were calculated. The 
drift times (tD) of poly-Ala were determined under exactly the same TWIM-MS 
instrument conditions (N2 gas as buffer) used for the Trcs and the CCS areas (Ω) of 
poly-Ala were obtained from literature 68. The standard curve was obtained by 
correcting the drift times (tD’) and CCS areas (Ω’) of poly-Ala using Equations 3.1 
and 3.2 and subsequently plotting lnΩ’ against lntD’30. The tD’ and Ω’ equations are 
as follows: 
𝑡𝐷






    3.1 
Where tD is the observed poly-Ala drift time in milliseconds (ms),  m/z is the mass to 
charge ratio of the poly-Ala ion observed and c is the Enhanced Duty Cycle (EDC) 
delay coefficient which is an instrument dependent parameter 30.  








     3.2 
Where Ω is the literature CCS area of the observed poly-Ala ion, z is the ion charge, 
m is the molecular weight of observed poly-Ala ion, and MG is the molecular mass of 
N2 gas 30. 
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A linear trendline was fitted to the lnΩ’ versus lntD’ plot (Figure 3.2) and the slope (X) 
which represent the exponential proportion factor and the fit-determined constant (A) 
was extracted from the linear fit equation (ln(Ω’) = Xln(t’D) + A) (Figure 3.2). 
 
Figure 3.2 The corrected CCS areas versus corrected drift time values of internal calibrant 
poly-Ala from which the exponential proportion factor (slope) and fit-determined constant 
was extracted. The equation of the linear fit and correlation coefficient (r2) are shown on the 
graph. The dotted lines indicate the 95 % confidence interval. 
The exponential proportion factor(X) was used to determine the doubly corrected 









          3.3 
Subsequently, the calibration curve was constructed by plotting literature CCS 
values of poly-Ala against t”D (Figure 3.3). The CCS values of the individual Trcs 
(TrcA, TrcB, TrcC and TpcC) were determined from the poly-Ala calibration curve 
(Figure 3.3) as described by Ruotolo et al. 28. TrcA was chosen as representative 
peptide to illustrate the TWIMS-MS drift profiles generated (Figure 3.4 A-E) for each 
of the Trc peptides and the peptide formulations. The peptide ion drift times and 
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percentage ionic species contribution were determined from the generated TWIM-
MS drift profiles.  
 
Figure 3.3 The calibration curve constructed by plotting the CCS areas (Ω) of poly-Ala ions 
obtained from literature 68 versus doubly corrected drift time (t”D) values of the observed 
poly-Ala ions. The equation of the linear fit and correlation coefficient (r2) are shown on the 
graph. The dotted lines indicate the 95 % confidence interval. The missing data-points on the 
graph are due to the absence of either CCS values or failure to detect the molecular ion in 
the poly-Ala preparation during the TWIM-MS analysis. 
Previous studies by our group (Rautenbach et al., unpublished data) showed that 
higher order structures of the Trcs up to hexamers were detected using TWIMS-MS. 
From the TWIMS-MS drift profiles of all the peptides in this study it was evident that 
the signals of trimers, tetramers and other oligomeric species ([nYA+nH]n+) are very 
low when analysing the peptides at 50 M rather than 200-250 M, as with previous 
studies. In this study the signal to noise ratio were insufficient making the 
determination of accurate drift times and subsequently the oligomeric ionic species 
signal contribution very difficult (results not shown). The focus was therefore directed 
on to the monomeric and dimeric ionic species for all the peptides, as well as their 
formulations. Regardless of all the precautions to avoid contaminants in our 
samples, a contamination by a general plasticiser (bis(2-ethylhexyl) phthalate, 
detected m/z =413.2679, theoretical m/z= 413.2662) from micropipette tips, used in 
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the final sample preparation, was observed at drift time 4.55 ms in the TWIM-MS 
profile of TrcA (Figure 3.4 A). This contaminant was present in all the peptide 
preparations but did not seem to interfere with the analysis. It was in fact used as 
internal standard to monitor that the ion signal remains consistent from run to run 
(results not shown). The CCS parameter of selected ionic species of the peptides 
(TrcA, TrcB, TrcC and TpcC) were determined, except for the singly charged 
monomers [WC+H]+ of TpcC due to partial detection of the IM-MS peak of this ionic 
species,  and are summarised in Table 3.2 
Table 3.2 Summary of the average CCS areas of the Trc ionic species as determined from 
their drift times and Poly-Ala calibration curve. Each CCS area was determined from three 




CCS Ω (Å2) ± SD 
[M+H]+ [M+2H]2+ [2M+2H]2+ 
TrcA YA F3-f4-Y7 366.7 ± 0.00 386.3 ± 0.00 552.1 ± 0.00 
TrcB YB W3-f4-Y7 373.2 ± 0.58 389.7 ± 0.00 561.8 ± 0.00 
TrcC YC W3-w4-Y7 379.0 ± 1.14 396.7 ± 0.00 571.7 ± 0.00 
TpcC WC W3-w4-W7 ND* 396.7 ± 0.00 573.2 ± 1.44 
aThe first letter in the abbreviation represent the residue at position 7 in the structure of the Trcs. 
b D- and L-amino acids are represented by lower case and upper-case letters, respectively. 
*Unknown drift time which prevented CCS area calculation.   
The CCS areas of the singly charged monomers [M+H]+ of the Trcs increase in the 
following order, TrcA<TrcB<TrcC with CCS areas determined as 366.7, 373.2 and 
379.0 Å2, respectively. The larger Trc peptides have a larger CCS area which is an 
expected result and correlates well with previous result from our group. The same 
trend is observed for the doubly charged monomers [M+2H]2+ of the 
cyclodecapeptides with CCS areas increasing in the following order, 
TrcA<TrcB<TpcC=TrcC with CCS areas determined as 386.3, 389.7, 396.7 and 
396.7 Å2, respectively.  




Figure 3.4 The TWIM-MS drift profiles generated for representative peptide, TrcA. The top 
graph is a 3D chromatogram showing the drift time (Bins) on the x-axis, total signal counts 
on the y-axis and the m/z ratio on the z-axis. A) The 2D chromatogram of all the ionic 
species of TrcA (50 µM) separated by TWIMS-MS showing plasticiser contamination at 4.55 
ms drift time. The drift times of B) doubly charged monomeric [YA+2H]2+ species, C) doubly 
charged dimeric [2YA+2H]2+ species and singly charged monomeric [YA+H]+ species, and 
D-E) oligomeric species [nYA+nH]n+ are shown. The m/z ratio range of each ionic specie are 
given on the individual drift profiles. The enlarged MS spectra of the monomeric and dimeric 
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The CCS areas of the monomeric species are directly related to the molar mass of 
the peptide, which is indicative that the cyclodecapeptides have similar 
conformations in vacuo. 
The CCS of doubly charged monomers [M+2H]2+ of all the peptides were found to be 
larger (± 20 Å2) than the singly charged monomers [M+H]+. This difference is 
probably due to a more “relaxed or open” peptide conformation to accommodate the 
extra positive charge. 
The doubly charged dimers [2M+2H]2+ of the Trcs and TpcC also increased as the 
molar mass of the peptide in the dimer increased from TrcA<TrcB<TrcC<TpcC with 
CCS areas determined as 552.1, 561.8, 571.7 and 573.2 Å2, respectively (Table 3.2). 
It was expected that the CCS areas of the doubly charged peptide dimers will be 
about twice the size of the singly and doubly charged monomers. However, less than 
a 2-fold increase in the CCS areas were observed for the doubly charged dimers 
[2M+2H]2+ of the cyclodecapeptides. This indicated that the packing of the dimers is 
denser possibly due to specific hydrogen bonding and electrostatic interactions 
between peptide molecules thereby decreasing the overall size/surface area of the 
dimeric species. The overall decrease of the CCS area of all the peptide dimers 
confirms the previous work by Munyuki et al. 12 and Loll et al. 13 that the Trc dimers 
are the result of strong specific interactions.  
The influence of the peptide concentration on the oligomerisation of the Trcs and 
TpcC were assessed by determining the percentage signal contribution of the ionic 
species at four different concentrations 50, 25, 12.5 and 6.13 µM (Figure 3.5 A-D). 
Similar mirror sigmoidal dose response trends are observed for TrcA, TrcB, TrcC 
and TpcC where the doubly charged monomers [M+2H]2+ decreases and both the 
singly charged monomers [M+H]+ and doubly charged dimers [2M+2H]2+ increase as 
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the concentration of peptide increases (Figure 3.5 A2-D2). The increase of dimeric 
species with increase in concentration is an expected result, but the fact that the 
singly charged monomeric species follows a similar trend (Figure 3.5 A-D) is very 
interesting and indicate this specie could be derived from dissociation of dimers and 
larger oligomers. A decrease in doubly charged monomeric ions directly correlates 
with an increase in doubly charged dimers for all the peptides (Figure 3.5 A-D), 
which indicates that the doubly charged monomers are the monomeric species in 
solution that decreases with concentration dependent oligomerisation.  
The total signal contribution of each of the ionic species of the peptides alone and in 
formulations at 50 M were investigated to gain insight into the influence of the 
formulants (CS, LPC and C16) on the contribution of monomers versus dimers. A 
relationship exists between the hydrophobicity of the peptides and the degree of 
oligomerisation with the observation of a higher dimer contribution for the more 
hydrophobic TrcA and TrcB (Figure 3.6 A and B) than the more polar TrcC and TpcC 
(Figure 3.6 C and D). Similarly, the doubly charged signal of the monomers also 
followed the same trend with TpcC>TrcC>TrcB>TrcA (Figure 3.6 A-D). 
For all the peptides in formulation with CS, LPC and C16 an increase in the % 
doubly charged monomers were observed, indicating a release of monomeric 
species from the formulations. Conversely, a decrease in the % doubly charged 
dimers were observed for all the LPC and C16 formulations, indicating that there 
may be less dimers (and higher oligomers) in the formulation. This correlated with 
the disruption of nanostructures by the formulants as observed by SEM. The CS 
influence on the % doubly charged dimers of the cyclodecapeptide depended on the  




Figure 3.5 The concentration dependence of the oligomerisation of the Trcs. A1) The 
percentage contribution of TrcA ionic species versus peptide concentration and A2) 
normalised signal contribution of TrcA ionic species versus peptide concentration fitted with 
Boltzman sigmoidal curve B1) The percentage contribution of TrcB ionic species versus 
peptide concentration and B2) normalised signal contribution of TrcB ionic species versus 
peptide concentration fitted with Boltzman sigmoidal curve. C1) The percentage contribution 
of TrcC ionic species versus peptide concentration and C2) normalised signal contribution of 
TrcC ionic species versus peptide concentration fitted with Boltzman sigmoidal curve. D1) 
The percentage contribution of TpcC ionic species versus peptide concentration and D2) 
normalised signal contribution of TpcC ionic species versus peptide concentration fitted with 
Boltzman sigmoidal curve.  
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peptide identity (Figure 3.6 A-D). In general, the % of singly charged monomers did 
not show major changes induced by the formulants (Figure 3.6 A-D).   
However, as the differences are minor in the latter two, further investigation must be 
done in order to determine if the changes are statistically relevant. 
There was a general decrease in dimers, corresponding with the increase in doubly 
charged monomers of the Trcs and TpcC when formulated with LPC and C16 
(Figure 3.6 A-D). This could be the disruption of electrostatic/ionic/hydrogen bonding 
by formulant and peptide polar group interaction or an induced conformational 
change which changes location of peptide polar groups which play a role in the 
oligomerisation of peptides. The formulants which decreased the proportion of 
dimeric species to the largest extent were LPC and C16, which correlates well with 
the SEM results (Figure 3.1 C and F). LPC possibly acts as a detergent (disrupting 
oligomerisation) and that C16 forms small micelles possibly leading to entrapment of 
peptide monomers preventing formation of oligomers. On the other hand, it seems 
as if CS had no marked influence on the dimer formation (Figure 3.6 A-D). However, 
the doubly charged monomers were increased and singly charged monomers 
decreased, which does indicate some changes in the oligomerisation, correlating 
with the SEM results. It must be noted that total TWIM-MS signal is decreased when 
formulated with LPC and C16 compared to the peptide controls (Figure 3.7), 
indicating that the ionic peptide species are not completely released from the LPC 
and C16 formulation which probably skews the results discussed above. This result 
also indicated that a significant amount of peptide molecules was trapped in stable 
neutral lipid complexes in the formulation. This result could indicate ionic interactions 
between the negative lipid group and the positive L-Orn9 in the cyclodecapeptides. 
 




Figure 3.6 The percentage contribution of positive peptide ions of the Trcs alone and in 
formulation with CS, LPC and C16 at fixed concentration of 50 µM. A) Percentage 
contribution of monomeric and dimeric ionic species of TrcA and formulations. B) 
Percentage contribution of monomeric and dimeric ionic species of TrcB and formulations C) 
Percentage contribution of monomeric and dimeric ionic species of TrcC and formulations. 
D) Percentage contribution of monomeric and dimeric ionic species of TpcC and 
formulations 






































Figure 3.7 Total TWIM-MS signal of the TrcA, TrcB, TrcC and TpcC and their respective 
formulations at a specific concentration of 50 µM.  
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Comparison of the TWIM-MS signals from the unformulated peptides with those 
formulated with CS, the role of hydrophobicity is again highlighted with both TrcA 
and TrcB signal increasing, indicating release from oligomeric structure, while the 
inverse is true for the Trp-rich TrcC and TpcC indicating trapping of more molecules 
in the formulation (Figure 3.7). This result on the CS formulations may also indicate 
that this formulation is less ESI-MS stable than the LPC and C16 formulations, 
because of more hydrophobic interactions that are removed in the mass 
spectrometer (MS). 
3.4.3 Fluorescence spectroscopy of the peptides and formulations  
The Trcs contain three intrinsic fluorophores i.e. Phe, Tyr and Trp. However, the 
emission maximum of Phe is at 282 nm, which is similar to the excitation 
wavelengths of Trp (λex 282 nm) and Tyr (λex 276 nm) 33, 34. To prevent spectral 
overlap of Phe emission and excitation of Tyr and Trp, Phe is usually not used during 
fluorescence studies 33, 34. In addition, the fluorescence of Tyr is overshadowed by 
that of Trp due to the low extinction coefficient and sensitivity to polar 
solvent/environment of Tyr and the high sensitivity of the Trp indole group to its local 
environment 33, 34, 54, 57, 58. Therefore, Trp was the major fluorophore used to 
investigate the self-assembled states of the Trcs and TpcC alone and in formulation 
during the present study. The peptides containing at least one Trp residues, TrcB, 
TrcC and TpcC, had emission maxima that were blue shifted (shorter wavelengths) 
from the expected 357 nm 33, 56 to 344 ± 2 nm (TrcB), 340 ± 2 nm (TrcC) and 340 ± 0 
nm (TpcC). 
These results correlate well with the findings by Vosloo 48 who observed that the Trp 
residues are located in a more hydrophobic environment possibly as a result of 
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oligomerisation of the Trcs when in an aqueous environment 33, 54, 55, 58. The spectral 
shift, if any, of TrcA could not be determined due to the lack of Trp residues in the 
structure. The fluorescence of TrcA is solely due to the Tyr residue at position seven 
which is expected to emit at 303 nm 33, 55. If a blue shift does occur (shifted to shorter 
wavelengths than 303 nm) in the spectrum of TrcA, it would not be observed 
because the fluorescence was scanned from 300 nm onwards. Therefore, quenching 
and quantum yield are the only parameters that were used to gain info on the 
aggregated states of TrcA.  Vosloo 48 found that the fluorescence of TrcB, TrcC and 
TpcC are quenched when placed in a membrane mimicking environment, therefore 
the same trend is expected for the peptides when in formulation with the three 
different lipid-based formulants used in the study. Indeed, this was the result with all 
peptides formulations having quenched fluorescence including Trcmix (Figure 3.8 A-
E). Interestingly, the quenched fluorescence of the peptides and Trcmix by CS was 
accompanied by a blue shift of the spectrum, with the exception of TrcA (Figure 3.8 
B-E). 
Quenching of fluorescence can be the consequence of various reasons including the 
molecular mechanisms such as collisional quenching via an aqueous environment, 
ground-state complex formation and excited state reactions with local polar groups 
present in the peptide backbone (amide groups) or side chains (amide groups of Asn 
and Gln, amino group of Orn and hydroxyl group of Tyr) 33, 54, 58 or even the polar 
groups of the formulants (sulfoxide group of CS, carboxyl group of C16 and  amino- 
or phosphate group of LPC) 69, 70. In general, the quenching of the Trcs by LPC and 
C16 was similar except for TpcC where LPC resulted in less quenching compared to 
C16 (Figure 3.8 A-E). The quenching of the Trcs fluorescence by the formulants can 
be caused by three scenarios: 1) Exposure of Trp residues to aqueous environments 
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leading to collisional quenching 33, 54, 58, 2) excited state reactions with the polar 
groups of peptide backbone and residue side chains 70 and 3) excited state reactions 
with polar groups of the formulants 69, 70. 
 
Figure 3.8 The fluorescence emission spectra of the Trcs alone and in formulation with lipid-
based molecules, CS, LPC and C16 in an aqueous environment at 1-hour maturation. The 
solutions were excited at 280 nm to and emission scanned from 300 nm to 400 nm to 
produce fluorescence spectra of A) TrcA and its formulations, B) TrcB and its formulations, 
C) TrcC and its formulations, D) TpcC and its formulations   and E) Trcmix and its 
formulations. The fluorescence quantum yield is given in relative fluorescent units (RFU). 
The variable residues at positions three, four and seven are given on each spectrum except 
for Trcmix which consists of the mixture of Trc analogues.  
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Considering the SEM and TWIM-MS results for LPC and C16 formulations, we 
hypothesise that small micellular structures were formed with a decreased Trc dimer 
content (Figure 3.1 and Figure 3.6). With this it is most likely that the quenching is 
collisional due to exposure of Trp residues to water molecules and/or quenching via 
excited state reactions of Trp with the polar groups of LPC and C16. Alternatively, 
the L-Orn9 residue could be in close proximity to the aromatic rings as a hydrogen 
bond partner in leading to quenching. 
On the other hand, SEM revealed that CS may cause the cyclodecapeptides to form 
some larger structures (Figure 3.1). TWIM-MS results indicated that hydrophobic 
interaction may be important in these structures and that the formulation retained a 
significant proportion of dimers (Figures 3.6 and 3.7). This would point to 
fluorescence quenching by CS as the consequence of excited state reactions of the 
Trp residues with the polar sulphate group of CS, the peptide backbone and/or the 
side chains of peptides residues. The blue shift of emission spectra observed for the 
CS formulations (Figure 3.8) suggests that the Trp residues are in a more 
hydrophobic environment 33, 34.  
Trp generally has a higher fluorescence when blue shifted 33, 71 but with the Trp-rich 
peptides in this study CS leads to quenching. The quenching is possibly due to the 
aromatic  ring stacking of aromatic residues as proposed by Munyuki et al.12.  The 
blue shifts observed for CS formulations were as follows: for TrcB from 344 nm to 
322 nm, for TrcC from 340 nm to 327 nm, TpcC from 340 nm to 328 nm and for 
Trcmix from 342 nm to 323 nm. Note that this is a 22-32 nm blue shift from the 357 
nm maximum of Trp  56 which is highly significant, and could be explained by a 
combinatorial effect of aromatic ring stacking of Trp residues and a highly non-polar 
local environment 12, 33, 34, 70, 71.   
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The fact that the same trend was seen for each of the peptides formulated with CS 
suggests that the CS (non-polar and polar groups of CS) does not have preference 
for any of the different variations of the aromatic dipeptide unit. Considering the blue 
shift and quenching caused by CS it is more likely that the CS probably interacts with 
other group/groups of the Trcs and TpcC inducing hydrophobic aromatic ring 
stacking (causing the blue shift) and quenching via excited state reactions between 
the dipeptide unit and polar groups within the peptide structures and the sulphate 
group in CS. Neither LPC nor C16 caused spectral shifts of the maxima (Figure 3.8) 
indicating hydrophobic Trp ring stacking are not involved further strengthening the 
theory that the fluorescence quenching observed for the LPC and C16 formulations 
are due to collisional quenching of fluorophores by water molecules or polar groups 
of the formulants. TWIM-MS also indicated that neutral complexes may exist in the 
C16 and LPC formulations, correlating with this result.  
The stability of the Trcs and TpcC alone and in formulation was investigated by 
allowing 24-hour maturation before measuring the fluorescence (Table 3.3). Overall, 
similar trends were observed for all the peptides at 1-hour and 24-hour maturation 
with regards to the quenching of the fluorescence by CS, LPC and C16 and a blue 
shift observable for the CS formulations. However, the total quantum yields of all the 
peptides and their formulations revealed either less or more quenching at 24-hour 
maturation compared to 1-hour maturation depending on the peptide and formulation 
(Table 3.3). For TrcA and its CS and C16 formulations, even more quenching of FS 
is observed at 24-hour maturation compared to 1-hour maturation whereas LPC had 
similar total quantum yields between the two maturation periods. This indicates over 
time the oligomeric states of TrcA within the CS and C16 formulation changes. It is 
possible that TrcA within the CS formulation requires more time to form new nano-
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structures leading to increased quenching, whereas the Tyr residues within the 
TrcA:C16 formulation becomes more exposed to the aqueous environment and/or 
carboxyl group of C16 as time progresses leading to increased collisional quenching. 
Both TrcB and TrcA experienced quenching by CS, which could indicate a role of 
Tyr7 in the maturation. Conversely TrcC, TpcC and the Trcmix were dequenched 
over time in the CS formulation. This could be due to the D-Trp4 residue that is 
contained in all three peptide preparations mowing into a more hydrophobic 
environment. LPC led to dequenching in all the preparations containing Trp3, namely 
TrcB, TrcC and TpcC which could point to a role in maturation of the residue in the 
aromatic dipeptide unit. In comparison with TrcA, TrcC, TpcC and Trcmix and their 
formulations, dequenching was observed at 24-hour compared to 1-hour maturation, 
for the most part, with the exception Trcmix which had more quenching at 24 hours. 
TrcB, which is an intermediate peptide between the A and C analogues, were the 
least influenced, except for the CS formulation, after 24 hours.  
The decrease in quenching for the CS, LPC and C16 formulations may indicate that 
as time progresses that one or both the Trp residues in the aromatic dipeptide unit 
become less exposed to aqueous environment/polar groups in the formulant. The 
changes in the total quantum yield of the peptides and their formulations when 
allowed different maturation time periods cannot be fully explained, however, it is 
certain that minor conformational changes do occur within the peptides and 
formulation, but the major differences between the formulations are stable over time. 
If the FS and TWIM-MS results are compared there is an exponential relationship 
(R2=0.8), with the exception of the CS formulations of the three peptides with Trp 
residues (Figure 3.9). A number of conclusions on the role of certain residues and 
molecular interactions can be derived from this interesting correlation.  
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Table 3.3 Comparison of fluorescence spectra of the Trc alone and in formulation at 1-hour 
and 24-hour maturation period. The total fluorescence quantum yield and the emission 
maxima of the Trcs and their formulations at 1 hour and 24 maturation period are given. The 
maxima of TrcA and TrcA formulations could not be determined.  
Identity 





Maximum wavelength ± SD 
(nm) 
1 hour 24 hours 
TrcA 
 
Quenched N.A. N.A. 
TrcA:CS Quenched N.A. N.A. 
TrcA:LPC No influence N.A. N.A. 
TrcA:C16 Quenched N.A. N.A. 
TrcB 
 
No Influence 344 ± 2 342 ± 0 








339 ± 2 338 ± 0 
TrcC 
 
Dequenched 340 ± 2 341 ± 1 
TrcC:CS Dequenched 327 ± 1 328 ± 0 




340 ± 2 339 ± 1 
TpcC 
 




328 ± 2 329 ± 1 
TpcC:LPC Dequenched 338 ± 0 336 ± 2 
TpcC:C16 No influence 337 ± 2 339 ± 2 
Trcmix 
 
Quenched 342 ± 0 341 ± 1 
Trcmix:CS Dequenched 323 ± 1 326 ± 0 
Trcmix:LPC Dequenched 339 ± 2 337 ± 3 
Trcmix:C16 No influence 339 ± 4 338 ± 0 
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The C16 formulant led to decreased total TWIM-MS and FS signals of the peptides 
(Figure 3.9, Table 3.3). This indicates that the side chains of the Trp and Tyr 
residues are moved to a polar environment (FS quenching) and do not form part of 
assemblies with aromatic stacking which would lead to better TWIM-MS signal 
(because of loss of such interactions in the MS instrument).  
The C16 carboxylate group probably associates with L-Orn9 leading to neutral 
complexes which explains the low MS signal intensities. LPC led to moderate loss in 
total FS signals, but low TWIM-MS signals. Similar to C16, the phosphate group may 
associate with L-Orn9 leading to neutral complexes. However, only few of the Trp 
and Tyr residues may be exposed to polar environment, leading to some quenching 
in FS signals (Table 3.3). CS led to pronounced quenching in all the peptides with 
Trp (Table 3.3, Figure 3.9), which indicates that one or more of the residues in the 
aromatic dipeptide moiety are part of aromatic stacking, as the MS signal is only 
moderately influenced. The Tyr on the other hand is placed in a hydrophobic 
environment in the CS formulation highlighted by the increased total FS signal of 
TrcA:CS. The sulphate group of CS does not seem to have such a strong 
association with the L-Orn9 of the peptides as the negative groups in C16 and LPS, 
as the TWIM-MS signal is still maintained.  




Figure 3.9 The relationship between the normalised total FS signals and the total TWIM-MS 
signals of the peptides and peptide formulations. The dotted line shows the exponential 
curve fitted to data points (R2=0.80), with exclusion on the CS formulations of TrcB, TrcC 
and TpcC.   
3.5 CONCLUSION 
Clear correlation between CCS areas of ionic species and molecular mass of all the 
peptides were observed indicative of similar peptide conformation adoption in vacuo. 
Higher dimer contribution was observed for the more hydrophobic TrcA and TrcB 
than the more polar TrcC and TpcC peptides, with an expected concentration 
dependant increase in dimerisation observed for all the peptides.  
In correlation with the SEM results where the detergent-like effects of LPC and C16 
led to disruption of the self-assembly of TpcC into uniform spheres, the dimer 
contribution of all the peptides were decreased within these formulations. In addition, 
the LPC and C16 formulants led to loss in total TWIM-MS signal compared to 
controls, indicating entrapment of peptide within stable neutral lipid complexes 
possibly due to ionic interaction between anionic lipid group and cationic L-Orn9 of 




































Stellenbosch University  https://scholar.sun.ac.za
3-33 
 
the peptides. There is a direct relationship between the quenching of total FS signal 
and loss of ionic species TWIM-MS signal of the peptides in formulation with C16 
and LPC. With these results, as well as the SEM and other TWIM-MS results, we 
hypothesise that formulation with LPC and C16 induces stable neutral lipid-
complexes which entraps peptides (via ionic interaction between the anionic lipid 
headgroup and cationic L-Orn9), decreases dimer formation and exposes the 
aromatic peptide unit to a polar environment which could be the aqueous 
environment (collisional FS quenching) and/or the polar groups of the LPC and C16 
(FS quenching via excited state reactions).  
The dimer contribution of the CS formulations was not markedly influenced 
compared to the controls and depended on the peptide identity. Furthermore, the 
total TWIM-MS signal of the CS formulations were largely maintained, indicating less 
stable formulation due to loss of hydrophobic interactions in the TWIM-MS 
instrument. This result agrees with the significant blue shifts and quenching 
observed in the FS spectra of the peptides when formulated with CS, indicative of a 
combinatorial effect of hydrophobic aromatic ring stacking and excited state 
reactions between dipeptide unit and the polar groups within peptide conformations.  
 It is evident that both the dipeptide unit and peptide characteristics have an 
influence on the self-assembly of the peptides into higher order structures and that 
these higher order structures can be further influenced by solvent systems, peptide 
concentration and formulants. As the oligomerisation of the Trcs have been shown to 
dictate their antimicrobial activity, it is expected that the formulations will have 
influences on the biological activity of the peptides which will be investigated in 
Chapter 4.  
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Chapter 4  
THE INFLUENCE OF FORMULANTS ON THE 
BIOLOGICAL ACTIVITY OF THE TYROCIDINES AND 
ANALOGUES 
4.1 INTRODUCTION 
The search for alternative chemotherapeutic drugs for the treatment of cancer has 
been ongoing for many years, yet no drug has been found that is successful in treating 
cancer without causing severe side effects or resistance development 1. In this regard, 
antimicrobial peptides (AMP’s) have been at the forefront in the search for alternative 
chemotherapeutic drugs due to speculation that the rapid membranolytic activity of 
AMP’s, including the tyrocidines from Brevibacillus parabrevis, lowers the risk of drug 
resistance development towards them 2, 3. Although the activity of the tyrocidines 
against various microorganisms (the Gram-positive bacteria 4, 5, fungi 6 ,7, malaria 
parasite Plasmodium falciparum2) and human erythrocytes (haemolytic activity) 8 are 
well established, little information is available about the anticancer activity of the 
tyrocidines. Results by Rautenbach et al.2 revealed that the tyrocidines do not possess 
selectivity between cervical cancer cells (HeLa cells) and an immortal cell line namely 
human pulmonary epithelial (A549 cells). It is proposed that the cationic nature of the 
tyrocidines will allow interaction with negatively charged cell membranes of cancer 
cells 9 and not with the neutral cell membranes of healthy human tissue 10. The low 
selectivity of many potential chemotherapeutic compounds prevents their use in the 
medical industry and strategies have been employed to eliminate the problem 11. One 
such strategy is the formulation of drugs with lipid-based molecules which act as 
carrier systems for the drugs to the desirable target cell or area 12, 13. Therefore, the 
tyrocidines will be formulated with three different lipid-based molecules (cholesterol, a 
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fatty acid and phospholipids) with the aim of reducing haemolytic activity and toxicity 
of the peptides while retaining their anticancer activity. It has been shown that the 
dipeptide unit plays an important part in the oligomerisation of the tyrocidines with 
dimers being the proposed active conformation for antimicrobial activity14-18. It is 
expected that the formulants will have influences on the aggregation/self-assembly of 
the peptides 19 and therefore insight into the structure-activity relationship of the 
peptides alone and in formulation will help to develop these peptides into successful 
chemotherapeutic agents. In this chapter, selected purified cyclodecapeptides, TrcA, 
TrcB, TrcC and TpcC, as well as the Trcmix were formulated with cholesterol sulphate 
(CS), palmitic acid (C16), and lysophosphatidylcholine (LPC) and a combination of CS 
and C16 (denoted as CSC16) and the activity towards human erythrocytes (haemolytic 
activity), three cancer cell lines (anticancer activity) and healthy human immortal cell 
lines (toxicity) was determined. Selectivity indexes were calculated from the HC50, IC50 
and LC50 values which eluded the peptide formulation with the greatest potential as 
chemotherapeutic formulation lead. Relationships between the structural 
characteristics of the peptides and the activity of the peptides alone and in formulation 
were also determined to give insight into possible mode of action of the peptides and 
how the formulations influence their mode of action.  
4.2  MATERIALS 
4.2.1 General materials 
The cholesterol sulphate (CS), palmitic acid (C16), commercial tyrothricin extract, 
gramicidin S (GS), methanol (MeOH), Roswell Park Memorial Institute media (RPMI-
1640), hydroxyethyl piperazineethanesulfonic acid (HEPES), hypoxanthine, 
gentamicin, sodium bicarbonate and Resazurin sodium salt were supplied by Sigma-
Aldrich (St Louis, USA). Avanti® polar lipids (Alabama, USA) supplied the soy 
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lysophosphatidylcholine (LPC).  The acetonitrile (ACN, HPLC-grade, far UV cut-off) 
was from Romil Ltd (Cambridge, United Kingdom). The ethanol (EtOH), chloroform 
and D-glucose was obtained from Merck (Darmstadt, Germany). Analytical grade 
water was prepared by filtering water from a reverse osmosis plant through a Millipore-
Q® water purification system (Milford, USA). Mixed cellulose syringe filters (0.22 m) 
were purchased from Merck-Millipore (Massachusetts, USA). Becton Dickson 
Labware (Lincoln Park, USA) supplied Falcon® tubes and Lasec (Cape Town, South 
Africa) supplied microfuge tubes and petri dishes. The nitrogen (N2) gas was from 
AFROX (Johannesburg, South Africa). The 96-well flat bottom polypropylene 
microtiter plates were supplied by Thermo Fisher Scientific (Denmark). The phosphate 
buffered saline (PBS) ingredients (NaCl,  KCl, Na2HPO4 and KH2PO4 were from Merck 
(Darmstadt, Germany). Packed erythrocytes (A+) from anonymous donors were 
supplied by the Western Cape Blood services (National Health Laboratory, South 
Africa) as a 300 mL enriched erythrocyte fraction containing 100 mL saline-adenine-
glucose mannitol preservative and 63 mL citrate-phosphate-dextrose anticoagulant.  
4.2.2 Materials for cell culture 
The European Collection of Cell Cultures (ECACC) (England, UK) and the American 
Type Culture Collections (ATCC) (Manassa, VA, USA) supplied the human prostatic 
adenocarcinoma (LNCaP)  and human embryonic kidney (HEK293) cells, 
respectively. The human prostatic carcinoma (C4-2B) cells and human colorectal 
adenocarcinoma (HT-29) cells were given by Professor D Neal from Oxford University 
(UK) and Dr Stefan Abels from Cape Peninsula University of Technology (CPUT, Cape 
Town, South Africa) as generous gifts, respectively. Dulbecco’s modified Eagles 
medium (DMEM) and RPMI-1640 media were supplied by Sigma Aldrich (St Louis, 
USA). The foetal calf serum (FCS), foetal bovine serum (FBS), sodium pyruvate and 
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HEPES were from Biochrom (Cambourne, UK). Gibco® (Gaithersburg, MD,USA) 
supplied the Penicillin-Streptomycin. 
4.3 METHODS 
4.3.1 The preparation of peptide formulations 
The preparation of peptide formulations has been previously described in Chapter 3, 
section 3.3.1. A fourth formulant (mixture of CS and C16 in equimolar amounts, 1:1) 
was used to prepare five more peptide formulations (TrcA:CSC16, TrcB:CSC16, 
TrcC:CSC16, TpcC:CSC16 and Trcmix:CSC16) in a similar manner.  
4.3.2 Cell culturing  
The LNCaP, C4-2B and HEK 293 cells were obtained from various post-graduate 
students in the group of Dr. Karl Storbeck and Prof Amanda Swart in the Biochemistry 
department (University of Stellenbosch, Stellenbosch, South Africa). The cells were 
cultured by using standard cell culturing methodologies. For details about the cell 
culturing methodologies, refer to MSc thesis of Monique Barnard 20. The HT-29 cells 
were cultured and obtained from Dr. Tanja Davis from the Physiology department 
(University of Stellenbosch, Stellenbosch, South Africa). All cells were grown in 90 % 
humidity and 5 % CO2 at 37 °C. A summary of each cell line and the culture media 
supplementation is given in Table 4.1  







10 % FBS, 1.5 g/L NaHCO3, 2.5 g/L D-(+)-Glucose, 1 % 
HEPES, 1 % sodium pyruvate and 1 % penicillin-
streptomycin. 
C4-2B RPMI-1640 
10 % FBS, 1.5g/L NaHCO3, 2.5 g/L D-(+)-Glucose and 
1 % penicillin-streptomycin 
HT-29 DMEM 10 % FBS and 1 % penicillin-streptomycin 
HEK293 DMEM 
10 % FCS, 1.5 g/L NaHCO3, 1 % sodium pyruvate and 
1 % penicillin-streptomycin 
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4.3.3 Haemolytic dose response assay 
The haemolytic activity of the peptides and the peptide formulations towards human 
erythrocytes was analysed by a haemolysis assay adapted from Rautenbach et al.2. 
Erythrocytes (A+) from anonymous donors was washed twice with modified RPMI 1640 
media (10.4 g/L RPMI 1640, 4 g/L glucose, 6 g/L HEPES, 5 g/L Albumax TM II, 2.1 g/L 
sodium bicarbonate and 50 mg/L gentamycin). During each washing step, the 
supernatant was removed after centrifugation at 1200xg for 3 minutes. The washed 
red blood cells were subsequently diluted to 2 % in PBS media (8 g/L NaCl, 0.2 g/L 
KCl, 1.44 g/L Na2HPO4 , 0.24 g/L KH2PO4) and stored at 4 °C. The dried pure peptides 
and peptide formulations were sterilised by using two methods: 1)  resuspension in 50 
% ACN in water (v/v) followed by lyophilisation; 2) placement in a glass desiccator 
saturated with chloroform vapour for 20 minutes. The sterilised pure peptides and 
peptide formulations were then made up to 1.00 mM in filter sterilised 15 % EtOH in 
analytical quality water (v/v) and analytical quality water, respectively. The sample 
solutions were then sonicated for ± 5 minutes and allowed to stand for either one hour 
or 24 hours before used in the assay. A doubling dilution series of the pure peptide 
and peptide formulation solutions were prepared in a sterile 96-well microtiter plate 
(dilution plate). Subsequently, 10 μL of peptide and peptide formulation were 
transferred from the dilution plate to a 96-well microtiter plate (assay plate) containing 
90 μL of 2 % blood in PBS in each well, resulting in 10X dilution of the peptides and 
peptide formulation in the assay plate (concentrations ranging from 100 µM to 1.56 
µM). The positive control (100 % haemolysis) was gramicidin S (100 μM in water) and 
the negative controls (0 % haemolysis) were water and 1.5 % EtOH in water. The 
assay plates were incubated for two hours at 37 °C, followed by centrifugation at 900xg 
for 10 min. The supernatants (10 µL of each well) were transferred to a 96-well 
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microtiter plate containing 90 μL of PBS in each well. The absorbance of the wells was 
measured at 415 nm with a Biotek PowerWave 340 spectrometer. The measured 
absorbance converted to percentage haemolysis as described by Equation 4.1 
% haemolysis = (
𝐴415𝑛𝑚 of well−Average 𝐴415𝑛𝑚 of  0 % haemolysis
Average 𝐴415𝑛𝑚 of 100 % haemolysis−Average 𝐴415𝑛𝑚 of 0 % haemolysis
)   4.1 
4.3.4 Cell viability dose response assay  
The dried pure peptides and peptide formulations were sterilised by using method 2 
as described in Section 4.3.2. The sterilised pure peptides and peptide formulations 
were then made up to 0.50 mM in filter sterilised 15 % EtOH in water (v/v) and water, 
respectively. The sample solutions were then sonicated for ± 5 minutes and allowed 
to stand for either 1 hour or 24 hours before used in the assay. A doubling dilution 
series of the pure peptide and peptide formulation solutions were prepared in a 96-
well microtiter plate (dilution plate). Subsequently, 10 μL of peptide and peptide 
formulation solution was transferred from the dilution plate to a 96-well microtiter plate 
(assay plate) containing 90 µL of target cells (LNCaP/HT-29/HEK293) at 
concentrations of 1x105 cells/mL (for LNCaP and HEK293) and 1x104 cells/mL (for 
HT-29), resulting in 10X dilution of the peptides and peptide formulation in the assay 
plate (concentrations ranging from 50 µM to 0.39 µM). The positive control (100 % 
proliferation inhibition) was gramicidin S (50 μM in water) and the negative controls 
(100 % proliferation) were water and 1.5 % EtOH in water (v/v). The assay plates were 
incubation for 20 hours in 90 % humidity and 5 % CO2 at 37 °C, followed by addition 
of 10 µL resazurin reagent (0.30 mg/mL) to each well. The assay plates were 
incubated for another four hours (in 90 % humidity and 5 % CO2 at 37 °C) except for 
the HT-29 assay plates which were incubated for another 24 hours. For C4-2B (1x105 
cells/mL) the activity of the peptides and peptide formulations were only tested at a 
single concentration of 50 µM. The absorbance of each well was measured at 570 nm 
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and 600 nm with a Biotek PowerWave 340 spectrometer. The measured absorbance 
ratio of 570nm/600nm was converted to % proliferation inhibition as described by 
Equation 4.2 





 of 100 % proliferation
Average 𝐴570𝑛𝑚
600𝑛𝑚
 of 100 % proliferation inhibition−Average 𝐴570𝑛𝑚
600𝑛𝑚
 of 100 % proliferation
)     4.2 
4.3.5 Activity data analysis  
Duplicate dose response assays with two repeats were performed for each peptide 
and its formulations against each target cell. All data analysis was performed by using 
GraphPad Prism® V 5.0 software (San Diego, CA, USA). Non-linear regressions were 
performed and a sigmoidal curve with variable slope (Hill slope less than 7) were fitted 
to the dose response data.  The sigmoidal curves were fitted using equation 4.3 21. 
𝑌 =
𝑏𝑜𝑡𝑡𝑜𝑚+(𝑡𝑜𝑝−𝑏𝑜𝑡𝑡𝑜𝑚)
1+ 10𝑙𝑜𝑔𝐼𝐶50𝑋 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑠𝑙𝑜𝑝𝑒               4.3 
The top and bottom represent the percentage haemolysis/proliferation inhibition at 
high and low peptide and peptide formulation concentrations, respectively. The 50 % 
haemolytic activity (HC50), 50 % LNCaP/HT-29 proliferation inhibitory concentrations 
(IC50) and 50 % lethal concentration (LC50) for HEK293 cells were determined as 
described by Rautenbach et al. 21. The selectivity was determined by ratios of 
HC50/IC50 or LC50/IC50 and was defined as selectivity indexes. Statistical analyses 
were performed by determining Row totals/means with standard deviation (SD) 
followed by One-way analysis of variance (ANOVA) with Bonferroni multiple/selected 
comparison post test. 
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4.4 RESULTS AND DISCUSSION 
4.4.1  Haemolytic activity of the peptides and peptide formulations  
The tyrocidines have been shown to possess haemolytic activity in the micromolar 
(µM) range8 which ultimately prevents their use as drugs for the systemic treatment of 
bacterial and fungal infections as well as for cancer. It has been shown that the 
formulation of such toxic peptides with various molecules (including lipids, polymers 
and steroids) can significantly reduce the toxic activity of AMPs by acting as delivery 
systems for the peptides to the target cells11-13.Therefore, the tyrocidines (TrcA, TrcB, 
TrcC and TpcC) were formulated with three lipid-based molecules CS, LPC and C16 
and the haemolytic activity of each determined. To ensure sterility of the peptides and 
peptide formulations, two different methods were tested : in method 1 the peptides 
and peptide formulations were incubated in a glass vessel saturated with chloroform 
vapour; and in method 2 the peptides and peptide formulations were resuspended in 
50 % ACN in water (v/v) and lyophilised. The haemolytic activity of the peptides and 
peptide formulations were first determined by using sterilisation method 1. The 
samples were then resuspended in 15 % EtOH in water (for pure peptides) and in 
water (for the formulations) and allowed to stand for 24 hours before performing the 
haemolytic dose responses. The haemolytic dose responses revealed that the HC50 
values increases in the following order (TrcB,TrcA,TpcC) <TrcC, with peptides in 
brackets having statistically similar HC50 values (Table 4.2). TrcA, TrcB  and Trcmix 
all had HC50 values of less than 15 µM (Table 4.2). These values correlate well with 
previously determined HC50 values for these Trcs in the range of 2-11 µM 2, 22, 
especially TrcB which was also found by Rautenbach et al. 2 to be the most haemolytic. 
On the other hand, the HC50 values for TrcC and TpcC were much higher than reported 
by other studies 2, 23 (making them the peptides with the lowest haemolytic activity in 
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this study), possibly due to the effects of the peptide and peptide formulations 
preparation which entails the suspension in 90 % MeOH in water (v/v) followed by 
evaporation with N2 gas (refer to methods, Section 4.3.1). Another possible 
explanation could be peptide self-assembly during the 24-hour maturation period, 
which would allow the peptides to form different self-assembly structures, especially 
for the C analogues that contain at least two Trp residues (unpublished data from a 
member of our group,  V. Kumar and M. Rautenbach). It has also been shown that 
Phe allows deeper penetration into the cell membrane of target cells than Trp 
residues2, 24-26, therefore it makes sense that the peptides with the most Trp residues 
(TrcC and TpcC) will have less haemolytic activity (higher HC50 values) than their Phe 
(TrcA and TrcB) counterparts. The L-Lys9/Orn9 has been proposed to insert into the 
negatively charged membranes of target cells via the so called “snorkelling effect” 
thereby causing cell lysis 2, 27. The fact that the C analogues present the lowest 
haemolytic activity suggests that self-assembly of the C analogues with the bulkier Trp 
residues may place the L-Orn9 in a position that sterically prevents it from readily 
associating and inserting into the cell membrane of red blood cells which may then 
also lower the haemolytic activity of the peptides in an additional way. Of the 
formulations, the CS and C16 had the largest influence on all the peptides, with 
significant increases in HC50 seen for TrcA:CS/C16, TrcB:CS/C16, TrcC:CS/C16, 
TpcC:CS/C16 and Trcmix:CS (Table 4.2). It is proposed that the anionic sulphate 
group of CS interacts with the cationic amino group of L-Orn9, thereby shielding it and 
preventing red blood cell membrane interaction, whereas the hydrophobic ring/carbon 
tail of CS in turn associates with the aromatic dipeptide unit preventing their membrane 
interaction.  
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Table 4.2 A summary of the haemolytic activities (HC50 in µM) of the peptides and peptide 
formulations. The dose response curves for each of the peptides with the respective 
formulations are given. Each HC50 is represented by two biological assays, each with two 
technical repeats. 
Identity Abbr. Dose response curve 
HC50 ± SD (n) 
(µM) 
Tyrocidine A formulations (Cyclo-(fPFfNQYVOL) 
Tyrocidine A TrcA 
 
12.8 ± 1.3 (2) 
Formulated with CS TrcA:CS *851 ± 210 (2) 
Formulated with LPC TrcA:LPC 12.2 ± 0.5 (2) 
Formulated with C16 TrcA:C16 65.7 ± 5.5 (2) 
Tyrocidine B formulations Cyclo-(fPWfNQYVOL) 
Tyrocidine B TrcB 
 
9.63 ± 0.9 (2) 
Formulated with CS TrcB:CS *211± 9.4 (2) 
Formulated with LPC TrcB:LPC 12.6 ± 1.0 (2) 
Formulated with C16 TrcB:C16 54.7 ± 0.3 (2) 
Tyrocidine C formulations Cyclo-(fPWWNQYVOL) 
Tyrocidine C TrcC 
 
46.3 ± 1.4 (2) 
Formulated with CS Trcc:CS *419 ±4.5 (2) 
Formulated with LPC TrcC:LPC 17.3 ± 1.4 (2) 
Formulated with C16 TrcC:C16 90.1 ± 28 (2) 
Tryptocidine C formulations Cyclo-(fPWWNQWVOL) 
Tryptocidine C TpcC 
 
35.9 ± 12 (2) 
Formulated with CS Tpcc:CS *4690 ± 1020 (2) 
Formulated with LPC TpcC:LPC 42.1 ± 12 (2) 
Formulated with C16 TpcC:C16 *300 ± 4.0 (2) 
Tyrocidine mixture formulations 
Tyrocidine mixture Trcmix 
 
8.59 ± 0.5 (2) 
Formulated with CS Trcmix:CS *287 ±110 (2) 
Formulated with LPC Trcmix:LPC 9.33 ± 0.9 (2) 
Formulated with C16 Trcmix:C16 20.0 ± 1.4 (2) 
The number of repeats is represented by n; * Predicted HC50 values from dose-response; Refer to addendum Table 4.8 for 
statistical analysis of the haemolysis data.  
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The TpcC:CS resulted in the largest increase in HC50, possibly due to the lack of L-
Tyr7 which implicates this residue in the facilitation of haemolytic activity. LPC as 
formulant did not have a significant influence on the haemolytic activity of TrcA, TrcB, 
TrcC, TpcC and Trcmix (Table 4.2).  
Interestingly, LPC increased the haemolytic activity of TrcC (not significantly), which 
may indicate that the interaction of LPC with L-Trp4 in the dipeptide unit places the L-
Tyr7 residue in a position which facilitates increased haemolytic activity.  
The fact that LPC did not have the same effect on TpcC, which also contains L-Trp4 
but not L-Tyr7, further strengthens the hypothesis that the position of L-Tyr7 is 
important to elicit haemolytic activity. The C16, similarly to CS, increased HC50 values 
of TrcA, TrcB and TrcC, with the greatest effect on TpcC. However, TrcB was the only 
peptide formulated with C16 which had significantly higher HC50 value compared to 
peptide alone. This increase in HC50 by C16 as formulant indicates that the anionic 
carboxyl group and hydrophobic carbon tail of C16 possibly interacts with the L-Orn9 
and the aromatic dipeptide unit thereby preventing membrane insertion and changing 
the position/exposure of L-Tyr7. 
The haemolytic activity of the peptides and peptide formulations were tested using 
sterilisation method 2 which entails the resuspension in 50 % ACN in water (v/v) 
followed by lyophilisation. Subsequently, the peptides and peptide formulations were 
resuspended in 15 % EtOH in water and water, respectively, and the dose responses 
were performed. The HC50 values were expected to remain constant, however, the 
opposite was observed. Almost all the HC50 values decreased (increased haemolytic 
activity), with significant decreases observed for all the CS formulations and C16 
formulations of TrcB and TrcC,  by using the sterilisation method 2 (Table 4.3). This 
indicates the effect that solvent systems and preparation methods have on the self-
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assembly of the peptides alone or in formulations. It has been shown that solvent does 
affect the aggregation of the peptides 19 , therefore it is proposed that the acetonitrile 
combined with the lyophilisation step in method 2 is responsible for the disruption of 
interaction of the formulants with the peptides which eliminates the suppression of the 
haemolytic activity. It was therefore decided that sterilisation method 1 will be used to 
decontaminate all peptide and peptide formulation samples used in the rest of the 
activity assays.  
To assess whether the haemolytic activity will be influenced if the peptides and peptide 
formulations were allowed less time to mature, the % haemolytic activity at one peptide 
concentration (50 µM) were determined after samples were one hour old (Figure 4.1 
A-E). In general, no significant changes were observed in the haemolytic activity of the 
peptides alone and in formulation with LPC between 1-hour and the 24-hour 
maturation period. However, the haemolytic activity of TrcC decreased when allowed 
to mature for 24 hours which may be due to formation of more compact aggregates 
leading to less exposure of the polar groups of L-Orn9and L-Tyr7, hypothesised in this 
study to be responsible for elicitation of haemolytic activity (Figure 4.1 C). For TrcA, 
TrcC and TpcC (Figure 4.1 A, C and D) opposite effects were observed for the CS and 
C16 formulations. The % haemolytic activity at 50 M of the TrcA, TrcC and TpcC CS 
formulations did not significantly increase when allowed 24-hour maturation, whereas 
that of the C16 formulations were decreased significantly, except for TpcC:C16 (Figure 
4.1 A, C and D). It is likely that the assembly and disassembly induced by the CS 
doesn’t reach an equilibrium at one hour, therefore polar groups and the side chains 
of the dipeptide unit may become more exposed in the peptides after 24-hour time 
period. Conversely, the C16 possibly increases shielding of the peptides over time 
leading to less exposure of the polar groups and dipeptide unit. TrcB (Figure 4.1 B) 
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follows the same trend as the other peptides (% haemolysis of TrcB:CS significantly 
increased) except that the haemolytic activity of the C16 formulation did not increase 
significantly over time. 
Table 4.3-Summary of the haemolytic activity (HC50 in µM) of the peptides and peptide 
formulations observed between two different sterilisation methods. The HC50 values were all 
determined from 2 biological repeats each with duplicate technical repeats. 
Identity 
HC50 ± SD 
Influence a 
Sterility method 1 Sterility method 2 
TrcA 12.8 ± 1.2 7.23 ± 0.1 slight 
TrcA:CS 851 ± 210* 26.7 ± 3.3 negative 
TrcA:LPC 12.2 ± 0.5 9.20 ± 2.8 no influence 
TrcA:C16 65.7 ± 5.5 18.9 ± 5.6 negative 
TrcB 9.63 ± 0.9 9.97 ± 0.4 no influence 
TrcB:CS 211 ± 9.4* 56.7 ± 1.8 negative 
TrcB:LPC 12.6 ± 1.0 10.9 ± 0.4 no influence 
TrcB:C16 54.7 ± 0.3 18.0 ± 1.8 negative 
TrcC 46.3± 1.4 10.7 ± 1.2 negative 
TrcC:CS 419 ± 4.5* 20.6 ± 1.0 negative 
TrcC:LPC 17.3 ± 1.4 11.3 ± 0.2 slight 
TrcC:C16 90.1 ± 28 13.9 ± 0.2 negative 
TpcC 35.9 ± 12 15.1 ± 1.8 negative 
Tpcc:CS 4691 ± 1018* 46.1 ± 0.3 negative 
TpcC:LPC 42.1 ± 12 14.4 ± 3.0 negative 
TpcC:C16 300 ± 4.0* 24.5 ± 7.4 negative 
Trcmix 8.59 ± 0.5 8.30 ± 1.0 no influence 
Trcmix:CS 287 ± 112* 71.9 ± 4.6 negative 
Trcmix:LPC 9.33 ± 0.9 9.83 ± 0.7 no influence 
Trcmix:C16 20.0 ± 1.4 10.8 ± 0.7 negative 
aA >2fold decrease of HC50 value by using sterilisation method 2 is deemed negative. * Predicted HC50 values from 
dose-response. Refer to addendum Table 4.9 for statistical analysis of the haemolysis data. 
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Figure 4.1 The haemolytic activity of the peptides and peptide formulations at 50 µM when 
allowed a 1 hour versus a 24-hour maturation period. Haemolytic activity for the A) TrcA with 
formulations, B) TrcB with formulations, C) TrcC with formulations, D) TpcC with formulations 
and E) Trcmix with formulations. Each bar represents the average of 4 repeats from two 
biological repeats, each with two technical repeats. Refer to addendum Table 4.10 for 
statistical analysis of the haemolysis data. P-values > 0.05 ns (not shown on graph), P-values 
< 0.05 = *, P-values < 0.01 = **, P-values < 0.001 = ***.  
The haemolytic activity for Trcmix formulation with LPC and C16 did not change over 
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rest of the peptides (Figure 4.1 E). It is clear that the self-assembled states and 
exposure of certain groups of these peptides are everchanging and can be influenced 
by many different factors including preparation method (Table 4.3) and time (Figure 
4.1 A-E) which in turn dictates their activity. Taken together, the CS formulation 
influenced the toxicity of the peptides to the largest extent and lower haemolytic 
activities for the CS formulations were observed at 1-hour maturation period compared 
to 24-hour maturation for all the peptides.  
Therefore, one hour of maturation was allowed for all the samples for the rest of the 
biological activity studies done in this chapter. Because C16 also lowered the 
haemolytic activity of the peptides substantially for all the peptides (excluding Trcmix), 
it was decided to test the combination of CS and C16 on the haemolytic activity of the 
peptides. The combination revealed TpcC:CSC16 had the lowest % haemolytic activity 
at 50 µM (Figure 4.2) which agrees with the hypothesis that substitution of L-Tyr7 with 
Trp results in less insertion of residue 7 which may play a role in haemolytic activity. 
Overall, the CSC16 formulation decreased the haemolytic activity of all the peptides 
significantly, with an increase in % haemolysis observed in the following order 
TrcA<TrcB<TrcC  (Figure 4.2). This gradual increase indicates that the dipeptide unit 
is implicated in the haemolytic activity of the combinatorial formulation with an addition 
of Trp residue each time leading to an increase in %  haemolysis.  
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Figure 4.2  Comparison of the % haemolysis induced by the peptides alone and the peptides 
in formulation with CS, C16 and a combination of CS and C16 (CSC16). The percentage 
haemolysis was determined at peptide or peptide formulation concentration of 50 µM and 1-
hour sample maturation period. Each bar represents the average of 4 repeats. Refer to 
addendum Table 4.8 for statistical analysis of the haemolysis data. P-values > 0.05 ns, P-
values < 0.05 = *, P-values < 0.01 = **, P-values < 0.001 = ***.  
 
This is likely due to larger aggregates forming when there are more Trp residues 
thereby hampering both the shielding of cationic L-Orn9 by CSC16 and the exposure 
of L-Tyr7. An increase in haemolytic activity is also observed for the CS formulations 
of TrcA, TrcB and TrcC in the order of TrcA>TrcB>TrcC (Figure 4.2), similar to the 
CSC16 formulations. This is not the case for the C16 formulations alone, indicating 
that the influence of C16 on the peptide aggregation/self-assembly is overpowered by 
the CS in the CSC16 formulations. It is likely that the sulphate group and/or the 
hydrophobic ring/tail structure of CS forms a stronger interaction with the polar 
residues and dipeptide unit compared to C16.  
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4.4.2 Biological activity of the peptides and peptide formulations 
The Trcs possess activity against a broad spectrum of different microorganisms 
including Gram-positive bacteria such as Listeria monocytogenes and Micrococcus 
luteus 4, 5, 23, fungi such as Candida albicans 7, Botrytis cinereal and Fusarium spp 6, 
and the malaria parasite Plasmodium falciparum 2. The activity of the Trcs doesn’t stop 
at microorganisms, as results from Rautenbach et al. 2 showed activity against HeLa 
cervical cancer cells with IC50 values ranging from 13 to 28 µM for the six major Trcs. 
These results sparked an interest in the activity of the Trcs against other types of 
cancer. Therefore, the anticancer activity of the Trcs and the formulations against 
three different cancer cell lines (LNCaP, C4-2B and HT-29), two of which are prostate 
cancer cell lines (LNCaP, C4-2B) were investigated. It is also important that the toxicity 
of these peptides and their formulations are tested against mammalian non-cancerous 
cells, as to evaluate selectivity of the peptide formulations. The Trcs and formulations 
were therefore also tested against human embryonic kidney cells (HEK293) an 
immortal cell line.  
Full dose responses were only performed on LNCaP, HT-29 and HEK293 cells with 
all the peptide and formulations, but the CSC16 formulations could only be tested 
towards HT-29 and HEK293 cells due limited amount of the pure and fully 
characterised peptides. As a result, the activity of the Trcs and formulations could only 
be tested at one concentration against the C4-2B cancer cells. A representative 
peptide, TrcA, was chosen to display the dose response data acquired for each of the 
peptides and their formulations against each of the cancer cell lines (Figure 4.3). The 
IC50 values (for LNCaP and HT-29) and LC50 values (for HEK293) are summarised in 
Table 4.4. The HT-29 IC50 values for the peptides alone (including Trcmix) ranged 
from 6.86 to 8.49 µM and in formulation with CS, LPC, C16 and CSC16 ranged 
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between 6.87 to 27.6 µM (Table 4.4). The LNCaP IC50 values were in similar ranges 
as observed for HT-29, with IC50 values for the peptides alone (including Trcmix) 
ranging from 6.62-13.2 µM, and in formulation with CS, LPC and C16 ranging between 
6.09-44.1 µM (Table 4.4). From the IC50 values of the peptides alone and in 
formulation, no clear trend could be observed indicating that the primary structure does 
not dictate the anticancer activity of the peptides and that membranolytic activity is 
likely not the sole mechanism of action of the peptides towards cancer cells. It is 
probable that the peptides may be translocated/internalised into the cancer cells, 
considering that multiple internal targets have been proposed for AMPs such as the 
enzymes of the electron transport chain, RNA and DNA, and nucleic acid and protein 
synthesis. Furthermore, it was observed that CS, C16 and CSC16 lower the activity of 
all the peptides (with a few significant increases in IC50 values) towards HT-29 and 
LNCaP to some extent (less than observed for haemolytic activity), whereas LPC has 
no marked influence on the activity of the peptides. This indicates and further 
strengthens the theory that the mechanism of action of the Trcs towards red blood 
cells and cancer cells are different.   
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Figure 4.3 Representative dose response assays to determine the activity of TrcA and TrcA 
peptide formulations against A) LNCaP, B) HT-29 and C) HEK293 cells. Each data point is 
represented by two technical repeats from duplicate biological repeats, with error bar 
indicating the SD.  
 
Considering the internalisation and targeting of internal targets, it is reasonable that 
the CS and C16 hamper the internalisation of the peptides or the release of the 
peptides once internalised into cancer cells leading to decrease in anticancer activity. 
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Unfortunately, the formulation of peptides did not decrease the toxicity of the peptides 
to a large extent towards non-cancerous (HEK293) cells for most of the peptides.  The 
LC50 values against HEK293 cells for the peptides alone (including Trcmix) ranged 
from 3.47-7.81 µM, and in formulation with CS, LPC, C16 and CSC16 ranged between 
5.03-57.4 µM (Table 4.4). Similar to the observed results for HT-29 and LNCaP, no 
clear relationship was observed between the primary structures of the peptides and 
the activity towards HEK293 cells. However, a decrease in toxicity of the peptides is 
also observed when formulated with CS (significant decreases seen for TrcB and 
Trcmix) and C16 (significant decreases seen for all of the peptides). The fact that the 
activity (IC50 and LC50 values) of the peptides towards the cancer cells and the non-
cancerous cells are similar, indicates that neither the overall negative charge of the 
target cell nor the cationic L-Lys/L-Orn9 of the Trcs is necessary for activity and that 
alternative targets exist.  
The % haemolysis/proliferation inhibition of the peptides alone and in formulation with 
CS, C16 and CSC16 (where applicable) are displayed at 50 and 25 µM (Figure 4.4 A-
H) to assess which peptide and formulation had the lowest activity towards human 
erythrocytes (RBC) and HEK293 cells, while retaining activity towards cancer cells 
(HT-29, LNCaP and C4-2B where applicable). At 50 µM, the CSC16 formulation 
decreased the % toxicity of TrcA, TrcB and TrcC (Figure 4.4 A, B, C) the most, 
whereas the C16 formulation decreased the toxicity of TpcC (Figure 4.4 D) the most. 
Although the toxicity of TrcA, TrcB, and TrcC was decreased with the CSC16 
formulation, the activity towards HT-29 and C4-2B were also decreased. However, for 
TrcA:CSC16 and TrcB:CSC16 the activity towards HT-29 and C4-2B was ± 10% 
higher than towards HEK293 cells, indicating decreased toxicity (Figure 4.4 A and B).  
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Table 4.4 The activity of the peptides and peptide formulations towards HT-29, LNCaP and 
HEK293 cells. The IC50 and LC50 values were determined from duplicate biological assays 
each consisting of two technical repeats. 
Identity 
IC50 ± SD (µM) LC50 ± SD (µM) 
Towards HT-29 Towards LNCaP Towards HEK293 
TrcA 6.86 ± 2.3 13.2 ± 2.8 4.46 ± 0.7 
TrcA:CS 20.5 ± 5.3 26.3 ± 7.9 10.6 ± 5.7  
TrcA:LPC 9.39 ± 1.8 19.0 ± 4.6 6.31 ± 1.4 
TrcA:C16 25.1 ± 1.7 36.1 ± 3.7 20.6 ± 4.5 
TrcA:CSC16 10.9 ± 0.5 N.A.a 10.8 ± 3.8 
TrcB 8.49 ± 1.3 8.71 ± 1.2 7.81 ± 0.6 
TrcB:CS 8.64 ± 1.5 15.3 ± 1.0 11.2 ± 0.1  
TrcB:LPC 7.93 ± 0.2 11.0 ± 0.1 8.51 ± 0.3 
TrcB:C16 26.6 ± 0.2 44.1 ± 3.7 29.8 ± 1.5 
TrcB:CSC16 11.2 ± 2.0 N.A.a N.A.a 
TrcC 6.96 ± 1.8 12.3 ± 2.1 6.65 ± 1.0 
Trcc:CS 6.87 ± 1.8 18.7 ± 2.6 10.9 ± 1.2 
TrcC:LPC 6.95 ± 1.2 8.82 ± 1.7 8.58 ± 0.2 
TrcC:C16 17.0 ± 0.8 27.4 ± 3.7 18.5 ± 6.1 
TrcC:CSC16 8.49 ± 4.1 N.A.a 5.40 ± 0.7 
TpcC 7.23 ± 2.1 6.94 ± 0.1 3.47 ± 1.6 
Tpcc:CS 7.44 ± 3.2 13.7 ± 0.9 5.03 ± 1.7 
TpcC:LPC 8.08 ± 0.2 11.4 ± 3.6 8.01 ± 0.2 
TpcC:C16 N.A.a 36.2 ± 5.9 57.4 ± 3.5 
TpcC:CSC16 8.49 ± 4.1 N.A.a 6.90 ± 3.2 
Trcmix 7.10 ± 0.3 6.62 ± 0.5 5.00 ± 0.4 
Trcmix:CS 27.6 ± 3.9 27.0 ± 3.2 13.5 ± 4.0 
Trcmix:LPC 7.55 ± 0.4 6.09 ± 0.3 6.04 ± 0.1 
Trcmix:C16 15.4 ± 0.1 10.4 ± 0.5 13.3 ± 0.4 
Trcmix:CSC16 12.0 ± 5.2 N.A.a 8.50 ± 0.1 
a Data not feasible for determination of IC50 or LC50 values. Refer to addendum Table 4.11 and 4.12 for statistical 
analysis of the anticancer and toxicity data. 
 
The toxicity of TpcC:C16 towards HEK293 cells was decreased to below 55 % at 50 
µM concentration, while still retaining more than 80 % and 65% activity towards C4-
2B and LNCaP, respectively (Figure 4.4 D). At 25 µM, the C16 formulation decreased 
the % toxicity of TrcB and TpcC the most, whereas the CSC16 and C16 formulations 
both decreased the toxicity of TrcA and TrcC the most (Figure 4.4 E-H).  
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Figure 4.4 Comparison of the activities of the Trcs and Trc formulations toward human red 
blood cells (RBC), HEK293, HT-29, LNCaP and C4-2B cells at a specific concentration of 
50µM (A-D) and 25 µM (E-H) with A and E) TrcA alone and in formulation; B and F) TrcB 
alone and in formulation C and G) TrcC alone and in formulation D and H) TpcC alone and 
in formulation. Note that the CSC16 formulation was not evaluated against the LNCaP cells. 
The dotted line in each graph indicates which peptide formulation has the lowest activity 
toward HEK293 cells. Refer to addendum table 4.13 for statistical analysis of the anticancer 
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Their activity towards HT-29 and LNCaP of TpcC:C16 is 10-20 % higher than towards 
HEK293 cells (Figure 4.4 E-H). Therefore, at both 50 µM and 25 µM the TpcC:C16 
formulation has the lowest toxicity toward RBC and HEK293 cells, while retaining more 
than 50 % activity toward at least one of the cancer cell lines. 
4.4.3 Selectivity and structure-activity analysis of the peptides and 
peptide formulations 
From the biological activity analysis, it was evident that CS and C16 were the 
formulations that worked the best. To gain insight into structure-activity relationships 
of the Trcs (TrcA, TrcB, TrcC and TpcC) alone and in formulation with CS and C16, 
two physicochemical parameters were correlated with biological activity (HC50, IC50 
and LC50) and in vitro selectivity (HC50/IC50 and LC50/IC50). The retention time (Rt) and 
the Ʃ side chain surface area (SCSA) were the two physicochemical parameters 
chosen to represent the apparent hydrophobicity and peptide size/volume, 
respectively. The retention times were determined from the C18 UPLC chromatograms 
(refer to Chapter 2) of the pure peptides and the side chain surface areas were taken 
from Frecer 28, as calculated from Connolly surfaces 29. A summary of al the 
physicochemical descriptors of the peptides are given in Table 4.5.  
Table 4.5 Summary of the physicochemical descriptors of the tyrocidines with the variable 
amino acid residues at position 3, 4, 7, and 9 are given where Phe, Trp, Tyr and Orn depicted 





Ʃ side chain surface 
areac (Å) 
TrcA F3-f4-Y7-O9 10.78 796.7 
TrcB W3-f4-Y7-O9 9.68 825.6 
TrcC W3-w4-Y7-O9 9.19 854.5 
TpcC W3-w4-W7-O9 9.49 873.6 
a D-amino acids and L-amino acids are represented by lower case and upper-case letters, respectively. 
b Retention times were determined from C18 UPLC chromatograms of the purified peptides 
c The sum of the side chain surface areas of the constituent amino acids of the peptides were determined from 28 
as calculated from Connolly surfaces 29  
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The physicochemical parameters were correlated with the biological activity and 
selectivity of the non-formulated peptides first, as to establish any structure-activity 
relationship that may exist before investigating the influence of the formulations on 
these relationships. No direct relationship could be observed between the IC50 or LC50 
values and the retention times (hydrophobicity) and SCSA of the Trcs (Figure 4.5 A 
and B). However, the haemolytic activity of the peptides is influenced by both the 
hydrophobicity and peptide size/volume (Figure 4.5 A and B). The above-mentioned 
results agree with the theory mentioned previously that the mechanism of action 
toward RBC and cancerous/non-cancerous cells are different. As hydrophobicity 
increases (TrcC<TpcC<TrcB<TrcA) the haemolytic activity increases indicating that 
Phe containing peptides are more haemolytic, possibly due to deeper penetration into 
cell membrane by Phe residue side chains 25, 26. The opposite trend is observed for 
the SCSA, with decreasing haemolytic activity observed as SCSA increases 
(TrcA<TrcB<TrcC<TpcC), suggesting that larger sized peptides (containing more than 
one Trp residue) cannot penetrate the cell membrane as deep as the Phe residues 
leading to decreased red blood cell membrane disruption 24. Taken together, smaller 
more hydrophobic peptides (TrcA and TrcB) are more haemolytic, possibly due to 
deeper insertion of Phe residues into the cell membrane and stronger interaction with 
hydrophobic phospholipid tails of the cell membrane lipid bilayer.  
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Figure 4.5 The relationship between the tyrocidine activity and peptide hydrophobicity or Ʃ 
side chain surface area. A) The peptide activity towards erythrocytes (HC50), HT-29 and 
LNCaP cancer cells (IC50 ) and HEK293 mammalian cells (LC50) plotted against the C18 UPLC 
retention time of the tyrocidines.  B) The peptide activity towards erythrocytes (HC50), HT-29 
and LNCaP cancer cells (IC50 ) and HEK293 mammalian cells (LC50) plotted against the Ʃ side 
chain surface area of the tyrocidines.   
Now that it has been established that there is no trend between the peptide size or 
apparent hydrophobicity and the activity of the peptides towards cancer and 
mammalian immortal cell lines, the effect of the C16 and CS formulations on the 
activity of the peptides can be determined. Opposing or mirror trends are seen 
between the activity of both CS and C16 formulations and the SCSA and 
hydrophobicity of the peptides indicating that CS and C16 have opposite effects on 
the anticancer activity of the peptides (Figure 4.6 A-B). These opposite effects seem 
to be more pronounced for TpcC (Ww-W) and TrcB (Wf-Y), indicating interaction of 
the formulants with the dipeptide unit leading to decreased or increased anticancer 
activity. Assuming internalisation and attack of internal targets of cancer cells by the 
tyrocidines, it is probable that the hydrophobic parts of the formulants (C16 carbon tail 
and CS carbon ring/tail structure) associate differently with the smaller more 
hydrophobic peptide dipeptide unit, leading to either entrapment (stronger C16-
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Considering the SEM and TWIM-MS data from Chapter 3, where C16 causes 
increased disruption of self-assembled spheres and loss of ionic specie signal 
compared to CS stabilising the spheres and maintained ionic signal, it is possible that 
less peptide molecules are internalised in an interacting lipid-peptide “bolus” and 
released from the C16 formulation compared to CS formulation due to stronger C16-
peptide interaction.  
 
Figure 4.6 The relationship between the activity of the peptide formulations (CS and C16) and 
peptide hydrophobicity or Ʃ side chain surface area. A) The activity of the peptide formulations 
towards HT-29 and LNCaP cancer cells (IC50 ) plotted against the Ʃ side chain surface area 
of the tyrocidines.  B) The activity of the peptide formulations towards HT-29 and LNCaP 
cancer cells (IC50 ) plotted against the C18 UPLC retention time of the tyrocidines. 
To elucidate which formulation has the most potential as an alternative 
chemotherapeutic drug with minimised toxicity towards human erythrocytes and 
mammalian cells while retaining anticancer activity, the selectivity of the CS and C16 
formulations were determined.  The selectivity parameters for the CS and C16 peptide 
formulations are summarised in Table 4.6. Similar trends are seen between the 
selectivity of the CS and C16 formulations and the SCSA of the peptides (Figure 4.7 
A, C). From the correlation between selectivity of the formulated peptides (formulated 
with CS and C16) and the Ʃ side chain surface areas, it is evident that TpcC:C16 has 
the highest selectivity between erythrocytes and LNCaP cancer cells (HC50/IC50)  and 
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Table 4.6 A summary of the selectivity of the peptides formulated with CS and C16 determined 
from the ratios of the HC50 (from red blood cells), IC50 ( from HT-29 and LNCaP cells) and LC50  
(from HEK293 cells) values. 
Formulation HC50/IC50a ± SD LC50/IC50a  ± SD 
 HT-29 LNCaP HT-29 LNCaP 
TrcA:CS 44.3 ± 22 35.1 ± 19 0.50 ± 0.2 0.40 ± 0.1 
TrcB:CS 24.9 ± 5.3 13.9 ± 1.5 1.31 ± 0.2 0.73 ± 0.0 
TrcC:CS 63.2 ± 17 22.7 ± 3.4 1.67 ± 0.6 0.60 ± 0.2  
TpcC:CS 662 ± 146 342 ±  53 0.70 ± 0.1 0.40 ± 0.1 
TrcA:C16 2.61 ± 0.1 1.82 ± 0.0 0.82 ± 0.1 0.60 ± 0.1 
TrcB:C16 2.05 ± 0.0  1.24 ± 0.1 1.12 ± 0.1 0.70 ± 0.1 
TrcC:C16 5.36 ± 1.9 3.25 ± 0.6 1.08 ± 0.3 0.70 ± 0.3 
TpcC:C16 N.A. 8.41 ± 1.5 N.A. 1.61 ± 0.4 
a IC50 values of HT-29 or LNCaP used to calculate selectivity indexes. 
 
Figure 4.7 The relationship between the selectivity of the peptide formulations (CS and C16) 
and peptide Ʃ side chain surface area. A) The selectivity (HC50/IC50) of the CS peptide 
formulations between erythrocytes (HC50) and cancer cells (HT-29 and LNCaP cells)(IC50) 
plotted against the Ʃ side chain surface area of the tyrocidines.  B) The  selectivity (LC50/IC50) 
of the CS peptide formulations between HEK293 mammalian cells (LC50) and cancer cells 
(HT-29 and LNCaP cells)(IC50 ) plotted against the Ʃ side chain surface area of the tyrocidines. 
C) The selectivity (HC50/IC50) of the C16 peptide formulations between erythrocytes (HC50) 
and cancer cells (HT-29 and LNCaP cells)(IC50 ) plotted against the Ʃ side chain surface area 
of the tyrocidines. D) The  selectivity (LC50/IC50) of the C16 peptide formulations between 
HEK293 mammalian cells (LC50) and cancer cells (HT-29 and LNCaP cells)(IC50 ) plotted 
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Unfortunately, due to material and time-constraints, the IC50 of TpcC:C16 for HT-29 
cells could not be determined. However, it is likely that the selectivity between 
erythrocytes (HC50/IC50) or HEK 293 mammalian cells (LC50/IC50) and HT-29 cells 
would be high, if it follows the trend of the LNCaP selectivity. For the CS formulation, 
the selectivity of TpcC:CS is highest between erythrocytes and HT-29 cells (HC50/IC50)  
whereas, TrcC:CS has the highest selectivity between HEK293 mammalian cells and 
HT-29 cancer cells (LC50/IC50). Taken together, the TpcC:C16 formulation has the 
greatest potential as alternative chemotherapeutic lead formulation for cancer 
treatment.  
4.5 CONCLUSIONS 
A relationship was observed between the hydrophobicity as well as the size of 
dipeptide unit and the haemolytic activity of the peptides, with the smaller and more 
hydrophobic peptides, TrcA and TrcB, being more haemolytic. The CS and C16 
formulations led to a decrease of haemolytic activity (except for Trcmix:C16), with the 
largest influence induced by CS. The LPC had no marked effect on the haemolytic 
activity of the peptides.  
It was found that sample preparation may influence the self-assembled states of the 
peptides in formulation, as different sterility methods caused significant differences in 
the haemolytic activity of the CS formulations and some of the C16 formulations.  
Maturation periods influenced the haemolytic activities of some of the formulations, 
with significant differences only observed for three of the 15 peptide formulations.  
The structure-activity analysis of the peptides revealed no apparent relationships 
between the activity towards HT-29, LNCaP and HEK293 cells and the physical 
properties of the peptides (hydrophobicity and size), indicating an additional mode of 
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action(s) such as internalisation followed by attack of internal targets.  However, the 
CS and C16 formulations seem to have opposite/mirror effects on the anticancer 
activity of the peptides which appear to be more pronounced for TrcB and TpcC. The 
C16 formulation have lower anticancer activity compared to CS formulations which 
may indicate stronger C16-peptide interaction possibly leading to entrapment of 
peptides. Although the C16 formulations have lower anticancer activity compared to 
CS, it is the TpcC:C16 formulation that presents the highest combined selectivity 
indexes (HC50/IC50 and LC50/IC50) making TpcC:C16 the formulation with the greatest 
potential as lead formulation for alternative chemotherapeutic drug for the treatment 
of cancer.  
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4.7 ADDENDUM 
Table 4.7 Summary P-values from Bonferroni multiple comparison test of the HC50 values and 
% haemolysis at 50 µM for the pure peptides. The HC50 values and % haemolysis was 
determined from haemolytic dose responses performed and haemolysis assays, respectively, 
after different sterility methods and formulation maturation periods were used. The exact P-
values are less than the limit shown in the table with P-values > 0.05 denoted as “ns”. 
HC50 
 Sterility method 1; 24-hour maturation Sterility method 2; 1-hour maturation 
 TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix 
TrcA - ns 0.05 ns ns - ns ns 0.01 ns 
TrcB  - 0.05 ns ns  - ns 0.05 ns 
TrcC   - ns 0.05   - ns ns 
TpcC    - 0.05    - 0.05 
% Haemolysis at 50 µM peptide/formulation 
 Sterility method 1; 24-hour maturation Sterility method 1; 1-hour maturation 
 TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix 
TrcA - ns 0.001 0.001 ns - ns ns 0.05 ns 
TrcB  - 0.001 0.001 ns  - ns ns ns 
TrcC   - ns 0.001   - ns ns 
TpcC    - 0.001    - 0.01 
 
Table 4.8 Summary P-values from Bonferroni selected pair comparison test of the HC50 values 
and % haemolysis at 50 µM for the peptide formulations with CS, LPC and C16. The HC50 
values and % haemolysis was determined from haemolytic dose responses performed and 
haemolysis assays, respectively, after different sterility methods and formulation maturation 
periods were used. The X represents the peptide in each row, for instance the cell in column 
one row one represents TrcA:CS. The exact P-values are less than the limit shown in the table 
with P-values > 0.05 denoted as “ns”. 
HC50 
 Sterility method 1; 24-hour maturation Sterility method 2; 1-hour maturation 
 XCS XLPC XC16 XCS XLPC XC16 
TrcA 0.01 ns 0.01 0.05 ns ns 
TrcB 0.001 ns 0.05 0.001 ns 0.05 
TrcC 0.001 ns 0.05 0.01 ns ns 
TpcC 0.01 ns 0.001 0.01 ns ns 
Trcmix 0.05 ns ns 0.001 ns ns  
% Haemolysis at 50 µM peptide/formulation 
 Sterility method 1; 24-hour maturation Sterility method 1; 1-hour maturation 
 XCS XLPC XC16 XCS XLPC XC16 XCSC16 
TrcA 0.001 ns 0.001 0.001 ns 0.001 0.001 
TrcB 0.001 ns 0.001 0.001 ns 0.001 0.001 
TrcC 0.001 0.001 0.001 0.001 ns 0.05 0.001 
TpcC 0.001 ns 0.001 0.001 ns 0.001 0.001 
Trcmix 0.001 ns ns 0.001 ns ns 0.001 
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Table 4.9 Summary P-values from Bonferroni selected pair comparison test of the HC50 values 
for the pure peptides and peptide formulations. The HC50 values was determined from 
haemolytic dose responses performed after different sterility methods and formulation 
maturation periods were used. Only the same peptide and peptide formulation were compared 
to elucidate any significant effects caused by sample preparation. The exact P-values are less 
than the limit shown in the table with P-values > 0.05 denoted as “ns”. 




































 TrcA TrcA:CS TrcA:LPC TrcA:C16 TrcB TrcB:CS TrcB:LPC TrcB:C16 
TrcA ns        
TrcA:CS  0.001       
TrcA:LPC   ns      
TrcA:C16    ns     
TrcB     ns    
TrcB:CS      0.001   
TrcB:LPC       ns  
TrcB:C16        0.001 
 TrcC TrcC:CS TrcC:LPC TrcC:C16 TpcC TpcC:CS TpcC:LPC TpcC:C16 
TrcC ns        
TrcC:CS  0.001       
TrcC:LPC   ns      
TrcC:C16    0.001     
TpcC     ns    
TpcC:CS      0.001   
TpcC:LPC       ns  
TpcC:C16        ns 
 Trcmix Trcmix:CS Trcmix:LPC Trcmix:C16 
Trcmix ns    
Trcmix:CS  0.01   
Trcmix:LPC   ns  
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Table 4.10 Summary P-values from Bonferroni selected pair comparison test of the % 
haemolysis using 24-hour versus 1-hour maturation periods for the pure peptides and peptide 
formulations at 50 µM. The  % haemolysis  was determined from haemolysis assays 
performed after sterility method 1 and different maturation periods were used. Only the same 
peptide and peptide formulation were compared to elucidate any significant effects caused by 
maturation time. The exact P-values are less than the limit shown in the table with P-values > 
0.05 denoted as “ns”. 
 
Table 4.11 Summary P-values from Bonferroni selected pair comparison test of the IC50 or 
LC50 values of the peptide formulations towards LNCaP, HT-29 and HEK293 cells. The IC50 
and LC50 values were determined from cell viability dose responses performed after using 
sterility method 1 and a 1-hour maturation period. The X represents the peptide in each row, 
for instance the cell in column one row one represents TrcA:CS. The exact P-values are less 
than the limit shown in the table with P-values > 0.05 denoted as “ns”. P-values that could not 
be determined due to insufficient data are denoted by “N.A”. 
IC50 or LC50 
 LNCaP HT-29 HEK293 
 XCS XLPC XC16 XCS XLPC XC16 XCSC16 XCS XLPC XC16 XCSC16 
TrcA ns ns ns 0.05 ns 0.01 ns ns ns 0.05 ns 
TrcB ns ns 0.001 ns ns 0.001 ns 0.05 ns 0.001 N.A 
TrcC ns ns 0.05 ns ns 0.05 ns ns ns 0.05 ns 
TpcC ns ns 0.05 ns ns N.A. ns ns ns 0.001 ns 
Trcmix 0.01 ns ns 0.01 ns ns ns 0.05 ns 0.05 ns 
 
 




























 TrcA TrcA:CS TrcA:LPC TrcA:C16 TrcB TrcB:CS TrcB:LPC TrcB:C16 
TrcA ns - - - - - - - 
TrcA:CS - ns - - - - - - 
TrcA:LPC - - ns - - - - - 
TrcA:C16 - - - 0.01 - - - - 
TrcB - - - - ns - - - 
TrcB:CS - - - - - 0.001 - - 
TrcB:LPC - - - - - - ns - 
TrcB:C16 - - - - - - - ns 
 TrcC TrcC:CS TrcC:LPC TrcC:C16 TpcC TpcC:CS TpcC:LPC TpcC:C16 
TrcC 0.001 - - - - - - - 
TrcC:CS - ns - - - - - - 
TrcC:LPC - - ns - - - - - 
TrcC:C16 - - - 0.001 - - - - 
TpcC - - - - 0.01 - - - 
TpcC:CS - - - - - ns - - 
TpcC:LPC - - - - - - ns - 
TpcC:C16 - - - - - - - ns 
 Trcmix Trcmix:CS Trcmix:LPC Trcmix:C16 
Trcmix ns - - - 
Trcmix:CS - ns - - 
Trcmix:LPC - - ns - 
Trcmix:C16 - - - ns 
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Table 4.12 Summary P-values from Bonferroni multiple comparison test of the IC50 or LC50 
values of the pure peptides and peptide formulations towards LNCaP, HT-29 and HEK293 
cells. The IC50 and LC50 values were determined from cell viability dose responses performed 
after using sterility method 1 and a 1-hour maturation period. The X represents the peptide in 
each row, for instance the cell in column one row one represents TrcA:CS. The exact P-values 
are less than the limit shown in the table with P-values > 0.05 denoted as “ns”. P-values that 










IC50 or LC50 
Pure peptides 
 LNCap HT-29 HEK293 
 TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix 
TrcA - ns ns ns ns - ns ns ns ns - ns ns ns ns 
TrcB  - ns ns ns  - ns ns ns  - ns ns ns 
TrcC   - ns ns   - ns ns   - ns ns 
TpcC    - ns    - ns    - ns 
CS formulations 
 TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix 
TrcA - ns ns ns ns - ns ns ns ns - ns ns ns ns 
TrcB  - ns ns ns  - ns ns 0.05  - ns ns ns 
TrcC   - ns ns   - ns 0.05   - ns ns 
TpcC    - ns    - 0.05    - ns 
LPC formulations 
 TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix 
TrcA - ns ns ns ns - ns ns ns ns - ns ns ns ns 
TrcB  - ns ns ns  - ns ns ns  - ns ns ns 
TrcC   - ns ns   - ns ns   - ns ns 
TpcC    - ns    - ns    - ns 
C16 formulations 
 TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix 
TrcA - ns ns ns 0.05 - ns 0.01 N.A. 0.01 - ns ns 0.01 ns 
TrcB  - ns ns 0.01  - 0.01 N.A. 0.01  - ns 0.01 ns 
TrcC   - ns ns   - N.A. ns   - 0.01 ns 
TpcC    - 0.05    - N.A.    - 0.001 
CSC16 formulations 
 TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix TrcA TrcB TrcC TpcC Trcmix 
TrcA -. N.A. N.A. N.A. N.A. - ns ns ns ns - N.A. ns ns ns 
TrcB  -. N.A. N.A. N.A.  - ns ns ns  - N.A. N.A. N.A. 
TrcC   - N.A. N.A.   - ns ns   - ns ns 
TpcC    - N.A.    - ns    - ns 
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Table 4.13 Summary of P-values from Bonferroni selected pair comparison test of the % 
haemolysis and % proliferation inhibition of peptides and formulations towards RBC, LNCaP, 
HT-29, C4-2B and HEK293 cells at 50 µM and 25 µM. The exact P-values are less than the 
limit shown in the table. P-values > 0.05 denoted as “ns”. P-values that could not be 
determined due to insufficient data are denoted by “N.A”. The P-values in brackets were 
determined from data obtained at peptide and peptide formulation concentrations of 25 µM.  
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SUMMARY, CONCLUSIONS AND FUTURE STUDIES 
5.1 INTRODUCTION 
The ultimate goal of this study was to develop a formulation of the Trcs and analogues 
that reduces the toxicity of these cyclodecapeptides towards human red blood cells 
(erythrocytes)1-3 and non-cancerous mammalian cells 2, 3, while simultaneously 
retaining activity towards cancer cells. Before any experiment could be performed, the 
tyrocidines had to be produced and purified from crude Brevibacillus parabrevis culture 
extracts supplemented with amino acids. Subsequently, peptide formulations with 
different lipid-based molecules had to be prepared followed by determination of 
biophysical properties induced by the different formulants. After establishing the 
possible influence formulants have on the biophysical properties of the peptides, the 
activity towards human red blood cells (haemolytic activity), non-cancerous human 
immortal cells (HEK293 cells) and different cancer cells (LNCaP, C4-2B and HT-29) 
were investigated to elucidate potential peptide formulation(s) as alternative 
anticancer agent.  
5.2 EXPERIMENTAL CONCLUSIONS AND FUTURE STUDIES 
5.2.1 Production and purification of tyrocidine A, B, C and 
tryptocidine C 
Determination of the biophysical and biological activity of different tyrocidines and 
analogues required sufficient amounts of highly pure (>90 %) peptide. The 
supplementation of Br. parabrevis culture media with amino acids, as described by 
Vosloo et al. 4, successfully increased amount of the peptides of interest (TrcA, B and 
TpcC). Supplementation with Phe resulted in increased production of TrcA and B, 
whereas supplementation with Trp increased TpcC and TpcB amounts. Three 
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peptides, TrcA, TrcB and TpcC, were subsequently isolated from crude culture 
extracts and the fourth (TrcC) isolated from commercial Trc mixture (Trcmix) by means 
of established C18 semi-preparative reverse-phase HPLC (RP-HPLC) methodology 2, 
5. With UPLC analysis of the manually isolated peptides the identities and purities of 
all the peptides were determined. All the isolated peptides had purities of 90% or 
higher. 
5.2.2 Development of a C8 HPLC purification method 
The tyrothricin complex consists of a complex mixture of tyrocidines and analogues, 
all differing from each other with only one amino acid residue which makes their 
purification difficult especially separating Lys and Orn analogues (example TrcA/A1 
TrcB/TrcB1 and TrcC/C1) differing only from each other in CH2 group. Separation of 
the B-analogues (TrcB/B’/B1/ B1’) are further complicated where the aromatic 
dipeptide can be either Wf or Fw. Therefore a new purification method was developed 
by applying the current optimised C18 HPLC program2, 5 to an alternative column, a 
C8 column, to make purification of these peptides in the future more cost and time 
efficient. The optimised C8 HPLC purification method (program D at 25 °C, Chapter 2) 
improved the separation of the tyrocidines significantly with notable separation of the 
TrcC1 and TrcC, TrcB1 and TrcB, and TrcB and TrcB’/TpcC. Purities of 74.4 %, 95.5 
%, 90.2 %, 93.7 %, 90.8 % and 85.5 % were achieved for TrcA, TrcA1, TrcB, TrcB1, 
TrcC, and TrcC1. Isolation of all six major tyrocidines is a very significant result, 
however, manual collection of peaks remains time consuming. Collection of the peaks 
was attempted by using a fraction collector but was less successful than manual 
collection due to the delay between the signal of the HPLC detector and the fraction 
collector, as well as the aggregation/oligomerisation of these peptides over time 
leading to retention time drifts. This delay and retention time drift have a significant 
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effect due to close proximity of each peptide peak to one another resulting in the 
wrong/overlapping collection of peak fractions. Future studies should focus on 
correcting the time delay between the fraction collector and HPLC detector, as well as 
directed fraction collection via absorption and/or molecular mass (mass-directed 
fraction collection using a mass spectrometer as detector). Due to the success of the 
C8 HPLC purification method developed in Chapter 2, the method will be used in the 
future as the primary method for purification of the tyrocidines and analogues as soon 
as a C8 semi-preparative column is acquired in the BIOPEP Peptide Group.   
5.2.3 The influence of formulants on the peptide biophysical 
character  
The aim of Chapter 3 of this study was to elucidate the biophysical properties of four 
chosen Trcs (TrcA, TrcB, TrcC and TpcC) alone and in formulation with lipid-based 
molecules (CS, LPC and C16). The techniques chosen to do this were scanning 
electron microscopy (SEM), traveling wave  ion mobility mass spectrometry (TWIM-
MS) and fluorescence spectroscopy (FS).  
Oligomerisation of TrcA, TrcB, TrcC and TpcC: It has been shown that the 
cyclodecapeptides from tyrothricin form oligomers which is generally dictated by the 
variable residues of the aromatic dipeptide unit. The results from the TWIM-MS results 
of this study correlates well with previous results found by Vosloo 6 in which it was 
observed that the more hydrophobic Trcs (TrcA and TrcB) have a greater tendency to 
form dimers. Furthermore, the more hydrophobic and smaller TrcA and TrcB have 
lower cross-sectional (CCS) areas for both the monomeric ionic species and the 
dimeric species than that of the TrcC and TpcC. In contrast to what was expected, the 
CCS areas of the dimeric ionic species were observed be less than 2-fold that of both 
the singly and doubly charged monomeric species. This indicates that the forces 
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(hydrogen bonding, ionic interaction and hydrophobic interaction) that are involved in 
the dimerisation of the Trcs result in denser conformation of the peptides. Furthermore, 
an expected concentration dependent increase in dimerisation was observed for all 
the peptides.  
The SEM results revealed that TpcC self-assembles into well-defined spherical 
structures with high dispersity in the nanometre range, 13 nm to 349 nm, depending 
on concentration and solvent system used to prepare the samples. Larger spheres 
were formed with higher peptide concentration (1.00 mg/mL) and a less polar solvent 
(50 % EtOH in water (v/v)) ranging from 159 nm to 349 nm compared to the spheres 
formed with lower concentration (500 µM) and more polar solvent (15 % EtOH in water 
(v/v)) which ranged from 13 nm to 25 nm. Quasicrystals composed of multiple smaller 
uniform spheres were also observed to form by TpcC which signifies the ability of 
these peptides to form larger self-assembled structures. Preliminary studies showed 
that TrcA, TrcB and TrcC also formed nanospheres, as well as other larger structures. 
This study will now be taken further in a separate project.  
The FS studies revealed that the conformation of the peptides dictates the location of 
the Trp residues. Blue shifts of the fluorescence maxima observed in the spectra of 
TrcB, TrcC and TpcC from the expected 357 nm 7 to 344 nm, 340 nm and 340 nm, 
respectively, are indicative of translocation of Trp residues to a pure hydrophobic 
environment7-10. This signifies the influence peptide self-assembly and conformation 
have on the location of the aromatic dipeptide unit in oligomeric structures. 
Considering the SEM results of TpcC, it is likely that the Trp residues are positioned 
towards hydrophobic pockets of the spherical nano-constructs. 
Oligomerisation of the Trcs caused by lipid-based formulants: The proportion of the 
dimeric ionic species of the Trcs decreases when formulated with LPC and C16, as 
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determined by TWIM-MS. The SEM results of TpcC:LPC and TpcC:C16 revealed that 
LPC and C16 lead to either retardation or the disruption/prevention of the formation of 
uniform large spheres, which correlates with the decrease in proportion of doubly 
charged dimers observed by TWIM-MS for the LPC and C16 formulations. 
Additionally, the LPC and C16 formulants led to loss in total TWIM-MS signal 
compared to controls, indicating entrapment of peptide within stable neutral lipid 
complexes. Stable neutral lipid complexes are possibly formed due to ionic interaction 
between anionic lipid group and cationic amino group of the L-Orn9 residues of the 
peptides. Considering both the SEM and TWIM-MS results, the quenching of the 
fluorescence of the C16 and LPC formulations is therefore more likely due to exposure 
of the Trp residues to the aqueous environment or due to excited state reactions 
between the Trp residues and polar carboxyl group of C16 and the amino and 
phosphate groups of LPC 8, 9 10, 11.  
The direct relationship observed between the quenching of total FS signal and loss of 
ionic species TWIM-MS signal of the peptides in formulation with C16 and LPC, as 
well as the SEM and other TWIM-MS results led us to hypothesise the following:  
• C16 and LPC formulations with the cationic cyclodecapeptides form stable 
neutral lipid-complexes which entraps peptides (via ionic interaction between 
the anionic lipid headgroup and cationic L-Orn9);  
• C16 and LPC both act as detergents and decreases dimer formation and 
• the side-chains of the aromatic dipeptide unit is exposed to a polar environment 
which could either be the aqueous environment (collisional FS quenching) 
and/or the polar groups of the LPC and C16 (FS quenching via excited state 
reactions).  
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The SEM of TpcC formulated with CS induced the formation of large non-uniform 
spheres compared to smaller non-uniform spheres induced by LPC and C16. Some 
of spheres induced by CS were almost 10X the size (94 nm - 133 nm) of the majority 
of the spheres formed by TpcC alone (13 nm – 25 nm), indicating that CS may lead to 
merging of the small spheres into larger structures.  The TWIM-MS results revealed 
that the proportion of dimeric ionic species in the CS formulation is not markedly 
influenced compared to the control. However, some changes in monomeric species 
contributions were evident indicating some influence, correlating with the SEM results 
of TpcC:CS. Furthermore, the maintained total TWIM-MS signal observed for the CS 
formulations indicates less stable formulation due to loss of hydrophobic interactions 
(aromatic ring stacking) in the TWIM-MS instrument 12-14. The FS studies agrees with 
this result where significant blue shifts accompanied by quenching in the CS 
formulation spectrums were observed, indicating a combinatorial effect of ring stacking 
15 and excited state reactions between the dipeptide unit amino acid side chains and 
polar groups of the peptide backbones. 
5.2.4 Biological activity of the tyrocidines 
The aim of Chapter 4 was to minimise the toxicity of the Trcs towards human 
erythrocytes (RBCs) and human non-cancerous cells such as HEK293 cells. Four of 
the Trcs, TrcA, TrcB, TrcC and TpcC, as well as the mixture known as Trcmix, were 
formulated with CS, LPC and C16 (all lipid-based molecules) in an attempt to achieve 
the goal mentioned above. Decontamination of the formulations was achieved by 
means of sterility method 1 (which entails the saturation of formulations with 
chloroform vapour within a glass desiccator) and sterility method 2 (resuspension of 
samples in 50 % ACN followed by lyophilisation). The latter method resulted in the 
decrease of almost all the HC50 values (increase in toxicity) of the peptides and 
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formulations which signified the dependence of peptide aggregation/self-assembly on 
solvent systems and preparation methods. Therefore, the rest of the biological assays 
were performed using sterility method 1 for the decontamination of the samples prior 
to biological activity experiments.  
The haemolytic dose responses (24-hour maturation period, sterility method 1) 
revealed that TrcC and TpcC are less haemolytic than TrcB  and TrcA, with TrcB 
observed as the most haemolytic peptide. The HC50 values of TrcA and TrcB correlate 
well with previous results2, 16, where TrcB was also found to be the most haemolytic2. 
We hypothesise that the peptides with more than one Trp residue have hampered 
association with cell membranes of red blood cells because of the shallow insertion of 
Trp side chain compared to Phe side chain2, 17-19, as well as adjusted L-Orn9 
orientation (hampered “snorkelling” effect)20 caused by different induced 
oligomerisation structures of the C-analogues. 
The CS significantly increased the HC50 values of all the peptides, including Trcmix, 
indicating that the peptide structures that caused the haemolytic activity was 
neutralised in this formulation. It is proposed that CS shields the aromatic groups 
preventing them from penetrating the phospholipid membrane, as well as possibly 
competing with the interaction of the tyrocidines with the sterol, cholesterol 21. 
However, LPC, a lysophospholipid that is potentially a lipid target for many toxic 
membrane active peptides, had no significant effect on any of the HC50 values of the 
cyclodecapeptides. Formulation with C16 also significantly increased the HC50 values 
of the peptides and thus this lipid formulation also negated some of the haemolytic 
toxicity. It is probable that carboxyl group of C16 shields the cationic amino group of 
L-Orn9, while the aliphatic tail interacts with some of the hydrophobic groups, thereby 
hampering dimer formation and cell membrane interaction.  
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In general, the time allowed for the peptides and peptide formulations to mature had 
no marked influences on their haemolytic activities, with significant differences only 
observed for three of the 15 peptide formulations between two different maturation 
periods (1-hour vs 24-hours). Comparison of % haemolysis at 1-hour and 24-hour 
maturation periods (at 50 µM) of the peptides alone and in formulation with LPC 
revealed no significant changes, except for non-formulated TrcC and TpcC. Similar % 
haemolysis was observed for CS formulations at 24-hour compared to 1-hour 
maturations, except for TrcB:CS with significant increase. However, a decrease in % 
haemolysis for TrcA:C16 and TrcC:C16 were observed for C16 formulations at 24-
hour compared to 1-hour maturation period, except for TrcB:C16 where an increase 
was again observed. The self-assembled states and exposure of certain groups of 
these peptides change over time, and it is proposed to in turn affect their activity, as 
well as toxicity. This signifies the influence of different factors, including preparation 
method, solvent systems and time of maturation, have on the activity of the Trcs and 
their formulations.  
A 1-hour maturation period was allowed for all the samples for the rest of the activity 
assays in Chapter 4 because the CS formulation influenced the haemolytic activity of 
the peptides to the largest extent with decreased haemolytic activities observed at 1-
hour maturation period. 
Similar to the CS formulations, the combinatorial formulation, CSC16, increased the 
% haemolysis (1-hour maturation) of all the peptides at 50 µM with an increase 
observed in the following order TrcA<TrcB<TrcC suggesting that effects of C16 on the 
self-assembly of the peptides are overpowered by CS in the CSC16 formulation. 
However, CS remains the formulant that lowers haemolytic activity of the peptides the 
most.  
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All peptides and peptide formulations were active against LNCaP, HT-29, HEK293 
and C4-2B cells. In general, the CS and C16 formulations showed decreased 
anticancer and HEK293 activity. However, at both 25 µM and 50 µM the % proliferation 
inhibition of cancer cells by TpcC:C16 was higher than the % proliferation inhibition of 
HEK293 cells. 
No direct relationship could be observed between the IC50 (LNCaP and HT-29) or LC50 
(HEK293) values and the physicochemical characteristics (retention times and side 
chain surface area) of the peptides alone and in formulation, which suggest that the 
primary structure does not dictate their anticancer activity or activity towards non-
cancerous human cells. However, the haemolytic activity of the peptides is influenced 
by both the hydrophobicity and peptide size/volume with increased haemolytic activity 
observed for the smaller more hydrophobic peptides (TrcA and TrcB) possibly due to 
deeper insertion of Phe residues into the cell membrane and stronger interaction with 
hydrophobic phospholipid tails of the cell membrane lipid bilayer. It is therefore 
suggested that the mechanism of action of the Trcs  towards erythrocytes and 
cancerous/mammalian non-cancerous immortal cell lines are different and that the 
peptides are likely translocated/internalised into the cancer cells via the lipidic 
formulations as internal targets have been proposed as alternative mechanism of 
action for the tyrocidines 2, 16, 22-29. Furthermore, the fact that the activity of the peptides 
and peptide formulations are similar towards cancerous and non-cancerous 
mammalian cells suggests that neither the negative charge of the cancer cell nor the 
positive charge of the Trcs is necessary for activity and strengthens the theory that 
alternative targets exists.  
Opposite/mirror trends are seen between the anticancer activity and the surface side 
chain area (SCSA) and hydrophobicity of the peptides for both the CS and C16 
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formulations. This indicates that CS and C16 have opposite effects on the anticancer 
activity of the peptides. The C16 formulations have lower anticancer activity compared 
to CS formulation counterparts. With this result, and the results seen from  the SEM 
(disruption of spheres by C16) and TWIM-MS data (loss of ionic specie signal by C16) 
from Chapter 3, it is possible that less peptide molecules are internalised in an 
interacting lipid-peptide “bolus” and released from the C16 formulation compared to 
CS formulation due to stronger C16-peptide interaction.  
Despite the decreased anticancer activity of the Trcs by the C16 formulation, it is the 
TpcC:C16 formulation which had the best combined selectivity of HC50/IC50 (between 
erythrocytes and LNCaP) and LC50/IC50 (between HEK293 and LNCaP) which makes 
TpcC:C16 the peptide formulation with the most potential as future cancer 
chemotherapeutic drug formulation.  
5.3 FUTURE STUDIES 
This was the first exploratory study on Trc-formulation and must be expanded to test 
Trcs peptide formulations with different formulant molecules, such as polymer-type 
nanocarriers, cyclodextran, chitosan and many others. However, future studies on 
these peptides and their formulations must be undertaken with care, specifically in 
interpretation of results if methodology is not stringently controlled and standardised. 
As CS is a highly promising formulant, it is suggested that focus is placed on the 
optimisation of the CS formulations in terms of peptide:CS ratio, type and time of 
agitation, solvent systems, as well as utilising other types of amphipathic sterols. As 
TpcC:C16 formulation showed promise it would be beneficial to assess the influence 
on the length and saturation of the aliphatic tail of the fatty acid. Different types of 
headgroups can also be considered for detergent-type formulations. However, the 
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toxicity of the formulations is still an issue, therefore mixed-type formulation such as 
C16:CS type with targeting ligands on CS and/or C16 would improve the selectivity. 
Targeting ligands can include:  
• poly-glutamate or poly-glutamate folates for targeting the PSMA in prostate 
cancer. 
• Molecules such as folic acid (Vitamin B9), transferrin and hyaluronan used as 
ligand for targeting different receptors expressed in cancer cells. 
• CPPs such as transactivator of transcription protein (TATp).  
Covalent modification of the tyrocidines with palmitic acid was attempted in this study 
in order to modulate the toxicity of the peptides. The conjugation of C16 to tyrocidine 
mixture was successful with double conjugation of C16 also observed from ESI-MS 
analysis (data not shown). Unfortunately, purification of the conjugates proved to be a 
difficult task and preliminary activity studies revealed complete loss of activity. 
However, these constructs can be used as a co-formulants with the Trcs in place of 
C16 alone or with CS. Focus should also be placed on developing a prodrug-
nanoformulation of the tyrocidines, similar to the Trc-PVP nano-formulation to target 
the malaria parasite, or by implementing pH ( N,N’-dimethylaminoethyl methacrylate 
(DMAEMA)) or enzyme sensitive linkers (glycylphenylalanylleucylglycine (GFLG) 
tetrapeptide) between the conjugates and the peptides.  
This study has proven that the three major tyrocidines (A, B, C) and tryptocidine C 
have a broad-spectrum activity against cancers and that lipid formulation can modulate 
the activity of these peptides. From these promising results it is suggested that the 
search for the ideal nanocarrier system for the delivery of tyrocidines to cancer cells 
and tumours should be continued.  
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